Cardiology

Exam Map

Strongest Repeated Exam Themes & Revision Priorities:

• Fatal Medication Contraindications: The exam heavily tests what not to do. Memorize these absolute traps: AV-nodal blockers (adenosine, beta-blockers, CCBs, digoxin) are strictly contraindicated in WPW + Afib; nitrates in RV/Inferior MI; beta-blockers in acute decompensated HF and Prinzmetal angina; and short-acting oral nifedipine in hypertensive urgencies.
• The Unstable Patient: "Next best step" questions frequently pivot on hemodynamic stability. Pulseless VT/VFib = Immediate Defibrillation. Unstable but pulsing tachyarrhythmias (SVT/VT/Afib) = Synchronized Cardioversion.
• Arrhythmia Pairings: Link Multifocal Atrial Tachycardia (MAT) to severe pulmonary disease/COPD and treat with CCBs (never beta-blockers). Link SVT to structurally healthy hearts and treat with IV Adenosine.
• Re-infarction Detection: Troponin stays elevated for 10–14 days. You must select CK-MB (or its isoform assay) for detecting early re-infarction because it normalizes within 72 hours.
• Valvular Intervention Rules: Surgery is indicated before irreversible failure. Cutoffs are heavily tested: LVEF drops below 60% for Mitral Regurgitation and below 50% for Aortic Regurgitation. Remember that advanced age is never a contraindication for severe Aortic Stenosis intervention (TAVR/AVR).
• Heart Failure Mortality: You must differentiate between drugs that improve survival ("BAAS": Beta-blockers, ACEi/ARB/ARNI, Aldosterone Antagonists, SGLT2i) and those purely for symptom control (Furosemide, Digoxin).
• Aortic Dissection Paradigm: Medical management requires immediate reduction of shear stress. You must administer beta-blockers before vasodilators like nitroprusside to avoid a fatal reflex tachycardia that propagates the tear.
• Endocarditis Prophylaxis Traps: Prophylaxis is reserved only for highest-risk patients (prosthetic valves, prior IE) undergoing highest-risk procedures (dental/respiratory mucosa). Routine GI/GU procedures (e.g., colonoscopy) require no prophylaxis, even with a mechanical valve.
• Post-MI Complications: Differentiate by timing and presentation. A Ventricular Septal Defect (VSD) presents on days 3–5 with a new loud murmur, thrill, and right heart failure. Early post-MI pericarditis is treated with Aspirin only (standard NSAIDs and steroids are contraindicated to avoid myocardial rupture).
• Stroke & Permissive Hypertension: Do not lower BP in an acute ischemic stroke unless it exceeds 220/120 mmHg. However, if the patient is a candidate for thrombolytics (tPA), the strict threshold changes to < 185/110 mmHg.

Ischemic Heart Disease

Core Concepts

Coronary Physiology & Ischemia Myocardial ischemia occurs when oxygen demand exceeds oxygen supply.

• Myocardial Oxygen Supply Determinants:
  • Coronary blood flow (determined by vessel patency). Note: 80% of coronary flow occurs in diastole.
  • Hemoglobin level.
  • Arterial oxygen saturation.
  • Myocardial oxygen extraction (Note: This is fixed at 65%-75% even at rest, so the heart relies heavily on increasing flow to meet higher demands).
• Myocardial Oxygen Demand Determinants:
  • Heart rate.
  • Contractility.
  • Wall tension (ventricular pressure and radius).
  • Muscle mass (e.g., LVH).

Pathogenesis of Atherosclerosis

• Endothelial Dysfunction: Initiated by mechanical stress/inflammation. Upregulation of adhesion molecules attracts monocytes/T-lymphocytes.
• Fatty Streak: Macrophages consume oxidized LDL, becoming lipid-rich foam cells.
• Plaque Types:
  • Stable Plaque: Thick fibrous cap, lots of smooth muscle cells, intact endothelium, lack of inflammatory cells. (Causes stable angina).
  • Unstable Plaque: Thin fibrous cap, large necrotic lipid core, many inflammatory cells (activated macrophages), few smooth muscle cells, eroded endothelium. (Prone to rupture → ACS).

Diagnosis / Clinical Features

Coronary Syndromes

• Stable Angina: Typically arises with >70% luminal stenosis. Retrosternal pressure/heaviness lasting 2–10 mins. Precipitated by exertion/emotion; relieved by rest/nitrates.
• Variant (Prinzmetal) Angina: Vasospasm of epicardial coronary vessels. Frequently occurs at rest/at night. Presents with transient ST-segment elevation but negative troponin. Associated with females and other vasospastic conditions (migraine, Raynaud's).
• Cardiac Syndrome X: Exertional angina with a positive stress test, but anatomically normal coronary arteries on angiography. Caused by microvascular dysfunction. Excellent long-term prognosis.
• Stress-Induced (Takotsubo) Cardiomyopathy: Often triggered by severe emotional stress (e.g., fight with a spouse). Presents with chest pain and ST elevations resembling STEMI. Echo characteristically shows apical dyskinesia with basilar preservation of contraction.

Investigations

• ECG Localization:
  • Inferior (RCA): II, III, aVF
  • Anterior/Septal (LAD): V1 – V4
  • Lateral (LCx): I, aVL, V5, V6
• Stress Testing: Exercise tolerance test (ECG looking for ST depression), Stress Echo (looking for wall motion abnormalities), or Thallium/nuclear scan (shows decreased isotope uptake in ischemic areas during exercise).
• Coronary Angiography: Gold standard. Identifies anatomically significant occlusions.

Management

Stable Angina Management

• Prognostic Therapy (Mortality Reduction):
  • Aspirin.
  • Statins (Target LDL < 100 mg/dL, or < 70 mg/dL in high-risk).
  • ACE Inhibitors.
  • Revascularization (CABG/PCI) in specific anatomical variants (e.g., Left Main disease).
• Symptomatic Therapy (Symptom Control):
  • Beta-blockers (increase diastolic time, reduce HR/contractility).
  • Calcium channel blockers (decrease coronary tone, reduce HR).
  • Nitrates (decrease LV preload/wall tension by venodilation).
  • Metabolic modulators (e.g., Trimetazidine).

Management of Acute Chest Pain & STEMI

• Primary PCI vs. Thrombolytics: Primary PCI is superior to fibrinolysis. If a patient presents with a STEMI, do not wait for cardiac biomarkers (troponin) before initiating emergent management (PCI or thrombolytics).
• Cardiac Arrest: Sudden collapse with a provided monitor strip showing Ventricular Fibrillation (V-Fib) requires immediate Defibrillation (unsynchronized cardioversion). If a patient is found unresponsive and gasping for air on the floor, the absolute first step is to initiate CPR.

Complications / Prognosis

• Left Ventricular Function: The single most important prognostic indicator in CAD. Normal EF is 50-75%; an EF <50% significantly increases mortality.
• Extent of Ischemia: Single vessel disease has ~2% annual mortality vs. Left Main Stem disease with ~12% annual mortality.

Past-Paper High Yield

Acute Coronary Syndrome & Medications

• Thrombolytic Contraindications: Absolute contraindications include ischemic stroke within 3 months, intracranial AV malformation, history of intracerebral bleed, and aortic dissection. Active menstrual bleeding is NOT an absolute contraindication.
• Inferior MI & Hypotension: In an inferior STEMI (II, III, aVF) presenting with hypotension (e.g., 90/50 mmHg), use extreme caution with nitroglycerin as it can drop preload and cause severe cardiovascular collapse.
• TIMI Score Criteria: Used in ACS. Includes: Age ≥65, Aspirin use in the past 7 days, elevated cardiac biomarkers (troponin), ≥3 CAD risk factors, and ST depression on ECG.
• Beta-Blockers in Decompensated HF: While standard therapy for stable CHF, beta-blockers (e.g., metoprolol) are strictly contraindicated in ACUTE decompensated heart failure.

Differential Diagnosis of Chest Pain

• Pericarditis: Young patient, sharp pleuritic pain, worsened by lying flat and breathing, improved by sitting up. Often follows a URTI.
  • ECG: Diffuse concave ST elevation and PR depression.
  • Management: NSAIDs and Colchicine. (Colchicine specifically decreases recurrence).
  • Complication: Cardiac tamponade. Steroids are not first-line.
• Pulmonary Embolism (Massive): Presents with severe pleuritic chest pain, dyspnea, and right heart strain. Expected findings include tachycardia, parasternal heave, S3, and loud P2. Reversed splitting of S2 is UNEXPECTED (reversed splitting is seen in left-sided issues like severe aortic stenosis or LBBB).
• Constrictive Pericarditis / Right Heart Failure: Elevated JVP that increases with inspiration (Kussmaul sign). Best next diagnostic step is a Transthoracic Echocardiogram.

Systemic Pathology & Cardiology Intersections

• Cholesterol Crystal Embolization (Atheroembolism): Occurs after vascular procedures. Features include eosinophilia, elevated CRP, progressive decline in eGFR over weeks, and peripheral atherosclerosis (e.g., blue toe syndrome). A positive ANA is not a typical feature.
• Hypertrophic Obstructive Cardiomyopathy (HOCM): Young patient with dyspnea/chest pain on exertion. Beta-blockers (metoprolol), non-dihydropyridine CCBs (verapamil), and disopyramide are indicated. Digoxin is strictly contraindicated as its positive inotropic effect worsens LV outflow tract obstruction.
• Heterozygous Familial Hypercholesterolemia: Expected lipid profile will show drastically elevated Total Cholesterol (e.g., ~320 mg/dL) and LDL (e.g., ~265 mg/dL), with relatively normal HDL and Triglycerides.
• Rivaroxaban Mechanism: Exerts its anticoagulant effect via direct inhibition of Factor Xa.

Memory Pearls

• Nitrates are strictly contraindicated in Inferior MI with Right Ventricular involvement (watch for low BP + Leads II, III, aVF).
• Beta-blockers are strictly contraindicated in Prinzmetal/Variant angina (can worsen unopposed alpha-mediated vasospasm) and Acute Decompensated HF.
• Increased Estrogen is not a risk factor for CAD. Pre-menopausal women have a lower risk of CAD than men of the same age; the risk equalizes post-menopause.

Acute Coronary Syndrome

Core Concepts

• Spectrum of Disease: Stable Angina → Unstable Angina (UA) → NSTEMI → STEMI → Sudden Death.
• Pathophysiology: Characterized by a disrupted atherosclerotic plaque (rupture, erosion, or fissure).
  • Primary hemostasis: Platelet adhesion, activation, and aggregation (forms platelet plug).
  • Secondary hemostasis: Coagulation system activation (forms fibrin clot).
• Plaque Characteristics:
  • Stable Plaque: Thick fibrous cap, lots of smooth muscle cells, intact endothelium, foam cells, lack of inflammatory cells.
  • Vulnerable/Unstable Plaque: Thin fibrous cap, few smooth muscle cells, eroded endothelium, inflammatory cells (activated macrophages).
• Coronary Occlusion & Thrombus Type:
  • UA / NSTEMI: Incomplete (subtotal) occlusion. Prone to distal embolization.
  • STEMI: Complete (total) occlusion.
• Evolution of Infarction: Ischemic (but viable) myocardium begins necrotizing subendocardially within 30 minutes, extending transmurally over 6–12 hours. "Time is Muscle".

Diagnosis / Clinical Features

• Typical Presentation: Sudden, severe retrosternal compressive chest pain radiating to the left shoulder and arm. Lasts >30 minutes. Often at rest or early morning.
• Associated Symptoms: Sweating, nausea, vomiting, severe anxiety.
• Painless MI: Occurs in 10–15% of patients (classic in diabetics and the elderly). May present solely as hypotension, heart failure (e.g., basal crepitations), or arrhythmia.
• Physical Exam: Patient appears anxious and sweaty. Auscultation may reveal S3, S4, new murmurs, or pericardial rubs.
• Unstable Angina Definitions:
  • New onset angina (within 8 weeks).
  • Angina occurring at rest or minimal exertion.
  • Crescendo angina (increasing frequency, duration, or intensity).
  • Post-MI or post-revascularization angina (within 2 weeks).
• Differentials to always consider: Aortic Dissection, Massive Pulmonary Embolism, Acute Pericarditis.

Investigations

• 12-Lead ECG: Essential initial step (Normal ECG does not exclude MI).
  • Ischemic Cascade: Hyperacute T waves → ST-segment elevation → Q-waves → T-wave inversion.
  • STEMI Criteria (in V2–V3):
    • Men ≥40 years: ≥2 mm
    • Men <40 years: ≥2.5 mm
    • Women: ≥1.5 mm
    • ≥1 mm in at least two other adjacent chest or limb leads.
  • New LBBB: Treated as a STEMI. Use Sgarbossa Criteria to diagnose STEMI in the presence of old LBBB (a score ≥3 has 98% specificity).
  • Localization:
    • Inferior: II, III, aVF
    • Lateral: I, aVL, V5, V6
    • Anterior / Septal: V1–V4
• Cardiac Biomarkers:
  • Troponin (T, I): Highly sensitive and specific. Rises in 4–6 hours (high-sensitivity in 2–4 hours), remains elevated for 10–14 days. (Cannot detect early re-infarction). Elevated in myocarditis, PE, renal failure, and sepsis—but normal in pure pericarditis.
  • CK-MB: Rises in 4–6 hours, peaks at 17–24 hours, and normalizes by 72 hours. (Excellent for detecting early re-infarction).
    • Isoforms: CK-MB isoform assay (MB2/MB1 >1.5) is more sensitive than the routine CK-MB assay.
  • Myoglobin: Rises early (2–4 hours), peaks fast (6–12 hours), but lacks cardiac specificity.

Management

• Immediate General Treatment (MONAH):
  • Morphine: Analgesia and anxiolysis (decreases sympathetic tone and O₂ demand). Caution if hypotensive.
  • Oxygen: 2–4 L/min if hypoxemic (SaO₂ < 90%).
  • Nitroglycerin (Sublingual/Spray): Reduces preload and systemic vascular resistance. Contraindicated in hypotension, right ventricular (RV) infarction, or recent PDE-5 inhibitor use.
  • Aspirin: 150–325 mg chewed and swallowed.
  • Heparin: Unfractionated (5000 U IV) or LMWH.
• STEMI Reperfusion Strategy (Goal = Myocardial Salvage):
  • Primary PCI (Preferred): If door-to-balloon time <90 minutes (or within 120 mins of first medical contact).
  • Thrombolysis / Fibrinolysis: If <3 hours from symptom onset AND PCI is unavailable/delayed. Goal door-to-needle is <30 minutes.
    • Absolute Contraindications: Active internal bleeding, suspected aortic dissection, trauma or surgery <2 weeks, history of hemorrhagic stroke, BP >200/120 mmHg, prolonged CPR, recent head trauma / intracranial neoplasm, diabetic proliferative retinopathy, pregnancy.
• UA / NSTEMI Management:
  • NO THROMBOLYTICS.
  • Dual Antiplatelet Therapy (Aspirin + Clopidogrel/Ticagrelor).
  • Anticoagulation (LMWH is superior to unfractionated heparin in this setting).
  • Anti-ischemic therapies (Beta-blockers, Nitrates) and Statins.
  • Invasive PCI strategy for High-Risk patients (TIMI score factors: rest pain >20 min, pulmonary edema, hypotension, new MR/S3, transient ST changes, elevated troponins).

Complications / Prognosis

• Arrhythmias: Most common cause of pre-hospital death. Includes VT/VF, AF (15% in first 24h), and AV blocks.
• Heart Failure & Cardiogenic Shock: Classified by Killip I–IV.
• Mechanical Ruptures (first 10 days):
  • Ventricular Free Wall Rupture (causes tamponade).
  • Ventricular Septal Defect (VSD).
  • Papillary Muscle Rupture (causes acute severe MR).
• Pericardial Complications:
  • Early Pericarditis: Treat with Aspirin. (NSAIDs and steroids are strictly contraindicated).
  • Dressler's Syndrome: Autoimmune reaction 2–12 weeks post-MI. Treat with Aspirin or Ibuprofen.
• Poor Prognostic Indicators: High TIMI risk score, EF <40%, large infarct size, anterior MI, new BBB, re-infarction, advanced age (>70), or history of DM.

Past-Paper High Yield

• Cardiac Markers & Re-infarction: Troponin stays elevated for 10–14 days and cannot be used to detect a secondary ischemic event within the first week. CK-MB normalizes in 72 hours, making it the marker of choice for detecting early re-infarction.
• Isoform Sensitivity: The CK-MB isoform assay (specifically an MB2/MB1 ratio >1.5) is more sensitive than the routine CK-MB assay for early detection.
• Troponin Specificity Traps: Troponin levels are distinctly normal in acute pericarditis, but will be elevated in myocarditis.
• Mechanical Complications (VSD): A sudden drop in blood pressure accompanied by right-sided heart failure (elevated JVP), bilateral crackles, and a new loud systolic murmur with a palpable thrill on days 3–5 post-STEMI strongly indicates a post-infarction Ventricular Septal Defect (VSD). The immediate definitive management is surgical VSD repair.

Memory Pearls

• Time to Normalization: Myoglobin (1 day) → CK-MB (3 days) → Troponin (10–14 days).
• LBBB in ACS: A new LBBB with typical chest pain = STEMI equivalent (Go to Cath/Thrombolysis).
• Inferior MI Trap: Never give nitrates to an inferior STEMI patient with suspected RV extension (look for hypotension, clear lungs, elevated JVP). They are completely preload-dependent.
• Thrombolysis in NSTEMI: Never. Fibrinolytics are reserved strictly for STEMI/New LBBB presentations.

Cardiac Arrhythmias

Core Concepts

• Mechanisms of Arrhythmias: Include increased automaticity, triggered activity (early and delayed afterdepolarizations), and re-entry circuits (macro and micro re-entry).
• ECG Basics & Approach:
  • Rate Calculation:
    • Regular rhythm: 300 / number of large boxes or 1500 / number of small boxes.
    • Irregular rhythm: Number of R waves in a 10-second strip × 6.
  • Axis:
    • Normal: Leads I (+) and II (+).
    • Left Axis Deviation (LAD): Lead I (+), Lead II (-), Lead III (-).
    • Right Axis Deviation (RAD): Lead I (-), Lead II (+), Lead III (+).
  • Intervals:
    • PR: 120–200 ms (3–5 small squares).
    • QRS: < 120 ms (< 3 small squares).
    • QTc: < 460–470 ms (Men); < 470–480 ms (Women). A short QT is notably caused by digitalis toxicity.
  • Hypertrophy Criteria:
    • Right Atrial Enlargement (RAE): P wave amplitude > 2.5 mm in Lead II or > 1.5 mm in V1.
    • Left Atrial Enlargement (LAE): P wave duration ≥ 0.12s (notched in limb leads) or terminal negative portion in V1 ≥ 1 mm wide and deep.
    • Left Ventricular Hypertrophy (LVH): Cornell Criteria (S in V3 + R in aVL > 24 mm in men, > 20 mm in women).
    • Right Ventricular Hypertrophy (RVH): R/S ratio > 1 with negative T wave in V1, or R > 6 mm in V1.

Diagnosis / Clinical Features

• Bradyarrhythmias (Rate < 60 bpm):
  • Sinus Bradycardia: Caused by high vagal tone, ischemia, structural disease, medications, or high athletic conditioning.
  • Sick Sinus Syndrome (SSS): SA node dysfunction common in advanced age. Features marked persistent bradycardia, sinus pauses, and often co-exists with Tachy-Brady Syndrome.
  • AV Blocks:
    • 1st Degree: Prolonged PR interval (> 0.20s), no dropped beats.
    • 2nd Degree Type I (Wenckebach): Progressive PR prolongation followed by a dropped QRS.
    • 2nd Degree Type II: Constant PR interval with intermittently dropped QRS complexes.
    • 3rd Degree (Complete): Complete AV dissociation (P waves and QRS complexes beat independently). P rate > QRS rate. Presents with fatigue and presyncope/syncope.
• Tachyarrhythmias (Rate > 100 bpm):
  • Premature Complexes (PACs & PVCs): Frequent PVCs can take patterns (bigeminy, trigeminy) and run into Non-Sustained VT (NSVT, < 30 seconds).
  • Supraventricular Tachycardia (SVT): Most commonly AV Nodal Re-entrant Tachycardia (AVNRT). Regular, narrow QRS (unless aberrant). Typically presents in patients with structurally normal/healthy hearts. P waves are often hidden or retrograde (short RP).
  • Wolff-Parkinson-White (WPW) Syndrome: Pre-excitation syndrome featuring a Delta wave, short PR, and wide QRS on resting ECG. WPW + SVT can conduct antidromically (wide QRS).
  • Atrial Fibrillation (Afib): Irregularly irregular, absent P waves. High risk of thromboembolism (evaluate with CHA2DS2-VASc score) and LAA thrombus.
  • Atrial Flutter: Regular or irregular, characterized by typical "sawtooth" flutter waves (especially in inferior leads).
  • Multifocal Atrial Tachycardia (MAT): Irregularly irregular narrow-complex tachycardia with ≥ 3 distinct P wave morphologies. Highly associated with severe pulmonary disease (e.g., COPD exacerbations).
  • Ventricular Tachycardia (VT): Wide QRS complexes. Sustained if > 30 seconds. Most common cause is prior MI (scar-mediated re-entry). Polymorphic VT (Torsades de Pointes) is associated with prolonged QT.
  • Ventricular Fibrillation (VFib): Chaotic, irregular wide QRS deflections with no identifiable structure. Represents cardiac arrest.

Investigations

• ECG Analysis Framework for Tachycardia:

• Risk Stratification Scores:
  • CHA2DS2-VASc: Determines anticoagulation need in Afib (CHF, HTN, Age ≥ 75 [2], DM, Stroke/TIA [2], Vascular disease, Age 65-74, Female).
  • HAS-BLED: Estimates major bleeding risk in Afib patients on anticoagulation.

Management

• Bradyarrhythmias & Blocks:
  • Asymptomatic: Observation.
  • Symptomatic (Sinus brady / 1st degree / 2nd degree Type I): Atropine, beta-agonists.
  • High-grade blocks (2nd degree Type II & 3rd degree) or SSS: Indications for pacemaker placement. 3rd-degree block is a medical emergency requiring emergent pacing.
• Supraventricular Tachycardia (SVT):
  • Acute Stable: Vagal maneuvers followed by IV Adenosine (drug of choice for termination).
  • Unstable: Synchronized Direct Current Cardioversion (DCCV).
  • Preventative: Beta-blockers, CCBs, or Catheter Ablation.
• WPW Syndrome:
  • Stable wide-complex tachycardia (WPW + Afib or Antidromic AVRT): IV Procainamide is the treatment of choice.
  • Contraindications: AV nodal blockers are strictly contraindicated (Adenosine, Beta-blockers, CCBs, Digoxin) because they block normal conduction, driving all impulses down the accessory pathway and risking degeneration into VFib.
• Multifocal Atrial Tachycardia (MAT):
  • Treat the underlying cause (e.g., improve oxygenation and ventilation for COPD).
  • Medical control with Non-dihydropyridine CCBs (Diltiazem/Verapamil).
  • Avoid: Beta-blockers (if severe bronchospasm/wheezing is present) and Electrical Cardioversion (which is ineffective for MAT).
• Atrial Fibrillation:
  • Stable: Rate control (Beta-blockers, CCBs, Digoxin) + Anticoagulation (DOACs or Warfarin). Rhythm control (Amiodarone, Sotalol, Ablation, DCCV) if symptomatic despite rate control or in young/new-onset patients.
  • Unstable: Immediate synchronized cardioversion.
  • Cardioversion Rule: If Afib duration is > 48 hours (or unknown), a TEE must be done to rule out left atrial appendage (LAA) thrombus, OR the patient must be anticoagulated for 3 weeks prior to cardioversion.
• Ventricular Arrhythmias:
  • Stable VT: Treat underlying cause (ischemia, electrolytes). IV Amiodarone.
  • Unstable VT (Pulse but hypotensive): Synchronized Cardioversion.
  • Pulseless VT / VFib: Immediate Defibrillation and CPR (Code Blue).
  • Polymorphic VT (Torsades) / Long QT with syncope: Implantable Cardioverter Defibrillator (ICD) is indicated for structural heart disease or high-risk genetic long QT causing syncope.
• Pacemakers & Cardiac Devices:
  • PPM (Permanent Pacemaker): For persistent bradycardia/blocks.
  • ICD: Can pace AND shock. Contains Anti-Tachycardia Pacing (ATP) function.
  • CRT (Cardiac Resynchronization Therapy): Biventricular pacing for heart failure.
  • Magnet use: Placing a magnet over a pacemaker turns it to asynchronous pacing; placing it over an ICD turns the defibrillator OFF.

Complications / Prognosis

• Afib Post-CABG: A common postoperative complication. Preoperative administration of beta-blockers (e.g., Metoprolol) or Amiodarone/Sotalol effectively prevents it. Digoxin does not prevent post-op Afib.
• Electrolyte-driven Arrhythmias: Hypomagnesemia fundamentally disrupts calcium and potassium homeostasis, causing refractory hypokalemia and hypocalcemia. It must be aggressively corrected via IV Magnesium sulfate to stabilize myocardial membranes.

Past-Paper High Yield

• SVT vs. MAT distinction: A young patient with palpitations, HR > 150, normal BP -> SVT -> manage with IV Adenosine. A COPD patient with severe wheezing, palpitations, and irregular rhythm -> MAT -> manage with CCBs (Verapamil/Diltiazem); never give beta-blockers to a wheezing COPD patient, and know that adenosine/cardioversion fail in MAT.
• WPW Tachycardia Traps: If an Afib/WPW patient presents with wide-complex tachycardia, the absolute best next step is Procainamide (if stable) or Cardioversion (if unstable). Choosing Adenosine, CCBs, or Digoxin is a classic board trap that kills the patient.
• The Unstable Patient: "Unresponsive, BP 75/40, chaotic irregular wide QRS" means Ventricular Fibrillation. Do not give Amiodarone or synchronized cardioversion. Defibrillation is the only correct answer.
• SVT characteristics: It is heavily tested that SVT generally affects healthy (structurally normal) hearts, can absolutely be diagnosed via ECG, and is universally terminated by adenosine.
• QT Modifiers: Amiodarone, TCAs, and Macrolides prolong the QT interval (risk for Torsades). Digitalis therapy shortens the QT interval.
• Electrolyte cascades: If given a patient on chronic PPIs presenting with low Mg, low Ca, and low K, the best next step is replacing the magnesium (IV Magnesium Sulfate) to allow the correction of Ca and K.
• AV Block recognition: An older patient presenting with fatigue and presyncope, with an ECG showing P waves marching independently of QRS complexes (3rd-degree block) mandates a Permanent Pacemaker.

Memory Pearls

• Short QT? Think Digitalis. Long QT? Think Torsades (and Macrolides, TCAs, Amiodarone).
• WPW + Afib = FBI (Fast Broad Irregular). Avoid AV node blockers!
• Adenosine is the diagnostic and therapeutic reset button for regular, narrow complex tachycardias.
• Synchronized vs. Unsynchronized: If they have a pulse but are crashing (unstable SVT/Afib/VT), Synchronize. If they are pulseless (VFib/Pulseless VT), Defibrillate (Unsynchronized).
• MAT = Lung issue. Fix the lungs, and give a CCB.

Hypertension

Core Concepts

• Essential Hypertension: Primary elevation of blood pressure (BP) without an identifiable underlying cause; accounts for ~90% of cases.
• Secondary Hypertension: Elevation of BP due to an identifiable, often treatable, underlying cause (e.g., renovascular disease, primary aldosteronism).
• White Coat Hypertension: Consistently elevated office readings but normal out-of-office (home/ambulatory) readings.
• Masked Hypertension: Normal office readings but elevated out-of-office readings; carries a cardiovascular risk similar to sustained hypertension.
• Resistant Hypertension: BP that remains above goal despite concurrent use of 3 antihypertensive agents of different classes (one must be a diuretic) at optimal doses, OR BP controlled but requiring ≥ 4 medications.
• Refractory Hypertension: Resistant HTN that cannot be controlled even with maximal medical therapy ( ≥ 4 drugs) under a specialist.
• Pseudo-Resistant Hypertension: Uncontrolled BP attributable to external factors (poor adherence, inaccurate measurement/cuff size, suboptimal dosing, or white coat effect) rather than true pharmacologic resistance.

Diagnosis / Clinical Features

• Accurate BP Measurement (The "5 Rs"):
  • Rest for 5 minutes before measurement.
  • Refrain from talking, caffeine, smoking, or exercise for 30 minutes prior.
  • Remove upper arm clothing.
  • Rest arm on a supported surface at heart level.
  • Rest feet flat on the floor in a seated position.
  • Note: The bladder width should be at least 40% of arm circumference, and length 80%.
• Diagnostic Thresholds:
  • Clinic: ≥ 140/90 mm Hg (based on JNC-8/traditional) or ≥ 130/80 mm Hg (ACC/AHA 2017 guidelines for elevated risk). Requires at least 2 readings on at least 2 separate visits (unless >180/110 or target organ damage).
  • Home BP Monitoring (HBPM): ≥ 135/85 mm Hg.
  • 24-Hour Ambulatory BP Monitoring (ABPM): 24-hr average ≥ 130/80 mm Hg; Daytime ≥ 135/85 mm Hg; Nighttime ≥ 120/70 mm Hg.
• Signs of Target Organ Damage:
  • Cardiac: Left ventricular hypertrophy (LVH) presenting as an S4 gallop and a left ventricular heave.
  • Vascular: Aortic dissection (tearing chest/back pain, widened mediastinum), generalized atherosclerosis.
  • Renal: Proteinuria, albuminuria, elevated creatinine.
  • Retinopathy: Cotton wool spots, silver wiring, AV nipping (Grade II), flame hemorrhages, papilledema (Grade IV/Malignant).
• Clues for Secondary Hypertension:
  • Renal Artery Stenosis: Abdominal bruits, abrupt onset, recurrent "flash" pulmonary edema, unexplained rise in Cr after starting ACEI/ARB.
  • Primary Aldosteronism: Unprovoked or diuretic-induced hypokalemia, muscle cramps.
  • Pheochromocytoma: Paroxysmal headaches, sweating, tachycardia, pallor.
  • Coarctation of the Aorta: Young patient, high BP in arms + low BP in legs, radial-femoral delay, systolic murmur over the back or right 2nd intercostal space.
  • Obstructive Sleep Apnea (OSA): Obesity, loud snoring, daytime sleepiness.

Investigations

• Primary Workup (for all newly diagnosed patients):
  • Fasting blood glucose / HbA1c (screen for DM).
  • Lipid profile (calculate ASCVD risk).
  • Serum creatinine with eGFR, Serum Na+, K+, Ca2+.
  • Urinalysis (dipstick for protein/blood) and optional Urinary albumin-to-creatinine ratio (UACR).
  • TSH.
  • 12-lead ECG (screen for LVH, prior MI, atrial fibrillation).
• Secondary Workup (Indicated if abrupt onset, <30 years old, drug-resistant, or disproportionate organ damage):
  • Renovascular disease: Renal Doppler ultrasound (best initial), MRA, or CTA.
  • Primary Aldosteronism: Plasma aldosterone/renin ratio.
  • Pheochromocytoma: 24-hour urinary fractionated metanephrines or plasma free metanephrines.
  • Coarctation of Aorta: Echocardiogram.
  • OSA: Sleep study with polysomnography.

Management

• Lifestyle Modifications:
  • DASH Diet: Most effective non-pharmacological intervention (approx. 11 mm Hg reduction).
  • Weight Loss: Approx. 1 mm Hg reduction per 1 kg of body weight lost.
  • Sodium Reduction: <1,500 mg/day optimal (approx. 5-6 mm Hg reduction).
  • Exercise: 90–150 min/week of dynamic/aerobic resistance.
• Pharmacological Therapy:
  • First-line agents: Thiazide diuretics, Calcium Channel Blockers (CCBs), ACE inhibitors (ACEI), Angiotensin Receptor Blockers (ARBs).
  • Beta-blockers are NOT first-line unless there is a compelling indication (e.g., post-MI, HFrEF, stable ischemic heart disease).
  • Thiazide specifics: Chlorthalidone is preferred over Hydrochlorothiazide (HCTZ) due to its significantly longer half-life (40 hrs vs 6-9 hrs) and greater potency.
  • Important Contraindication: Never combine an ACEI with an ARB (increases risk of hyperkalemia and acute kidney injury).
• Comorbidity-Specific Choices:
  • Diabetes / CKD with albuminuria: ACEI or ARB (renal protective). Best combination: ACEI/ARB + CCB.
  • Heart Failure (HFrEF): ACEI/ARB + Beta-blocker + Spironolactone + Diuretic. Avoid non-DHP CCBs (Verapamil/Diltiazem).
  • Pregnancy/Pre-eclampsia: IV Labetalol, oral Methyldopa, or Nifedipine. ACEIs and ARBs are strictly contraindicated.
  • Atrial Fibrillation: ARBs are useful for preventing recurrence. Ensure stroke risk stratification (HTN gives +1 point on CHA2DS2-VASc; uncontrolled HTN also increases bleeding risk on HAS-BLED).
• Managing Resistant Hypertension (Stepwise):
  1. Confirm compliance, exclude white coat effect (using ABPM), and ensure low sodium diet.
  2. Remove interfering medications (e.g., NSAIDs, oral contraceptives, sympathomimetics, licorice).
  3. Substitute optimally dosed thiazide-like diuretic (use Chlorthalidone or Indapamide).
  4. Add a mineralocorticoid receptor antagonist (MRA) (e.g., Spironolactone).
  5. Add a Beta-blocker (if HR > 70) or central alpha-agonist.
  6. Add a direct vasodilator (Hydralazine or Minoxidil).

Complications / Prognosis

• Hypertensive Crises: SBP >180 and/or DBP >120 mm Hg.
  • Urgency: No target organ damage. Reinstitute/intensify oral therapy; do not drop BP too rapidly.
  • Emergency: Acute, ongoing target organ damage (e.g., encephalopathy, acute pulmonary edema, MI). Requires ICU admission and IV medications.
  • General BP Lowering Rule: Reduce SBP by max 25% in the first hour, then to 160/100 over 2-6 hours.
  • Exceptions (Rapid lowering required):
    • Aortic Dissection: Rapidly lower SBP to <120 mm Hg and HR to <60 bpm within the 1st hour (IV Labetalol or Esmolol).
    • Pre-eclampsia/Eclampsia: Rapidly lower to <140 mm Hg (IV Labetalol).
• Acute Pulmonary Edema Secondary to HTN: Treat with IV Nitroglycerin, IV Furosemide, and O2. Morphine is no longer standard of care and is generally avoided.

Past-Paper High Yield

• Resistant HTN + Flash Pulmonary Edema or Bruit: Suspect renal artery stenosis. Next step: Renal Doppler ultrasound.
• Pregnancy / Postpartum Seizures (Eclampsia): BP management relies heavily on IV Labetalol.
• Aortic Dissection Trap: A patient presenting with severe tearing chest/back pain and high BP needs diagnostic imaging (CT Aorta with contrast) before intervention if asked for the "next step in diagnosis/ED management".
• JNC 8 First-Line Rule: Beta-blockers are explicitly excluded as first-line general therapies.
• Thiazide Side Effects: Hydrochlorothiazide and Chlorthalidone elevate uric acid and can trigger acute Gout attacks.
• Physical Exam in Chronic HTN: Non-compliance over decades leads to severe LVH, manifesting as an S4 gallop and left ventricular heave.
• Medication Contraindications:
  • Combining ACE inhibitors (e.g., Lisinopril) and ARBs (e.g., Valsartan) is contraindicated.
  • Sildenafil (PDE5 inhibitor) is absolutely contraindicated with Isosorbide mononitrate (nitrates) due to profound hypotension.
• Coarctation of the Aorta: Suspect in young healthy patients with headaches, high BP in upper extremities, normal/low in lower extremities, and a systolic murmur. Next step: Echocardiogram.
• Valvular Complications: An elderly patient with HTN and severe aortic stenosis (valve area 1 cm², gradient 50 mmHg) should be referred for aortic valve replacement.
• Drug Interference: Remember that NSAIDs can antagonize the effects of almost all antihypertensive classes (except CCBs) by promoting sodium/water retention.

Memory Pearls

• First-line anti-hypertensives: Think A-C-D (ACEI/ARB, CCB, Diuretics). Leave the B (Beta-blockers) for the Broken hearts (HF, IHD).
• Aortic Dissection BP Target: "120 in 20" – SBP <120 mm Hg as fast as safely possible (within the first hour).
• Chlorthalidone vs HCTZ: Chlorthalidone is the "Champion" (longer half-life, stronger evidence for CV reduction).
• Aldosterone/Renin ratio: High Aldo + Low Renin = Primary Aldosteronism (Conn's). High Aldo + High Renin = Secondary (Renovascular stenosis).

Valvular Heart Disease

Core Concepts

• General Principle for Valvular Intervention: Operate for severe disease when accompanied by any symptoms, a drop in LVEF below specific thresholds, or marked LV dilation.
• Volume vs. Pressure Overload:
  • Regurgitant lesions (MR, AR): Cause volume overload. Long asymptomatic phase with progressive LV dilation until decompensation (low output, pulmonary congestion).
  • Stenotic lesions (AS): Cause pressure overload, leading to concentric hypertrophy (Laplace’s law) and eventual LV dysfunction.
• Acute vs. Chronic Regurgitation:
  • Acute (MR, AR): Heart lacks time to dilate/compensate. Presents as abrupt cardiogenic shock or pulmonary edema. Murmurs are often short, soft, or completely absent.
  • Chronic (MR, AR): Gradual dilation accommodates volume, leading to loud, classic murmurs and a prolonged asymptomatic phase.

Diagnosis / Clinical Features

• Aortic Stenosis (AS)
  • Etiology by Age: Congenital bicuspid/unicuspid (<30 yrs), Calcified bicuspid or rheumatic (40–60 yrs), Senile degenerative calcification (>70 yrs, most common overall, occurs on native 3-cusp valve).
  • Symptoms: Angina, Syncope, Dyspnea (Heart Failure).
  • Exam: Late-peaking systolic ejection murmur, soft or absent A2, S4.
  • Subtypes: Supravalvular (loud A2, thrill in suprasternal notch/R carotid); Subvalvular (discrete ridge, frequently accompanied by AR).
• Aortic Regurgitation (AR)
  • Etiology: Intrinsic valve (degenerative, bicuspid, endocarditis, rheumatic, anorectics) vs. Aortic root (dissection, Marfan, Giant cell arteritis).
  • Exam: Wide pulse pressure, de Musset’s (head bobbing), Quincke’s (capillary pulsations), Corrigan’s (water-hammer pulse), Duroziez’s (pistol-shot femoral).
  • Acute AR Exception: May lack bounding pulses; urgent presentation.
• Mitral Regurgitation (MR)
  • Etiology: Primary/Valve (Degenerative, Rheumatic); Secondary/Ventricle (Dilated CM, Ischemic/Papillary muscle tethering). Acute causes include chordal rupture, endocarditis, ischemic papillary rupture.
  • Exam: Pansystolic murmur, loud P2, S3 (early filling).
• Mitral Stenosis (MS)
  • Etiology: Rheumatic (most common), degenerative calcification.
  • Exam: Loud S1, opening snap, mid-to-late diastolic rumble.
  • Pathophysiology: Normal LV function, but elevated LA pressure → pulmonary hypertension, atrial fibrillation, RV failure, hemoptysis, and systemic emboli.
• Tricuspid Regurgitation (TR)
  • Etiology: Primary (rheumatic, pacemaker lead, carcinoid, endocarditis) vs. Secondary (pulmonary HTN, dilated CM, AFib/annular dilation).
  • Exam: Elevated JVP, pulsatile enlarged liver, peripheral edema/ascites.
  • Murmur: Pansystolic murmur at the left lower sternal border that increases with inspiration (Carvallo's sign).

Investigations

• Transthoracic Echocardiogram (TTE): First-line test to assess severity, etiology, and chamber anatomy.
  • Note on Acute Lesions: Acute MR may show a hyperdynamic LV with only "mild" MR due to equalization of pressures.
• Transesophageal Echocardiogram (TEE): Indicated if TTE is negative/inconclusive, especially for suspected infective endocarditis (IE), chordal rupture, or aortic dissection.
• AS Hemodynamic Criteria: Mean gradient ≥ 40 mmHg is severe (a mean gradient of ~20-22 mmHg is moderate, not severe).

Management

• Aortic Stenosis
  • Medical: Mild AS + AFib → standard AFib management (rate control/anticoagulation); valve does not require intervention yet.
  • Surgical (AVR/TAVR): Indicated for severe AS with symptoms, LV dysfunction, or exercise-induced symptoms. Advanced age is not a contraindication for valve replacement.
• Aortic Regurgitation
  • Acute AR: Beta-blockers and vasopressors (afterload enhancers) are strictly contraindicated! Use afterload reducers (vasodilators) and inotropes as a bridge to urgent surgery.
  • Chronic AR: AVR indicated if severe AR + (Symptoms OR LVEF < 50% OR severe LV dilation). No vasodilators if asymptomatic with normal LV.
• Mitral Regurgitation
  • Acute MR: Afterload reduction (vasodilators, IABP). Immediate surgery for papillary muscle rupture or dehisced prosthesis.
  • Chronic Primary MR: Surgery (repair/MVR) if symptomatic, LVEF < 60%, or LV dilation. No vasodilators if asymptomatic with normal LV.
  • Chronic Secondary MR: GDMT for heart failure, treat ongoing ischemia. Consider percutaneous Mitra-Clip if severe symptoms persist.
• Mitral Stenosis
  • Symptom-driven. Percutaneous mitral balloon commissurotomy (PMBC) if feasible; otherwise, surgery. Mandatory anticoagulation for concomitant AFib.
• Tricuspid Regurgitation
  • Operate if severe/symptomatic and failing diuretics, or if left-sided surgery is already planned. If pacemaker-induced, remove lead. If AFib-induced, attempt rhythm control first.
• Infective Endocarditis (IE) Prophylaxis
  • Indicated: Prosthetic valves (e.g., prior MVR/AVR, bioprosthetic or mechanical) undergoing dental procedures.
  • Not Indicated: Native bicuspid aortic valves, or a history of rheumatic fever without valvular involvement.

Complications / Prognosis

• Aortic Stenosis Progression: Once symptomatic, prognosis drops precipitously. Heart failure (dyspnea) has the worst prognosis (~2 years), followed by syncope (~3 years) and angina (~5 years).
• Acute Non-Valvular Mimics: A young patient with acute heart failure (e.g., LVEF 30%, S3, pulmonary congestion), fever, and tachycardia but no evidence of valvular disease likely has viral myocarditis. Treatment is Guideline-Directed Medical Therapy (GDMT) for HFrEF (e.g., Captopril and Carvedilol)—do not empirically give antibiotics, tPA, or steroids.

Past-Paper High Yield

• The 81yo with severe AS and angina:
  • The most likely etiology is senile degenerative, meaning the native valve usually has 3 cusps (not bicuspid or rheumatic).
  • Age is never an absolute contraindication for aortic valve replacement (TAVR is highly utilized).
  • A mean gradient of 22 mmHg is not severe (must be >40 mmHg).
  • Dyspnea (Heart Failure) has the worst prognosis, not angina.
• Murmur Differentiation: A pansystolic murmur at the left lower sternal angle that increases with inspiration is TR, not MR.
• Myocarditis vs. Valvular Emergency: A patient presenting with fever, acute dilated cardiomyopathy/HFrEF, and normal valves on echo does not get Vancomycin/Ceftriaxone. Standard HF therapy (Captopril + Carvedilol) is the correct answer.
• Prophylaxis Trap: Dental prophylaxis is required for an MVR placed 5 years ago, but not for an unoperated bicuspid valve or a history of rheumatic fever without valve damage.
• Asymptomatic AFib + Mild AS: Do not intervene on the valve. Manage the AFib medically (rate control/anticoagulants) and monitor the AS.

Memory Pearls

• Surgery LVEF cutoffs for Asymptomatic Regurgitation:
  • MR = EF drops below 60%
  • AR = EF drops below 50%
• Acute AR Medical Rules: Vasodilators = Good. Pressors/Beta-blockers = Fatal (worsens regurgitant time/pressure).
• AS Symptoms (SAD): Syncope (3 yrs), Angina (5 yrs), Dyspnea (2 yrs - worst prognosis).
• Right-sided murmurs (TR): IN-spiration IN-creases right-sided murmurs.

Infective Endocarditis

Core Concepts

• Definition: Infection of the endocardial surface of the heart, most commonly affecting the heart valves.
• Microbiology:
  • Staphylococcus aureus: Most common cause of acute infective endocarditis (IE), right-sided (IV drug use) IE, and cardiac device-related infections.
  • Viridans group Streptococci: Most common cause of subacute IE, heavily associated with dental procedures.
  • Enterococcus species: Associated with genitourinary or gastrointestinal pathology.
• When to suspect:
  • New left-sided valvular regurgitation.
  • Unexplained fever ≥ 48 hours + Risk factors (valvular heart disease, prosthetic valves, IV drug use, congenital heart disease, immunocompromised state).

Diagnosis / Clinical Features

Diagnosis is established using the Modified Duke Criteria.

• Definite IE: 2 Major OR 1 Major + 3 Minor OR 5 Minor (or pathological evidence).
• Possible IE: 1 Major + 1 Minor OR 3 Minor.
• Rejected IE: Alternative diagnosis established, resolving with <4 days of antibiotics, or no pathological evidence with <4 days of antibiotics.

Major Criteria

1. Positive Blood Cultures: Multiple positive sets of typical microorganisms, or a single positive culture for Coxiella burnetii.
2. Endocardial Involvement: Vegetation, abscess, prosthetic valve dehiscence, or new valvular regurgitation.

Minor Criteria

1. Predisposition: High-risk heart condition or IV drug use.
2. Fever: ≥ 38.0°C (100.4°F).
3. Vascular Phenomena (Septic/Embolic):
   • Janeway lesions: Painless septic emboli on palms/soles.
   • Splinter hemorrhages (embolic).
   • Mycotic aneurysms, cerebral hemorrhage, conjunctival hemorrhages, embolic infarcts (e.g., renal, splenic).
4. Immunologic Phenomena (Immune-complex mediated):
   • Osler's nodes: Painful necrotizing vasculitis on pads of fingers/toes.
   • Roth spots: Exudative retinal lesions with pale centers.
   • Glomerulonephritis, positive Rheumatoid Factor (RF).
5. Microbiologic Evidence: Positive blood cultures not meeting Major criteria.

Investigations

• Blood Cultures: Must be drawn BEFORE initiating antibiotics.
  • Acute: 2-3 sets drawn >1 hour apart.
  • Subacute: 3 sets drawn >6 hours apart.
• Echocardiography:
  • TTE (Transthoracic): First-line test for all suspected IE.
  • TEE (Transesophageal): Indicated if TTE is non-diagnostic, complications are suspected (e.g., abscess), intra-cardiac leads are present, prosthetic valve + persistent fever, or S. aureus bacteremia.
• Cardiac CT: Useful if perivalvular extension/abscess is suspected.

Management

Medical Therapy

• Requires prolonged (typically weeks), parenteral (IV), and bactericidal antibiotics.
• Target most likely organisms (Viridans Strep, Staphylococcus, Enterococcus).
• Right-Sided IE (Classic in IVDU with S. aureus):
  • Uncomplicated MSSA: Beta-lactam x 2–6 weeks.
  • MRSA: Vancomycin x 6 weeks.

Anticoagulation in IE

• Absolute Rule: Discontinue ALL forms of anticoagulation for ≥ 2 weeks if a patient with mechanical valve IE develops a CNS embolic event (ischemia or hemorrhagic stroke).
• Do NOT start aspirin or antiplatelet agents as adjunctive therapy in IE.

Surgical Management

• Indications for early surgery: Valvular destruction causing heart failure, perivalvular extension (e.g., abscess causing heart block), extensive stroke/hemorrhage (though surgery is delayed 4 weeks if extensive CNS hemorrhage occurs), relapsing prosthetic valve IE, or large vegetation ≥ 20 mm with recurrent pulmonary emboli.
• Device Infections (Pacemakers/ICDs):
  • S. aureus bacteremia + vegetation requires complete removal of both the device generator and all leads, even if the pocket appears clean.
  • Re-implantation: Wait for negative blood cultures (72 hours post-removal for simple bacteremia, 14 days if valves were involved). Place in the contralateral site.

Complications / Prognosis

• Local: Valvular destruction → Heart Failure (most common cause of death).
• Perivalvular extension: Abscess formation into the conduction system → Heart Block (look for new PR prolongation or complete block).
• Systemic: Embolization to CNS (stroke/mycotic aneurysm), kidneys (flank pain/hematuria), or spleen.

Past-Paper High Yield

• Most Common Pathogen: Staphylococcus aureus is the most common cause of acute infective endocarditis.
• Prophylaxis Indications Trap: You must have both a high-risk patient AND a high-risk procedure.
  • High-Risk Patients: Prosthetic valves/material, prior IE history, unrepaired cyanotic congenital heart disease, or heart transplant with valvulopathy. (Note: Bicuspid aortic valve, MVP, and acquired valve disease do NOT require prophylaxis).
  • High-Risk Procedures: Dental procedures involving gingival manipulation/mucosal perforation, or respiratory tract incision/biopsy (e.g., bronchoscopy with biopsy).
  • NO Prophylaxis Needed: Routine GI/GU procedures (e.g., colonoscopy) require NO prophylaxis, even in a patient with a mechanical valve.
• Prophylaxis Regimen: Amoxicillin 2g PO (single dose 30-60 minutes before the procedure) targeting Viridans group Streptococci.
• Anticoagulation Trap: If a patient on warfarin for a mechanical valve gets IE and suffers a stroke/TIA, the correct answer is to STOP warfarin completely (do not bridge, do not switch to DOAC/Aspirin).

Memory Pearls

• Osler's nodes = Ouch (painful, immune complex).
• Janeway lesions = Just septic emboli (painless).
• New conduction abnormality (Heart Block) + Endocarditis = Aortic root abscess (perivalvular extension).
• *Right-sided IE (Tricuspid) = IVDU = S. aureus. Embolizes to the L*ungs (septic pulmonary emboli).

Heart Failure

Core Concepts

• Definition: A clinical syndrome caused by structural or functional cardiac abnormalities that impair ventricular filling (diastole) or ejection (systole).
• Pathophysiology: Initial compensatory mechanisms (Frank-Starling law, neurohumoral activation via RAAS and sympathetic nervous system) maintain cardiac output but eventually cause deleterious left ventricular (LV) remodeling, myocyte apoptosis, and systemic fluid overload.
• Phenotypes based on LVEF:
  • HFrEF (Reduced): LVEF ≤ 40% (systolic dysfunction).
  • HFpEF (Preserved): LVEF ≥ 50% (diastolic dysfunction).
  • Borderline/Mid-range: LVEF 41–49%.
• Clinical Classification:
  • ACC/AHA Stages (A–D): Based on structural disease progression (A = high risk, no structural disease; D = refractory end-stage).
  • NYHA Class (I–IV): Based on functional capacity and symptom severity (I = no limitations; IV = symptoms at rest).
  • Hemodynamic Profiles: Assessed by perfusion ("Warm" vs. "Cold") and congestion ("Dry" vs. "Wet").

Diagnosis / Clinical Features

• Left-Sided Failure (Low Output & Pulmonary Congestion):
  • Fatigue, orthopnea, paroxysmal nocturnal dyspnea (PND).
  • Physical exam: Bibasilar rales, S3 gallop (in acute volume overload), laterally displaced point of maximal impulse (PMI), pulsus alternans (end-stage indicator).
• Right-Sided Failure (Systemic Congestion):
  • Elevated JVP, hepatosplenomegaly, peripheral edema, weight gain.
  • Cardiac Ascites: Presents with a high Serum-Ascites Albumin Gradient (SAAG > 1.1) and high ascitic fluid protein (> 2.5 g/dL or 25 g/L), distinguishing it from cirrhotic ascites (which has low protein).

Investigations

• Echocardiography: The single most important initial test to evaluate chamber sizes, wall thickness, valvular function, and calculate LVEF.
• Biomarkers (BNP & NT-proBNP):
  • The most accurate biomarker for diagnosing HF and differentiating cardiac from non-cardiac causes of dyspnea.
  • A normal level in an untreated patient virtually excludes heart failure.
  • Prohormone Physiology: Cleaved into biologically active BNP and inactive NT-proBNP.
  • Caveats: Levels increase naturally with age and renal dysfunction; levels are falsely decreased in obese patients.
• Electrocardiogram (ECG): Look for arrhythmias (AFib), evidence of prior MI (Q waves), or conduction abnormalities like LBBB (which impacts device therapy decisions).
• Chest X-Ray: Cardiomegaly, pulmonary venous redistribution, interstitial edema (Kerley B lines), and pleural effusions.
• Invasive Hemodynamics (Swan-Ganz): A pulmonary capillary wedge pressure (PCWP) > 18 mmHg confirms cardiogenic pulmonary edema, whereas a PCWP < 18–19 mmHg indicates ARDS.

Management

Core Prognostic Therapy for HFrEF (The "Pillars" that reduce mortality):

1. ARNI / ACEI / ARB: Sacubitril/valsartan (ARNI) is now the preferred first-line agent over ACEI/ARB to reduce hospitalizations and death.
2. Beta-Blockers: Specifically bisoprolol, carvedilol, or sustained-release metoprolol.
3. Mineralocorticoid Receptor Antagonists (MRAs): Spironolactone or eplerenone. (Watch for hyperkalemia and gynecomastia).
4. SGLT2 Inhibitors: Dapagliflozin or empagliflozin are heavily recommended for HFrEF, regardless of whether the patient has diabetes.

Symptomatic Therapy:

• Loop Diuretics (Furosemide): Relieve congestion but have no proven mortality benefit.

Adjunctive Therapies (Condition-Specific):

• Hydralazine + Isosorbide Dinitrate: Indicated for symptomatic African American patients despite optimal therapy, or for patients unable to tolerate RAAS inhibitors due to hyperkalemia or renal failure.
• Ivabradine: Selectively inhibits the I_f current in the SA node. Indicated for patients in normal sinus rhythm with a resting HR ≥ 70 bpm and EF ≤ 35% who are already on maximally tolerated beta-blockers.
• Digoxin: Acts via positive inotropy and negative dromotropy. Reduces HF hospitalizations and improves symptoms but does not reduce all-cause mortality.

Device Therapy:

• ICD (Implantable Cardioverter-Defibrillator): Primary prevention of sudden cardiac death for patients with an LVEF ≤ 35%.
• CRT (Cardiac Resynchronization Therapy): Biventricular pacing to reverse LV remodeling. Indicated for symptomatic patients (NYHA II–IV) with an LVEF ≤ 35% and a wide QRS complex (LBBB with QRS ≥ 120 ms).

Complications / Prognosis

• Heart failure is progressive and carries severe mortality (~20% at 1 year, ~40% at 5 years).
• Complications include pulmonary edema, deep vein thrombosis (DVT), arrhythmias, and in severe right heart failure, protein-losing enteropathy.
• Note: While diabetes is a common comorbidity and risk factor, developing Type 2 Diabetes is not a direct complication of heart failure.

Past-Paper High Yield

• Differentiating ARDS vs. Cardiogenic Edema: Always look at the PCWP. A wedge pressure < 19 mmHg confirms ARDS, ruling out a primary cardiogenic cause.
• Digoxin Toxicity: Commonly presents with anorexia, nausea, and vomiting. Remember the metabolic precipitants: hypokalemia, hypomagnesemia, hypoxia, and renal failure. Trap: Hypocalcemia does NOT predispose to digoxin toxicity; rather, hypercalcemia is the sensitizing factor.
• BNP Traps: You must know that circulating levels of natriuretic peptides increase with age (do not be tricked by an option stating they decrease).
• Ascites Analysis: If a patient presents with increased abdominal girth, a high SAAG (> 1.1) coupled with high fluid protein (> 2.5 g/dL) is classic for congestive heart failure, NOT cirrhosis or nephrotic syndrome.
• Aortic Stenosis & HF: Heart failure is the most ominous presentation of severe AS. Trap: Using vasodilators in these patients is contraindicated and does not improve the presentation, as it can cause catastrophic hypotension.

Memory Pearls

• Survival Drugs in HFrEF: Beta-blockers, ARNI/ACEI/ARB, Aldosterone antagonists (MRAs), SGLT2 inhibitors. (BAAS improves survival; Diuretics/Digoxin do not).
• CRT Indication Rule of 3s: EF < 35%, NYHA class ≥ II, LBBB QRS > 120 ms.
• Digoxin Toxicity Precipitants: Low K+, Low Mg2+, High Ca2+.

Cardiomyopathies

Core Concepts

• Definition: A heterogeneous group of myocardial diseases associated with mechanical/electrical dysfunction, usually exhibiting inappropriate hypertrophy or dilation. They can be confined to the heart or part of a systemic disorder.
• WHO Classification:
  • Dilated: Enlarged ventricles with systolic dysfunction.
  • Hypertrophic: Thickened walls with diastolic dysfunction.
  • Restrictive: Stiff/rigid ventricles with diastolic dysfunction.
  • Arrhythmogenic RV Dysplasia (ARVD): Fibrofatty replacement of the RV.
  • Unclassified: Includes LV noncompaction and fibroelastosis.
• MOGES Classification System: Categorizes by Morphology (phenotype), Organ involvement, Genetics, Etiology, and Stage.

Diagnosis / Clinical Features

Hypertrophic Cardiomyopathy (HCM)

• Genetics: Autosomal dominant in ~50-55% of cases. Caused by mutations in genes encoding sarcomere proteins (most commonly β-Myosin Heavy Chain [β-MHC], Myosin binding protein C, Cardiac troponin T, and α-tropomyosin).
• Pathophysiology: Vigorous systolic function but severely impaired diastolic function (impaired relaxation leading to elevated diastolic pressures). Left ventricular hypertrophy occurs without pressure overload.
• Clinical Presentation: Exertional dyspnea is the most common symptom.
• Physical Exam:
  • Bisferiens pulse ("spike and dome") / jerky carotid pulse.
  • S4 gallop.
  • Crescendo-decrescendo systolic ejection murmur.
  • May also have a holosystolic apical blowing murmur (due to Mitral Regurgitation from Systolic Anterior Motion [SAM] of the mitral valve).
• Murmur Dynamics (HCM vs. Aortic Stenosis):

Dilated Cardiomyopathy (DCM)

• Characterized by myocyte damage leading to reduced systolic function ± heart failure.
• Frequently idiopathic; 3x more prevalent in males and African-Americans.
• May present primarily with arrhythmias before overt heart failure.

Restrictive Cardiomyopathy (RCM)

• Characterized by severely impaired ventricular filling (intraventricular pressure rises precipitously with small volume increases) with normal systolic function.
• Amyloidosis: Restrictive physiology due to interstitial deposits of misfolded protein fibrils (AL or ATTR) replacing contractile elements.
• Sarcoidosis: Non-caseating granulomas causing restriction, conduction system blocks, and ventricular arrhythmias (risk of Sudden Cardiac Death [SCD]).
• Endomyocardial Fibrosis: Endemic in equatorial Africa (15-25% of cardiac deaths). Associated with hypereosinophilic syndrome (Löffler’s endocarditis). Causes apical obliteration, MR, and basal inferior wall thickening.

Arrhythmogenic RV Dysplasia (ARVD)

• Genetics: Autosomal dominant mutations in desmosome genes (e.g., PKP2 [plakophilin-2] and DSP [desmoplakin]).
• Pathophysiology: Cell death and fibrofatty replacement of the RV free wall.
• Clinical: Causes regional RV wall motion abnormalities, ventricular arrhythmias, and SCD, classically in young athletes.

LV Noncompaction

• Hereditary condition featuring prominent trabeculations and deep recesses in the LV apex.

Investigations

• HCM:
  • ECG: Normal sinus rhythm, LVH, prominent septal Q waves.
  • Echocardiogram (Diagnostic): Shows asymmetric septal hypertrophy (septum >1.4x free wall), Systolic Anterior Motion (SAM) of the mitral valve, and an LVOT gradient.
  • Cardiac Catheterization: Brockenbrough-Braunwald Sign (failure of aortic pulse pressure to rise post-PVC).
• ARVD:
  • ECG: Epsilon wave (delayed repolarization notch following the QRS complex).
  • Echocardiogram: Enlarged RV with strictly normal LV size and function.
  • Imaging: Contrast-enhanced Cardiac MRI (CMR) is highly sensitive for assessing RV dysplasia and fibrofatty replacement.
• DCM / LV Noncompaction: Genetic testing is generally indicated for non-ischemic cardiomyopathies to determine etiology, prognosis, and ICD indications. Screen offspring.

Management

• HCM:
  • Medical: β-blockers (1st line to ↓ myocardial O2 demand, ↓ exercise gradient, and ↓ arrhythmias). Calcium channel blockers are also used.
  • Surgical: Surgical myectomy or alcohol septal ablation for severe symptoms with high outflow gradients.
  • Endocarditis: Antibiotic prophylaxis is recommended.
• ARVD:
  • Strict cessation of heavy physical exertion and competitive athletics.
  • Epicardial catheter ablation for recurrent VT.
  • Cardiac transplantation for intractable HF.
• Sarcoidosis: Glucocorticoids, supplemented by immunosuppressants if needed.
• ICD Indications:
  • HCM: Prior SCD, non-sustained VT, family history of SCD in young relatives, septal thickness ≥30 mm, unexplained syncope.
  • ARVD: Indicated for survivors of VF or refractory VT.

Complications / Prognosis

• HCM Sudden Cardiac Death: The incidence of SCD directly correlates with maximum left ventricular wall thickness (especially ≥30 mm). Mortality is ~1% per year.
• Endomyocardial Fibrosis: Extremely poor prognosis; 80-90% die within 1-2 years.
• LV Noncompaction: High risk of CHF, Ventricular Tachycardia/SCD, and intraventricular thrombosis.

Past-Paper High Yield

• HCM Physiology Trap: HCM is a diastolic dysfunction, not a systolic dysfunction. The echo is diagnostic, inheritance is ~50% autosomal dominant, exertional dyspnea is the most common symptom, and a jerky carotid pulse is classic.
• Pulsus Paradoxus Trap: A significant drop in blood pressure during inspiration (>10 mmHg) is a classic sign of Cardiac Tamponade, Severe COPD, Asthma, or massive PE. HCM does NOT cause pulsus paradoxus (highly tested distractor).
• ARVD Classic Presentation: A young female or athlete presenting with syncope after exercise, a family history of SCD, an ECG with Epsilon waves, and an Echo showing an isolated enlarged RV (normal LV) has ARVD.

Memory Pearls

• HCM Murmur Dynamics: "Stand up to HOCM" (Standing up / Valsalva decreases venous return, shrinks the LV cavity, worsens the obstruction, and makes the murmur louder).
• Cardiomyopathy Genes:
  • HCM = Sarcomere mutations (β-MHC, binding proteins).
  • ARVD = Desmosome mutations (cell-to-cell adhesion fails under mechanical stress of exercise).
• Brockenbrough-Braunwald Sign: Unique to dynamic LVOT obstruction (HCM). After a PVC, the compensatory pause leads to a stronger contraction, which actually worsens the outflow tract obstruction and drops the post-PVC aortic pulse pressure.

Pericardial Diseases

Core Concepts

• The Pericardium: A fibroelastic sac with visceral and parietal layers separated by the pericardial cavity (normally contains 15–50 mL of plasma ultrafiltrate). Provides mechanical protection, anchoring, and lubrication.
• Acute Pericarditis: Inflammation of the pericardial sac. Often viral/idiopathic but can be the first sign of systemic disease. Termed myopericarditis if myocardial inflammation is also present (positive biomarkers).
• Pericardial Tamponade: Accumulation of fluid under high pressure that compresses the heart, severely restricting venous return and cardiac output.
• Constrictive Pericarditis: Thick, dense fibrous obliteration and calcification of the pericardial sac. Encases the heart, limiting diastolic expansion and restricting cardiac output.

Diagnosis / Clinical Features

Acute Pericarditis

• Chest Pain (>95% of cases): Sudden onset, anterior, sharp, and pleuritic (worse with inspiration/coughing).
• Positional Relief: Characteristically improves by sitting up and leaning forward (reduces pressure on the parietal pericardium and allows diaphragmatic splinting).
• Pericardial Friction Rub: Highly specific. A superficial, scratchy/squeaking sound best heard with the stethoscope diaphragm over the left sternal border.
• Associated Symptoms: May be preceded by flu-like, respiratory, or GI symptoms.

Pericardial Tamponade

• Causes: Neoplasm (e.g., lymphoma), trauma, uremia, anticoagulation, infection.
• Beck's Triad: Hypotension, Jugular Venous Distension (JVD), and Muffled/distant heart sounds.
• Pulsus Paradoxus: An abnormally large drop in systolic blood pressure (>10 mmHg) during inspiration.
• Other features: Dyspnea, significant tachycardia.

Constrictive Pericarditis

• Causes: Prior cardiac surgery, viral infection/acute pericarditis, mediastinal radiation, rheumatoid arthritis, or connective tissue disease (CTD).
• Right Heart Failure Signs: Fatigue, JVD, hepatomegaly, ascites, and peripheral edema.
• Kussmaul's Sign: Paradoxical lack of fall, or actual elevation, of the JVP during inspiration.
• Pericardial Knock: An early diastolic sound.
• Arrhythmia: Atrial fibrillation occurs in 20% of cases.

Investigations

Electrocardiogram (ECG)

• Acute Pericarditis:
  • Stage 1 (Hours–Days): Diffuse, concave-upward ST elevation with PR segment depression. Reciprocal ST depression and PR elevation in leads aVR and V1 (reflects atrial current of injury).
  • Stage 2 (First Week): Normalization of ST and PR segments.
  • Stage 3: Diffuse T wave inversions (develops after ST segments become isoelectric).
  • Stage 4: Normalization, or indefinite persistence of T wave inversions ("chronic" pericarditis).
• Tamponade: Electrical alternans (beat-to-beat alteration in QRS amplitude) and low voltage QRS complexes.
• Chronic Post-MI (Differentials): Persistent ST-elevation years after an MI suggests a left ventricular aneurysm, not acute pericarditis.

Echocardiography (TTE)

• Acute Pericarditis: Often normal unless an associated effusion is present.
• Tamponade: Pericardial effusion, Right Ventricular (RV) diastolic collapse (highly specific), increased respiratory variation of peak inflow velocities across tricuspid and mitral valves, and a dilated IVC without respiro-phasic variation.

Imaging & Labs

• Chest X-Ray (CXR):
  • Pericarditis: Typically normal. Large effusions may show an enlarged cardiac silhouette with clear lung fields.
  • Constrictive Pericarditis: Pericardial calcification (Note: Absence of calcification does not rule out constrictive pericarditis).
• Labs: Leukocytosis, elevated ESR, elevated CRP. Elevated Troponin or CK-MB indicates myopericarditis.

Management

Acute Pericarditis

• First-line (Idiopathic/Viral): NSAIDs + Colchicine (combination therapy preferred).
• Post-Myocardial Infarction: Aspirin + Colchicine.
  • Crucial rule: AVOID other NSAIDs and glucocorticoids post-MI, as they interfere with myocardial healing and scar formation (risk of rupture).
• Glucocorticoids (Steroids): NOT first-line. Reserved for CTD, autoreactive pericarditis, uremic pericarditis non-responsive to dialysis, contraindications to NSAIDs, or refractory cases.
• Recurrent Pericarditis (up to 30% of cases): NSAID with a 2- to 4-week taper + at least 6 months of weight-adjusted Colchicine. Refractory cases use steroids, IL-1 inhibitors (anakinra, rilonacept), or immunosuppressants (Azathioprine, MTX, IVIG).
• High-Risk Features (Require admission/aggressive tx): High fever (>38°C), subacute onset, large effusion/tamponade, lack of response to NSAIDs after 1 week, myocardial involvement, immunosuppression, trauma, or oral anticoagulation.

Pericardial Tamponade

• Hemodynamically Unstable: Pericardiocentesis is the immediate next step (or surgical drainage). Provide aggressive IV fluids. Use Intra-Aortic Balloon Pump (IABP) for refractory hypotension. Minimize PEEP.
• Hemodynamically Stable: IV fluids, close monitoring, serial TTE, and treat the underlying cause.

Constrictive Pericarditis

• Initial: Diurese and rate-control with caution. Provide a 2-3 month trial of conservative measures.
• Definitive: Pericardiectomy.
  • Indicated in: NYHA Class II or III with persistent symptoms.
  • Negligible benefit in: NYHA Class IV, cachexia, cirrhosis, or markedly reduced cardiac output.

Past-Paper High Yield

• Tamponade vs. Next Step: A patient with a history of neoplasm (e.g., lymphoma) presenting with shock (hypotension, tachycardia), pulsus paradoxus, and Beck's triad has cardiac tamponade. The immediate next step is Pericardiocentesis.
• Constrictive Pericarditis Diagnosis: A patient with recurrent URTIs (viral etiology) presenting with dyspnea, Kussmaul's sign (↑ JVP on inspiration), and a CXR showing pericardial calcification has Constrictive Pericarditis.
• Colchicine's Role: In the treatment of acute pericarditis, Colchicine is specifically utilized because it decreases the recurrence rate. (Steroids are not first-line).
• ECG Distractors: A patient presenting years after an anterior MI with mild exertional dyspnea and stable, persistent ST-segment elevations (e.g., V2-V4) is exhibiting a Left Ventricular Aneurysm, not acute pericarditis, Dressler's syndrome (which occurs weeks post-MI), or coronary spasm.

Memory Pearls

• Kussmaul's Sign vs. Pulsus Paradoxus:
  • Kussmaul's sign (JVP ↑ with inspiration) = Constrictive Pericarditis (and restrictive cardiomyopathies/RV failure).
  • Pulsus Paradoxus (Systolic BP ↓ >10 mmHg with inspiration) = Cardiac Tamponade (also seen in severe asthma/COPD).
• Post-MI Pain: If the patient leans forward and the pain improves, it's acute pericarditis. Use Aspirin, not Ibuprofen or Corticosteroids.
• Electrical Alternans: The heart is literally swinging back and forth in a massive pool of fluid (Tamponade), changing the electrical axis beat by beat.

Hypertensive Emergencies

Core Concepts

• Definition: Severe hypertension characterized by a systolic BP > 180 mmHg and/or diastolic BP > 120 mmHg.
  • Hypertensive Emergency (Crisis): Elevated BP accompanied by acute impairment of an organ (end-organ damage).
  • Hypertensive Urgency: Elevated BP with potential risk but no acute end-organ damage.
• Pathophysiology:
  • The rate at which Mean Arterial Pressure (MAP) rises is more important than the absolute rise.
  • Acute rise → Autoregulation failure (failure of vasoconstriction) → Endothelial damage (shear stress).
  • Results in Fibrinoid Necrosis of arterioles → Activation of coagulation/inflammation and protein deposition in the vessel wall.
  • RAAS activation perpetuates the BP rise via vasoconstriction and fluid retention.
• Epidemiology: Highest risk in males, African Americans, and middle-aged patients (peak age 40–50 years).

Diagnosis / Clinical Features

Assess primarily for signs of acute end-organ damage across three main systems:

• Central Nervous System (CNS):
  • Hypertensive encephalopathy (headache, blurred vision, confusion, altered mental status, nausea/vomiting, seizures, stupor, coma).
  • Ischemic or hemorrhagic stroke (focal neuro deficits).
  • Fundoscopy: Papilledema, hemorrhages, and exudates.
• Cardiovascular System (CVS):
  • Heart failure / Pulmonary edema (shortness of breath, crackles, JVD, S3/S4 extra heart sounds, peripheral edema).
  • Acute myocardial infarction (angina).
  • Aortic dissection (tearing chest pain, unequal BP/pulses bilaterally).
• Renal System:
  • Acute renal failure (oliguria).
  • Hematuria.

Investigations

• Laboratory:
  • Urinalysis (look for hematuria, proteinuria, RBCs, and RBC casts).
  • CBC, Chemistry panel (BUN/Cr for AKI), cardiac enzymes.
  • Toxicology screen (rule out cocaine), pregnancy test (rule out eclampsia), endocrine work-up (pheochromocytoma, hyperaldosteronism) if secondary HTN suspected.
• Imaging & Diagnostics:
  • ECG (ischemia, LVH).
  • Chest X-ray (pulmonary edema, widened mediastinum).
  • Head CT (rule out stroke/hemorrhage), Chest CT (aortic dissection).

Management

General Principles:

• Hypertensive Urgency: Discharge with follow-up. Avoid giving rapid-acting oral meds (e.g., immediate-release nifedipine) in the ER; this is a common misconception and is dangerous, as chronic elevation implies adjusted autoregulation, and rapid drops cause severe organ hypoperfusion.
• Hypertensive Emergency: Admit to ICU. Lower BP rapidly but safely using IV medications, tailored to the damaged end-organ.

Condition-Specific Treatment Goals:

High-Yield Intravenous Agents & Adverse Effects:

• Nitroprusside: Instant onset. Risk of Cyanide / Thiocyanate toxicity.
• Nitroglycerin (NTG): 1-5 min onset. Causes flushing, headache, Methemoglobinemia.
• Nicardipine: CCB. Avoid in heart failure.
• Hydralazine: Causes reflex tachycardia. Avoid in Aortic Dissection and MI.
• Labetalol (α + β blocker) / Esmolol (β1 selective): Risk of heart block, orthostatic hypotension. Avoid in heart failure and asthma.
• Fenoldopam: Causes flushing, headache, tachycardia.
• Enalaprilat (IV ACEi): Risk of hypotension, renal failure, hyperkalemia.
• Phentolamine (α-blocker): Causes tachycardia, flushing, headache.

Complications / Prognosis

• Morbidity and mortality depend on the extent of initial end-organ damage and the quality of subsequent BP control.
• Untreated hypertensive emergencies carry a > 90% 1-year mortality rate.

Past-Paper High Yield

• The Nifedipine Trap: Never use oral/sublingual immediate-release nifedipine to rapidly lower BP in asymptomatic severe hypertension (urgency)—it predictably causes dangerous cerebral or myocardial hypoperfusion.
• Stroke Permissive Hypertension: Do not lower BP in acute ischemic stroke unless it exceeds 220/120 mmHg, unless the patient is a candidate for tPA (thrombolysis), where the strict threshold is < 185/110 mmHg.
• Aortic Dissection Paradigm: Unlike most hypertensive emergencies where gradual reduction is key, aortic dissection requires immediate and aggressive reduction of both shear stress (HR) and BP. Always give a beta-blocker before vasodilators like nitroprusside to prevent reflex tachycardia from worsening the dissection.
• Sympathetic Crisis Management: Cocaine toxicity, MAOI interactions, or pheochromocytoma require alpha-blockade (phentolamine) + benzodiazepines. Giving beta-blockers alone can lead to unopposed alpha-stimulation and paradoxical severe worsening of hypertension.

Memory Pearls

• Hydralazine rule: Reflex tachycardia limits its use; never use it in acute MI or Aortic Dissection.
• Nitroprusside toxicity: Prolonged use = Cyanide toxicity (altered mental status, lactic acidosis).
• Pathology buzzword: "Fibrinoid necrosis" of arterioles is the hallmark structural lesion of a hypertensive emergency.

Cardiogenic Shock

Core Concepts

• Definition: Severe impairment of myocardial performance resulting in diminished cardiac output (CO), hypoxia, and hypotension refractory to volume resuscitation. It causes end-organ hypoperfusion and requires pharmacological or mechanical intervention.
• Epidemiology & Etiology:
  • Acute MI is the leading cause (accounts for 81% of cases). Complicates 5–10% of acute MIs and is the leading cause of death post-MI.
  • STEMI vs. NSTEMI: STEMI has a 2-fold higher risk for developing cardiogenic shock (CS). However, NSTEMI-associated CS patients often face delayed cardiac catheterization/revascularization, leading to an increased mortality risk compared to those with STEMI-associated CS.
  • Demographics: Higher incidence observed in females, age >75 years, and Asian/Pacific Islanders.

Diagnosis / Clinical Features

• Clinical Criteria for Shock: Requires both hypotension and features of hypoperfusion.
  • Hypotension: SBP < 90 mmHg for > 30 minutes, OR MAP < 60 mmHg for > 30 minutes, OR requires vasopressors to maintain these targets.
  • Hypoperfusion: Decreased mentation, cold/mottled extremities (livedo reticularis), oliguria (UOP < 30 mL/h), and lactate > 2.0 mmol/L.
• SCAI (Society for Cardiovascular Angiography and Interventions) Stages of Shock:
  • Stage A (At Risk): Normal BP and normal perfusion, but high-risk pathology (e.g., large anterior MI, HF).
  • Stage B (Beginning / "Pre-shock"): Hypotension (SBP < 90, MAP < 60) and tachycardia (HR > 100), but normal perfusion (clear mentation, warm extremities, normal lactate).
  • Stage C (Classic): Hypotension plus hypoperfusion. Cold, ashen, altered mentation, low UOP, elevated lactate/LFTs, acidosis.
  • Stage D (Deteriorating): Worsening hemodynamics/perfusion despite escalating use of pressors or mechanical circulatory support (MCS).
  • Stage E (Extremis): Refractory shock, cardiac arrest with ongoing CPR, pulseless electrical activity (PEA), or recurrent VT/VF.

Investigations

• Hemodynamic Criteria (Right Heart Catheterization / PA Line):
  • Cardiac Index (CI): < 2.2 L/min/m²
  • Pulmonary Capillary Wedge Pressure (PCWP): > 15 mmHg
  • Cardiac Power Output (CPO): < 0.6 W (Formula: [CO × MAP]/451)
  • Shock Index: > 1.0 (Formula: HR / SBP)
• Isolated Right Ventricular (RV) Shock Indicators:
  • CVP > 15 mmHg
  • CVP / PCWP ratio > 0.6
  • Pulmonary Artery Pulsatility Index (PAPi) < 1.0 (Formula: [PASP - PADP] / CVP)

Management

• General Approach: Early revascularization is the most critical intervention to improve survival. Protocol-driven approaches by multidisciplinary shock teams are strongly recommended (Class IIa).
• Pharmacological Support (Class I): Use intravenous inotropes to maintain systemic perfusion.
  • Caution: Escalating numbers and doses of catecholamines correlates with higher mortality due to pro-arrhythmic effects and increased myocardial oxygen demand.
  • Dobutamine: Inotrope (increases CO, HR). Variable BP effects.
  • Dopamine: 5–10 mcg/kg/min (inotropic), >10 mcg/kg/min (vasopressor). Can cause significant tachyarrhythmias and tissue necrosis.
  • Norepinephrine: Potent vasopressor (strongly increases SVR). Can cause reflex bradycardia and tissue necrosis.
  • Epinephrine: Potent inotrope and vasopressor. Highly arrhythmogenic.
  • Milrinone (PDE-3 Inhibitor): "Inodilator" (increases CO, decreases SVR/PVR).
    • Special Consideration: Excreted renally; accumulates in acute kidney injury. Closely monitor kidney function and adjust dose.
• Mechanical Circulatory Support (MCS) (Class IIa):
  • Indication: Reasonable when end-organ function cannot be maintained by pharmacology.
  • Advantage: Provides robust cardiovascular support without the increased myocardial oxygen consumption seen with catecholamines.
  • Device Options:
    • IABP (Intra-Aortic Balloon Pump): Counter-pulsation decreases afterload and improves coronary perfusion.
    • Impella (Axial Flow Pump): Pulls blood from the LV and ejects it into the aortic root. Unloads the LV (decreases LVEDP/LVEDV and wall tension) while increasing forward flow (MAP and end-organ perfusion), definitively lowering myocardial O2 demand.
    • TandemHeart: Left atrial-to-femoral artery ventricular assist device.
    • VA-ECMO: Veno-arterial extracorporeal membrane oxygenation for full cardiopulmonary support.

Complications / Prognosis

• Despite overall improvements in diagnosis and access to in-hospital care, the 6- to 12-month mortality for cardiogenic shock remains exceptionally high at ~50% (unchanged over the past 2 decades).
• High risk for irreversible multi-organ failure (shock liver, AKI) and lethal arrhythmias if the ischemia-hypoperfusion cycle is not rapidly broken.

Past-Paper High Yield

• Hemodynamic Cut-Offs: Memorize the classic triad for confirming cardiogenic shock invasively: SBP < 90 mmHg, CI < 2.2 L/min/m², and PCWP > 15 mmHg.
• NSTEMI vs. STEMI Trap: Understand that while STEMI is more likely to cause shock, an NSTEMI patient presenting in shock has historically higher mortality directly driven by delays in cardiac catheterization and revascularization.
• SCAI Staging Distinction: The differentiator between Stage B (Pre-shock) and Stage C (Classic) is end-organ perfusion. A patient with SBP 85 but warm extremities and normal mentation/lactate is Stage B.
• MCS vs. Inotropes: Be prepared to identify that Mechanical Circulatory Support (like Impella) is superior physiologically because it unloads the heart and reduces myocardial O2 demand, whereas escalating inotropes increase O2 demand and provoke ischemia/arrhythmias.
• Milrinone toxicity: Always check renal function before initiating milrinone to avoid drug accumulation and refractory hypotension.

Memory Pearls

• Shock Index = HR / SBP. A normal index is < 0.8. An index > 1.0 means the heart rate has overtaken the systolic pressure, indicating profound shock.
• SCAI ABCDEs of Shock: At risk, Beginning (hypotension without hypoperfusion), Classic (hypotension + hypoperfusion), Deteriorating (refractory to initial meds), Extremis (cardiac arrest/PEA).
• Inotropes vs. MCS analogy: Catecholamines whip a tired, ischemic horse to run faster (increasing O2 demand). MCS (like Impella) takes the load off the horse's cart so it can recover (decreasing LVEDP/LVEDV).

Endocrine

Exam Map

Past-Paper Question Distribution

Recurring Exam Patterns & Revision Priorities

• DKA & HHS Triage Traps: The most heavily tested concept in diabetic crises is the mandatory sequence of management. Always choose IV Fluids first, check Potassium second, and only initiate Insulin third. Never select insulin before confirming potassium levels.
• Hypoglycemia Workup: You will frequently be asked to differentiate the cause of a hypoglycemic event using the 72-hour fast labs. Memorize the triad: High Insulin + High C-peptide + Negative OHA screen = Insulinoma. High Insulin + Low C-peptide = Exogenous injection.
• Confirming the DM Diagnosis: A classic trick involves an asymptomatic patient with one slightly elevated FBG or random glucose. The correct answer is always to repeat the test, not to initiate metformin or insulin. Conversely, classic symptoms + one abnormal test = definitive DM.
• Metformin-Induced B12 Deficiency: Be highly suspicious of a well-controlled diabetic on Metformin presenting with new-onset peripheral neuropathy or macrocytic anemia. The exam frequently uses this to trap students into selecting "diabetic neuropathy."
• Stepwise Cushing's Evaluation: Examiners rigorously test the diagnostic order. You must first screen (24h urine free cortisol or low-dose dexamethasone test) to confirm hypercortisolism before checking ACTH, and check ACTH before ordering any imaging (MRI/CT).
• Adrenal Crisis vs. Stable Workup: For hypotensive shock post-steroid withdrawal, the immediate next step is IV Hydrocortisone (do not wait for labs). For stable, vague symptoms of adrenal insufficiency, the next step is the ACTH stimulation test.
• Pheochromocytoma Pharmacotherapy: A recurring safety principle—never give beta-blockers before establishing alpha-blockade (phenoxybenzamine) to avoid unopposed alpha-adrenergic hypertensive crisis.
• Thyroid Nodule Algorithm: The initial step for a nodule is always TSH. If TSH is normal/high, the next step for a suspicious/solid nodule is Ultrasound-guided FNA. Only choose a radionuclide scan if the TSH is low.
• Hyperthyroidism in Pregnancy: Highly tested pharmacology crossover. Use PTU for the 1st trimester (or planning pregnancy) and switch to Methimazole/Carbimazole for the 2nd/3rd trimesters.
• Calcium Diagnostic Pathways: When evaluating hypercalcemia, the critical branch point is Intact PTH. If PTH is high/normal, the exam will test your ability to differentiate Primary Hyperparathyroidism from FHH using Urine Calcium. If PTH is suppressed, look for malignancy (PTHrP) or sarcoidosis (1,25-OH-Vit D).
• Hypogonadism Syndromes: Memorize the clinical buzzwords for definitive next steps: Anosmia + low LH/FSH = Kallmann syndrome. Small firm testes + tall stature + high LH/FSH = Klinefelter syndrome (next step: Karyotype).

Diabetes Mellitus 1

Core Concepts

• Pathogenesis of T1DM: Autoimmune destruction of beta cells (97%) or idiopathic (3%).
  • Bimodal age of onset: Peaks at 4–6 years and early puberty (10–14 years).
  • Risk factors: Viral infections, immunizations, early introduction of cow's milk, Vitamin D deficiency.
  • Counter-intuitive risk factor: Low birth weight decreases the risk of developing T1DM.
  • Genetics: Monozygotic twin lifetime risk is 50%. Affected father (5-8%) confers a higher risk than an affected mother (2-4%).
• Pathogenesis of T2DM: Progressive beta-cell dysfunction + Insulin resistance.
  • Insulin processing is impaired: Proinsulin makes up 40% of secreted insulin (normally 10-15%).
  • Risk factors: Obesity, aging, genetics, lipotoxicity, glucotoxicity.
  • Genetics: Very strong heritability. Monozygotic twins have 90% concordance. A first-degree relative has 5–10x higher lifetime risk.
• T1DM vs. T2DM Autoimmunity:
  • T1DM features antibodies to: GAD, Tyrosine phosphatase (IA2), Insulin, and Zinc transporter.

Diagnosis / Clinical Features

• Diagnostic Criteria for DM:
  1. Fasting Plasma Glucose (FPG) ≥ 126 mg/dL (no caloric intake for ≥ 8 hrs).
  2. 2-hour Plasma Glucose ≥ 200 mg/dL during a 75g OGTT.
  3. HbA1c ≥ 6.5%.
  4. Random Plasma Glucose ≥ 200 mg/dL with classic symptoms (polyuria, polydipsia, weight loss).
  • Note: In the absence of symptomatic hyperglycemia, criteria 1–3 must be confirmed by repeat testing.
• Interpreting Borderline/Repeated Labs:
  • FPG of 106 mg/dL then 124 mg/dL: Patient has Prediabetes (Impaired Fasting Glucose).
  • Asymptomatic patient with FPG 136 mg/dL: Next step is to repeat FPG to confirm.
  • Patient with polydipsia, polyuria, weight loss, and FPG of 135 mg/dL: Diagnosis of DM is confirmed (symptoms + 1 abnormal test).
• Clinical Presentation:
  • Symptoms: Polyuria, nocturia, thirst, weight loss, blurred vision, fatigue, numbness, impotence.
  • Signs: Muscle weakness, loss of tendon reflexes, decreased sensation, interdigital fungal infections, retinal changes.

Investigations

• Hypoglycemia Workup (72-Hour Fast):
  • Triggered in seemingly well subjects presenting with Whipple's Triad (Symptoms + Glucose ≤ 45/55 mg/dL + Relief with glucose).
  • Parameters measured: Plasma glucose, Insulin, C-peptide, Proinsulin, Beta-hydroxybutyrate (BOHB), and oral hypoglycemic agents (OHA) screen.
  • Insulinoma / Nesidioblastosis: ↑ Insulin (≥ 3), ↑ C-peptide (≥ 0.6), ↓ BOHB (≤ 2.7), Negative OHA screen.
  • Exogenous Insulin Abuse: ↑ Insulin (>> 3), ↓ C-peptide (< 0.6) (suppressed endogenous production), ↓ BOHB.
  • Sulfonylurea Abuse: ↑ Insulin (≥ 3), ↑ C-peptide (≥ 0.6), ↓ BOHB, Positive OHA screen.
• Insulinoma Localization:
  • Initial: CT, MRI, transabdominal US.
  • If negative: Endoscopic ultrasound (EUS) or Selective arterial calcium stimulation (sampling hepatic venous effluent; positive if insulin doubles or triples).

Management

• Diabetes Prevention:
  • Intensive lifestyle changes (7% weight loss, 150 min/week exercise) reduce risk by 58%.
  • Metformin reduces risk by 31%.
  • 16% reduction in DM risk for every 1 kg reduction in weight.
• Diabetic Ketoacidosis (DKA) Crisis Management:
  • In a T1DM patient presenting with N/V, polyuria, oliguria, tachycardia, hypotension, and Kussmaul respirations: Check K+ before giving Insulin (Insulin drives potassium intracellularly; giving it blindly can cause fatal hypokalemia).
• Pharmacotherapy Pearls:
  • Metformin: Decreases hepatic glucose output. Weight neutral. Contraindicated in renal impairment (SCr > 1.5 in males, > 1.4 in females), liver failure, advanced HF, and sepsis.
  • GLP-1 Agonists (Exenatide, Liraglutide): Glucose-dependent insulin release, slows gastric emptying. Causes weight loss. Side effects: pancreatitis, GI upset, possible medullary thyroid cancer risk.
  • SGLT2 Inhibitors: Provides CVS protection. Side effects: UTI, hypotension, dehydration.
  • TZDs (Pioglitazone): Insulin sensitizers. Side effects: Fluid retention/HF, hepatotoxicity, bone fractures, macular edema.
  • DPP4 Inhibitors: Weight neutral.
  • Pramlintide (Amylin analogue): Approved for T1DM and insulin-treated T2DM. Reduces food intake.
• Insulinoma Management:
  • Primary: Surgical resection.
  • Medical (if surgery not possible): Diazoxide (first-line), Octreotide.

Past-Paper High Yield

• Confirming T1DM/T2DM Diagnosis: Do not initiate therapy on a single asymptomatic elevated FBG. The strictly correct next step is to repeat the FBG (or another diagnostic test). Conversely, classic symptoms + one random glucose > 200 or FBG > 126 definitively confirms the diagnosis.
• DKA Triage: Always check electrolytes (potassium) before initiating an insulin drip in hyperglycemic crises.
• Perioperative Steroid Management: An SLE patient on chronic prednisone (e.g., 10 mg) undergoing a major stressor like CABG surgery requires stress-dose steroids. Next step: Start 100 mg hydrocortisone.
• Erectile Dysfunction in Youth: The most common cause of erectile dysfunction in a young (e.g., 29-year-old) healthy male is psychologic, rather than diabetes-related microvascular/neuropathic disease.
• Endocrine Miscellany (Tested alongside DM):
  • Turner Syndrome (45, XO): Characterized by primary ovarian failure. Due to lack of estrogen feedback, FSH and LH are highly elevated. Unlikely to find: FSH 3 (normal/low). Expect poor breast development.
  • Klinefelter Syndrome (47, XXY): Diagnosis confirmed by Karyotype. Characterized by small, firm testicles, azoospermia, and altered upper/lower body segment ratios. Unlikely to find: Soft normal testicles.
  • Pheochromocytoma: Presents with episodic HTN, headaches, palpitations, and sweating. When treating the HTN, Propranolol (beta-blockers) should NEVER be given before alpha-blockers to avoid unopposed alpha-adrenergic hypertensive crisis.
  • Hypercalcemia: A psychotic patient presenting with elevated calcium is likely taking Lithium.
  • Multiple Myeloma & Calcium: In a patient with multiple myeloma, constipation, and mildly elevated Ca (10.2), the next step is to check serum albumin to calculate the corrected calcium level.

Memory Pearls

• Whipple's Triad: 1) Hypoglycemic symptoms, 2) Low blood glucose, 3) Relief with glucose administration. Required to initiate a 72-hour fast workup.
• High Insulin + High C-peptide: Endogenous source (Insulinoma or SU). Check SU screen.
• High Insulin + LOW C-peptide: Exogenous injection (Factitious).
• 1 kg = 16%: Every 1 kg of weight loss reduces DM risk by 16%.
• Low birth weight paradox: Increases risk for insulin resistance/T2DM later in life, but decreases the risk of T1DM.

Diabetes Mellitus 2: Complications and Hypoglycemic Disorders

Core Concepts

• Acute Complications: Diabetic Ketoacidosis (DKA), Hyperglycemic Hyperosmolar State (HHS), and Hypoglycemia.
• DKA vs. HHS Pathogenesis:
  • Both involve insulin deficiency/resistance and glucagon excess.
  • Glucagon increases carnitine palmitoyl transferase I (CPT-I) activity, driving ketogenesis.
  • In HHS, there is enough endogenous insulin (only 10% needed) to suppress lipolysis and ketogenesis, but not enough to promote peripheral glucose utilization, preventing ketosis but allowing profound hyperglycemia.
• Whipple’s Triad: The hallmark of true hypoglycemia: (1) Low plasma glucose, (2) Symptoms of hypoglycemia, (3) Resolution of symptoms upon glucose administration.

Diagnosis / Clinical Features

Diabetic Ketoacidosis (DKA)

• Demographics: More common in younger patients (<65 years), primarily Type 1 DM (or T2DM under severe stress/infection).
• Timeline: Evolves rapidly (typically within 24 hours).
• Classic Signs: Compensatory hyperventilation (Kussmaul respirations), fruity breath odor.
• Abdominal Pain: Present in 46% of cases. Due to delayed gastric emptying and ileus from metabolic acidosis/electrolyte imbalance. Does not correlate with the severity of hyperglycemia.

Hyperglycemic Hyperosmolar State (HHS)

• Demographics: Older patients (>65 years), primarily Type 2 DM.
• Timeline: Evolves insidiously over several days.
• Classic Signs: Severe volume depletion. Neurologic symptoms are the hallmark (lethargy, obtundation, coma, focal signs like hemiparesis/hemianopsia, and seizures). Neurologic deterioration typically occurs when effective plasma osmolality > 320–330 mOsm/kg.
• Abdominal pain: Very unusual in HHS.

Hypoglycemia & Insulinoma

• Symptoms:
  • Sympathoadrenal: Palpitations, diaphoresis (sweating), tremors.
  • Neuroglycopenic: Confusion, visual changes, behavioral changes.
• Insulinoma Profile: Fasting hypoglycemia is most common. Associated with weight gain (18% of patients). Median duration of symptoms before diagnosis is 1.5 years; often misdiagnosed as a psychiatric or seizure disorder.
• MEN1 Association: 6% of insulinoma patients have MEN1 (in MEN1, 86% have multiple tumors, whereas sporadic insulinomas are typically solitary and benign).

Chronic Complications of DM

• Neuropathy: Distal symmetric polyneuropathy ("stocking-glove" pattern).
  • Large-fiber loss: Loss of vibration sense and proprioception. Decreased/absent ankle reflexes occur early.
  • Small-fiber loss: Impairment of pain, light touch, and temperature.
• Nephropathy: Progresses from normal (<30 mg/day) → Microalbuminuria (30-300 mg/day) → Macroalbuminuria (>300 mg/day).
• Retinopathy:
  • Nonproliferative (NPDR): Microaneurysms, hemorrhages, soft/hard exudates, venous beading.
  • Proliferative (PDR): Neovascularization of the disk/vitreous, preretinal hemorrhage.

Investigations

DKA vs. HHS Diagnostic Criteria

• Glucose: DKA >250 mg/dL | HHS >600 mg/dL (often >1000 mg/dL).
• Arterial pH: DKA <7.30 | HHS >7.30.
• Serum Bicarbonate: DKA <18 mEq/L | HHS >18 mEq/L.
• Anion Gap: DKA >10 | HHS Variable.
• Ketones (Serum/Urine): DKA Positive | HHS Small/Trace.
• Effective Serum Osmolality: Calculated as 2[Na] + [Glucose/18]. DKA is variable; HHS is definitively >320 mOsm/kg.

Hypoglycemia Evaluation (72-Hour Fasting Test)

• Endpoints to stop the test: Plasma glucose ≤45 mg/dL, signs/symptoms of hypoglycemia, 72 hours elapsed, or glucose <55 mg/dL if Whipple's triad was previously documented.
• Labs to draw: Glucose, Insulin, C-peptide, Pro-insulin, Oral Hypoglycemic Agent (OHA) screen, and Insulin antibodies.

Insulinoma Localization

• Imaging: CT, MRI, and transabdominal ultrasound are first-line.
• Invasive: If imaging is negative, use endoscopic ultrasound or Arterial Calcium Stimulation (injection of calcium gluconate with hepatic venous sampling for insulin).
  • Positive in ONE artery = Insulinoma.
  • Positive in MULTIPLE arteries = Islet cell hypertrophy / Nesidioblastosis.

Chronic Complications Screening

• Nephropathy: Screen yearly with Urine Albumin/Creatinine Ratio (ACR). Elevated ACR must be confirmed with 2-3 samples over several months.
• Neuropathy: Michigan neuropathy screening score (checks vibration sense, Achilles reflex, and foot inspection for ulcers/dry skin).

Management

DKA & HHS Protocol

1. IV Fluids: Initiate with 1–2 L Normal Saline (NS) bolus. Switch to ½ NS based on hemodynamics. Crucial transition: Switch to D5 ½ NS when blood glucose drops below 200 mg/dL (DKA) or 250-300 mg/dL (HHS) to prevent hypoglycemia while continuing to clear ketones.
2. Potassium: Check K+ before giving insulin!
   • If K < 3.3 mmol/L: HOLD IV insulin and add KCl.
   • If K 3.3 – 5.3 mmol/L: Add KCl to IV fluids once urine output >50 mL/hr.
   • If K > 5.3 mmol/L: Delay K supplementation and monitor.
3. Insulin: 0.1 U/kg IV bolus followed by 0.1 U/kg/hr IV infusion. Continue until resolution. Start SC insulin once the patient is eating.
4. Bicarbonate: Rarely indicated. Only give if arterial pH <6.90, severe hyperkalemia, or decreased cardiac contractility.
5. Phosphate: Add if PO4 <1.0 mg/dL, or in the presence of cardiac dysfunction, hemolytic anemia, or respiratory depression.

Hypoglycemia Management

• Mild-Moderate (Conscious): Oral glucose (15-20g), e.g., fruit juice.
• Severe (Unconscious/Hospitalized): Draw blood for diagnostic labs (C-peptide/insulin) if etiology is unknown, then immediately administer 50 mL of 50% Dextrose IV, or IM glucagon if no IV access.
• Insulinoma: Surgical resection is primary. Medical management (if poor surgical candidate): Diazoxide (1st line; adverse effects include edema and hirsutism) or Octreotide.

Chronic Complications Management

• Nephropathy: Optimal initial therapy in T2DM is an ACE inhibitor or ARB (do not combine them due to increased mortality). Indicated if persistent microalbuminuria or BP >140/80. SGLT2 inhibitors are also utilized.
• Neuropathy Pain Control:
  • First-tier: Tricyclic antidepressants (TCAs), duloxetine, pregabalin, controlled-release oxycodone.
  • Second-tier: Carbamazepine, gabapentin, tramadol.
• Macrovascular Risk Reduction: Near-normal glycemic control does not significantly reduce cardiovascular events in longstanding diabetes. Focus on BP control, treating dyslipidemia, smoking cessation, and daily aspirin.

Complications / Prognosis

• Cerebral Edema (DKA): Almost exclusively affects children/teens (<20 years). Symptoms begin 12-24 hours after initiating treatment (headache, lethargy, pupillary changes, bradycardia, respiratory arrest). Treatment: Prompt administration of Mannitol or 3% Hypertonic Saline. High mortality (20-40%).
• Mortality: HHS has a significantly higher mortality rate (5-20%) compared to DKA.
• Cardiovascular Death: Up to 80% of people with diabetes will die from cardiovascular disease.

Past-Paper High Yield

• Diagnostic priority in fasting hypoglycemia: If a patient presents with episodic sweating, weight gain, and fasting hypoglycemia (e.g., FBG 40 mg/dL), the immediate next diagnostic step is to order Fasting insulin and C-peptide to differentiate endogenous hyperinsulinism (insulinoma) from exogenous sources.
• Severe hypoglycemia emergency management: A hospitalized or unconscious patient with acute hypoglycemia should have blood drawn for C-peptide/insulin workup first (if etiology is unknown), and immediately be given 50 mL of Dextrose 50%. Do not rely on oral juice in severe/unresponsive cases.
• Differentiating Diabetic vs. Drug-induced Neuropathy: If a patient with well-controlled DM presents with new-onset peripheral neuropathy and is on a polypharmacy regimen including Metformin, highly suspect Metformin-induced Vitamin B12 Deficiency rather than typical diabetic neuropathy. This is a classic diagnostic trap.
• Evaluating hospital-onset hypoglycemia: If a patient develops hypoglycemia after an 8-hour hospital fast, measuring C-peptide is the definitive test to rule out exogenous insulin administration.

Memory Pearls

• High C-peptide = Endogenous; Low C-peptide = Exogenous: Exogenous insulin suppresses natural insulin and C-peptide production. If both insulin and C-peptide are high, think Insulinoma or Sulfonylurea abuse (check OHA screen to differentiate).
• DKA fluids rule: "Clear the sugar, then clear the ketones." Once glucose is <200 mg/dL, add dextrose (D5) to the fluids. This allows you to keep running the insulin infusion to fix the acidosis/ketosis without causing iatrogenic hypoglycemia.
• Insulinoma triad: Fasting hypoglycemia + Weight gain + High C-peptide.

Pituitary Disorders and Hypogonadism

Core Concepts

• Hypothalamic-Pituitary Axis Dynamics:
  • Dopamine (DA): Tonically inhibits Prolactin (strongest effect) and TSH.
  • TRH: Stimulates both TSH and Prolactin. (e.g., Hypothyroidism [↓T3/T4 → ↑TRH] can cause hyperprolactinemia).
  • Prolactin: Inhibits GnRH (Hyperprolactinemia → ↓GnRH → ↓LH/FSH → hypogonadism).
  • Somatostatin: Inhibits Growth Hormone (GH) and TSH.
• Gonadotropins:
  • LH: Stimulates Testosterone production in males.
  • FSH: Stimulates Spermatogenesis in males; Follicle stimulation and Estrogen production in females.
• Primary vs. Central Hypogonadism:
  • Primary (Gonadal failure): ↓ Sex hormones, ↑ LH/FSH (lack of negative feedback).
  • Central (Hypothalamic/Pituitary failure): ↓ Sex hormones, ↓ or inappropriately normal LH/FSH.

Diagnosis / Clinical Features

1. Hyperprolactinemia

• Pathophysiology: Symptoms result directly from ↑ Prolactin (galactorrhea) OR indirectly from ↓ Sex hormones (due to GnRH inhibition).
• Causes:
  • Physiologic: Pregnancy, breastfeeding, stress.
  • Pharmacologic: Dopamine antagonists (antipsychotics, metoclopramide), methyldopa, cimetidine, OCPs.
  • Pathologic: Hypothyroidism, Prolactinoma (micro <1cm; macro ≥1cm with mass effects like bitemporal hemianopsia).
• Clinical Presentation:
  • Females: Galactorrhea, oligomenorrhea/amenorrhea, infertility, hirsutism, osteoporosis.
  • Males: Erectile dysfunction, decreased libido, infertility, gynecomastia, rare galactorrhea.

2. Growth Hormone Disorders

• Acromegaly (Adults) / Gigantism (Children): GH over-secretion. GH is diabetogenic (anti-insulin effect).
• Dwarfism: Under-secretion of GH in children.

3. Hypogonadism Syndromes

• Kallmann Syndrome (Central): Hypogonadotropic hypogonadism (↓ GnRH) accompanied by anosmia (absent sense of smell) and delayed puberty.
• Klinefelter Syndrome (Primary - 47, XXY): Male karyotype with small firm testes, delayed puberty, tall stature with disproportionately long limbs, gynecomastia (relative ↑ Estrogen compared to ↓ Testosterone), and infertility.
• Turner Syndrome (Primary - 45, XO): Female karyotype with short stature, streak (absent/underdeveloped) ovaries causing primary amenorrhea, webbed neck, widely spaced nipples, aortic coarctation, and sensorineural hearing loss.
• Other Primary Male Causes: Viral orchitis, radiation, chemotherapy, hemochromatosis (infiltrative).

4. Associated Reproductive Endocrinology Conditions

• Congenital Adrenal Hyperplasia (21-hydroxylase deficiency):
  • ↓ Aldosterone: Hypovolemia, hyperkalemia, ↑ Renin.
  • ↓ Cortisol: Hypoglycemia, nausea/vomiting, ↑ ACTH (causing skin hyperpigmentation).
  • ↑ Androgens: Ambiguous genitalia (females), precocious puberty (males).
• Polycystic Ovarian Syndrome (PCOS): Driven by hyperinsulinemia/insulin resistance → alters hypothalamic feedback → ↑ LH:FSH ratio → ↑ Androgens from theca interna cells → unruptured follicles/anovulation.

Investigations

Hyperprolactinemia

• Prolactinoma vs. "Stalk Effect":
  • Prolactinoma: Tumor size directly correlates with prolactin levels (e.g., 3mm tumor = ~100 ng/mL; 2cm tumor = ~1000 ng/mL).
  • Stalk Effect: A large non-prolactinoma pituitary tumor (e.g., 2cm) compresses the infundibular stalk, preventing Dopamine from reaching the anterior pituitary. This disinhibits lactotrophs, causing a mild elevation in prolactin (e.g., 80 ng/mL) despite a huge tumor size.

Growth Hormone Disorders

• GH is secreted in a pulsatile manner and affected by sleep/circadian rhythm, making random GH levels unreliable.
• Acromegaly:
  • Screening: Serum IGF-1 levels (produced by the liver in response to GH; stable half-life).
  • Definitive: Oral Glucose Tolerance Test (OGTT) / Glucose Suppression Test. (Normal response is GH suppression; in acromegaly, GH fails to suppress).
• Dwarfism:
  • Screening: Serum IGFBP-3 (decreased because lower IGF-1 means less binding protein is needed/produced).
  • Definitive: Insulin-induced hypoglycemia (GH stimulation test). (Normal response is GH elevation; in dwarfism, GH fails to rise).

Hypogonadism

• Male Evaluation: Check free testosterone (morning, fasting, optimally 3 samples taken 1 hour apart).
• Differentiating Next Steps:
  • If ↓ Testosterone and normal/↓ LH/FSH (Central) → Pituitary MRI.
  • If ↓ Testosterone and extremely ↑ LH/FSH (Primary) → Chromosomal analysis (suspect Klinefelter).

Management

• Prolactinoma:
  • First-line: Dopamine agonists (Cabergoline 2x/week, Bromocriptine daily). They shrink tumor size effectively.
  • Note: Even with macroprolactinomas compressing the optic chiasm, DA agonists remain the primary treatment. Surgery is reserved only for refractory cases.
• Acromegaly:
  • Best definitive treatment: Trans-sphenoidal surgery.
• PCOS:
  • Weight reduction (↓ peripheral estrone formation).
  • OCPs (regulate cycle and prevent endometrial hyperplasia).
  • Clomiphene (for ovulation induction/fertility).
  • Anti-androgens like Spironolactone, Finasteride, or Flutamide (for hirsutism).

Complications / Prognosis

• PCOS: Increased risk of endometrial cancer due to unopposed estrogen from chronic anovulatory cycles.
• Untreated Hypogonadism: Osteoporosis, decreased muscle mass, persistent infertility, psychological distress.

Past-Paper High Yield

• Kallmann syndrome presentation: A young male with delayed puberty, underdeveloped secondary sexual characteristics, small testes, anosmia (absent sense of smell), and labs showing ↓ FSH, ↓ LH, and ↓ Testosterone. (Recognize as central hypogonadism).
• Acromegaly diagnostic test: The most accurate/best diagnostic test is the Oral Glucose Tolerance Test (OGTT) / Glucose Suppression Test.
• Acromegaly treatment: The best management is trans-sphenoidal surgery.

Memory Pearls

• "Stalk Effect" Rule of Thumb: Big tumor + mildly elevated Prolactin (<100 ng/mL) = Stalk effect (not a macroprolactinoma). Big tumor + massively elevated Prolactin (>1000 ng/mL) = Macroprolactinoma.
• Primary vs Central Labs: The defect is where the hormone is LOW. If Testosterone is low, gonads are failing (Primary) unless LH is also low (Central/Pituitary).
• TRH acts twice: Remember that uncontrolled Primary Hypothyroidism can masquerade as a prolactinoma because ↑ TRH stimulates prolactin release. Check TSH!

Adrenal Disorders

Core Concepts

• Anatomy: The adult adrenal gland is a 4g pyramidal structure lying immediately above the kidney.
• Hormone Secretion: Cortisol and ACTH have a circadian, pulsatile secretion rhythm. Levels peak in the early morning and hit a nadir at midnight. Note: Circadian rhythm is lost in Cushing's disease.
• Pharmacologic Steroid Potencies:

Diagnosis / Clinical Features

Cushing’s Syndrome (Glucocorticoid Excess)

• Clinical signs: Centripetal obesity, moon facies, hirsutism, plethora, livid abdominal striae, easy bruising (thin skin), and dorsal kyphosis (buffalo hump).
• True Cushing vs. Pseudo-Cushing: Proximal myopathy (e.g., difficulty rising from a sitting position) is a key clinical differentiator that strongly points toward true Cushing's syndrome rather than pseudo-Cushing's (e.g., severe obesity, depression, PCOS, alcoholism).
• Causes:
  • ACTH-dependent: Cushing's disease (pituitary adenoma), ectopic ACTH/CRH.
  • ACTH-independent: Adrenal adenoma/carcinoma, iatrogenic (pharmacologic steroids).

Glucocorticoid Deficiency

• Primary (Addison’s Disease): Autoimmune is the most common cause. Other causes include TB, HIV, bilateral adrenalectomy, and Waterhouse-Friderichsen syndrome.
  • Classic sign: Hyperpigmentation (palmar creases, buccal mucosa) due to excess POMC/ACTH cleavage.
  • Features: Both glucocorticoid and mineralocorticoid deficiency (salt-wasting).
• Secondary: Exogenous steroid withdrawal is the most common cause. Other causes include hypopituitarism and pituitary tumors.
  • Features: Only glucocorticoid deficiency; aldosterone is preserved (RAAS dependent). No hyperpigmentation.
• Adrenal Crisis: Severe hypotension, hyperkalemia, fever, and decreased level of consciousness. Frequently triggered by sudden cessation of chronic steroids or acute stress.

Congenital Adrenal Hyperplasia (CAH)

• 21-hydroxylase deficiency accounts for 90% of cases. Defective conversion of 17-OH progesterone to 11-deoxycortisol → low cortisol → high ACTH → androgen excess.
• Variants:
  • Salt-wasting (75%): Concomitant aldosterone deficiency. High neonatal mortality (hypotension, crisis in first week of life).
  • Simple virilizing: Ambiguous genitalia in females, precocious pseudopuberty in males.
  • Nonclassic (Late-onset): Presents in young adulthood with hirsutism, anovulatory infertility, and acne (often mimics PCOS).

Investigations

Stepwise Workup for Cushing's Syndrome (Highly Tested)

1. Does the patient have Cushing's? (Screening)
   • Initial test for symptomatic patients (obesity, striae, myopathy): 24-hour urine free cortisol, low-dose dexamethasone suppression test (LDDST), or late-night salivary cortisol.
2. What is the cause? (Once biochemically confirmed)
   • Next step: Check serum ACTH level.
   • Low ACTH + High Cortisol: ACTH-independent → Adrenal source. Confirms an adrenal tumor. Next step: Adrenal CT.
   • High/Normal ACTH + High Cortisol: ACTH-dependent. Next step: Pituitary MRI.

Workup for Adrenal Insufficiency

• Diagnostic Test of Choice: ACTH (Cosyntropin) stimulation test with baseline cortisol and ACTH.
• Imaging: Primary hypoadrenalism requires Adrenal CT; Secondary requires Pituitary MRI.

Workup for Adrenal Incidentalomas All incidentally discovered adrenal masses (found on imaging for unrelated reasons) must be screened for functionality and malignancy.

• Rule out hypersecretion: 24-hour urinary fractionated metanephrines (pheochromocytoma), LDDST (preclinical Cushing's).
• If hypertensive: Measure the Plasma Aldosterone Concentration to Plasma Renin Activity ratio (PAC/PRA ratio).

Management

Adrenal Insufficiency & Crisis

• Acute Adrenal Crisis (e.g., sudden cessation of chronic steroids):
  • Do NOT wait for laboratory results.
  • Immediate management: IV hydrocortisone (100 mg STAT, then q6h) + aggressive IV fluid resuscitation (2-3 L of 0.9% NaCl or D5W in 0.9% NaCl).
• Long-Term Primary AI (Addison’s):
  • Requires dual replacement: Glucocorticoid (Hydrocortisone BID) + Mineralocorticoid (Fludrocortisone orally).
  • Liberal salt intake, medical alert bracelet, and education on stress-dosing.
  • Note: The presence of essential hypertension is not an indication to increase the daily steroid replacement dose.

Adrenal Incidentalomas

• Non-functioning, Benign, < 4 cm: Do nothing acutely (conservative management, follow-up imaging in 6-12 months).
• > 6 cm or Suspicious features: Surgical removal (open adrenalectomy, not laparoscopic).

Pheochromocytoma

• Medical Management: Must establish alpha-blockade before beta-blockade to prevent unopposed alpha-receptor stimulation and severe hypertensive crisis.
• Next best step for a patient on ACEi/CCB with uncontrolled BP: Add phenoxybenzamine (alpha-blocker).

Primary Hyperaldosteronism (Conn's Syndrome)

• Classic presentation: Treatment-resistant hypertension and hypokalemia.
• Next step for incidentaloma + HTN: Aldosterone to renin ratio.

Complications / Prognosis

• Nelson's Syndrome: Occurs post-bilateral adrenalectomy for Cushing's disease. Lack of negative feedback causes rapid growth of a corticotropinoma (pituitary adenoma), leading to intense hyperpigmentation and local mass effect (e.g., CN III palsy).
• Adrenocortical Carcinoma: Aggressive tumor (often >6cm). 80% are functional (secreting glucocorticoids/androgens). Very poor prognosis (5-year survival <20%). Mitotane is used for medical control of hypersecretion and tumor growth.

Past-Paper High Yield

• Cushing's Diagnosis Sequence: You must follow the exact stepwise approach:
  • Suspected signs (obesity, myopathy) → Next step: 24-hour urine cortisol.
  • Confirmed hypercortisolism (high 24h urine/positive LDDST) → Next step: Serum ACTH.
  • High UFC + Low ACTH → Confirms Adrenal tumor.
  • High UFC + High ACTH → Next step: Pituitary MRI.
• Adrenal Crisis vs Stable Workup:
  • If a patient presents with hypotensive crisis (especially after stopping long-term steroids), the next step is IV Hydrocortisone.
  • If a patient presents with vague symptoms (fatigue, mild hypotension) and you need to confirm the diagnosis, the next step is the ACTH stimulation test.
• Incidentaloma Traps:
  • Incidentaloma + Normal BP + Negative Cushing/Pheo workup + Small (<4cm/e.g., 3cm) → Do nothing.
  • Incidentaloma + Hypertension (even if metanephrines/cortisol are normal) → Next step: Aldosterone to renin ratio (PAC/PRA).
• Addison's Therapy: A patient with autoimmune Addison's (indicated by hyperpigmentation) requires both mineralocorticoid and glucocorticoid replacement (e.g., Fludrocortisone + Hydrocortisone/Prednisone).
• True vs. Pseudo-Cushing: Difficulty raising from a sitting position (proximal myopathy) is a hallmark of true Cushing syndrome and is generally absent in pseudo-Cushing states.
• Pheochromocytoma BP Control: If BP is high on standard antihypertensives, the next best step is adding phenoxybenzamine. Never schedule immediate surgery without adequate alpha-blockade.

Memory Pearls

• Cushing’s Algorithm: Screen with Secretions (Urine/Saliva), Assess ACTH, Investigate Imaging.
• Steroid Replacement Rule: Primary AI needs Primary + Secondary hormones (Glucocorticoids + Mineralocorticoids). Secondary AI needs Secondary hormone replacement only (Glucocorticoids).
• Pheo Blockade: A before B (Alpha blockade with phenoxybenzamine before Beta blockade).

Thyroid Disorders

Core Concepts

• Anatomy: Normal weight is 15–20 g. Composed of two lobes and an isthmus.
• Blood Supply: Superior thyroid artery (from external carotid) and inferior thyroid artery (from subclavian). High blood flow (4–6 mL/min/g); in Graves' disease, flow can exceed 1 L/min, producing an audible bruit or palpable thrill.
• Histology:
  • Follicles: Spherical units filled with proteinaceous colloid (major constituent of thyroid mass).
  • Parafollicular (C) cells: Source of calcitonin. Hyperplasia occurs early in MEN2, giving rise to medullary thyroid carcinoma.
• Pathophysiology of Hypothyroidism-induced Hyperprolactinemia: Primary hypothyroidism elevates TRH, which directly stimulates lactotrophs, leading to hyperprolactinemia. This resolves with levothyroxine replacement.
• Polyglandular Autoimmune Syndromes: A patient with hypothyroidism, vitiligo, fatigue, weight loss, and hypotension suggests concurrent adrenal insufficiency (Schmidt syndrome/PAS type 2). Next step is an ACTH stimulation test.

Diagnosis / Clinical Features

• Hyperthyroidism (Graves' Disease):
  • Specific signs (highly tested): Thyroid bruit, exophthalmos, pretibial myxedema, and thyroid acropachy (clubbing/nail changes).
  • Labs: High free T4/T3, low TSH.
• Subacute Viral Thyroiditis:
  • Presents with palpitations, tachycardia, and a tender thyroid (or post-viral symptoms).
  • Labs/Imaging: Suppressed TSH, elevated T4, decreased iodine uptake.
• Thyroid Storm:
  • Acute, life-threatening hypermetabolic state.
  • Presentation: Fever, severe tachycardia, hypertension, neurological (agitation/delirium), and GI abnormalities. Diagnosis is primarily clinical.
• Myxedema Coma:
  • Life-threatening, decompensated hypothyroidism precipitated by cold, infection, or drugs.
  • Presentation: Altered mental status (lethargy, stupor, coma), severe bradycardia, and hypothermia.
• Thyroid Malignancies:
  • Papillary Carcinoma (70–80%): Most common. Females (30–50 yrs). Indolent, lymphatic spread. Associated with childhood radiation exposure. Histology: finger-like projections.
  • Follicular Carcinoma (10–15%): Females (40–60 yrs). Histology: spherical cells. Hematogenous spread (invades blood vessels -> bone/lung).
  • Medullary Carcinoma (5–10%): Arises from C-cells (calcitonin). Associated with MEN2A, MEN2B, or sporadic.
  • Anaplastic Carcinoma (<5%): Elderly (>65 yrs). Loss of normal structure, highly aggressive, invasive, and least responsive to treatment.

Investigations

• Thyroid Function Tests (TFTs): Initial step for almost all thyroid complaints.
  • Central Hypothyroidism: Post-pituitary surgery (e.g., transsphenoidal adenoma removal), TSH is an unreliable marker. Measure Free T4 to assess thyroid function.
• Radioactive Iodine Uptake (RAIU) Scan:
  • Increased Uptake: Graves' disease, toxic MNG, toxic adenoma, TSH-oma, hCG-induced (pregnancy, trophoblastic tumors).
  • Decreased Uptake: Subacute thyroiditis, iatrogenic/factitious thyrotoxicosis, struma ovarii, metastatic thyroid carcinoma.
  • Contraindication: Absolutely do not do during pregnancy.
• Thyroid Nodule Workup:
  • Step 1: Check TSH.
  • Step 2 (Normal or High TSH): Indicates a euthyroid or hypothyroid state. Next step for a suspicious, complex, or solid nodule (e.g., >1 cm, microcalcifications) is Ultrasound-guided Fine Needle Aspiration (FNA).
  • Step 2 (Low TSH): Next step is a Radionuclide Uptake Scan to differentiate "hot" (rarely malignant) vs. "cold" (higher malignancy risk) nodules.
  • Gold Standard for diagnosis: FNA or surgical pathology.

Management

• Hyperthyroidism:
  • General: Anti-thyroid drugs (carbimazole/methimazole, PTU), radioactive iodine (I-131), or surgery. Temporary beta-blockers for symptom control.
  • Pregnancy: PTU is used if planning pregnancy or in the 1st trimester (Methimazole is teratogenic in the 1st trimester). Switch to Carbimazole/Methimazole in the 2nd/3rd trimesters.
• Subacute Thyroiditis:
  • Self-limiting. Management is observation + Propranolol (for palpitations/tachycardia), NSAIDs, or steroids. Anti-thyroid meds are not indicated.
• Thyroid Storm:
  • Supportive care, Propylthiouracil (PTU), and Beta-blockers.
• Hypothyroidism:
  • Standard: Levothyroxine (no need for T3).
  • Elderly/Cardiac Patients: Start with a low dose and titrate slowly to avoid precipitating angina/ischemia.
  • Myxedema Coma: Supportive measures + IV levothyroxine. Must give stress-dose steroids after drawing cortisol, due to the risk of concurrent adrenal insufficiency.
• Thyroid Nodules / Goiter:
  • ATA does not recommend levothyroxine suppression therapy for benign solitary nodules or sporadic non-toxic MNGs in iodine-sufficient populations.
  • Surgical Indications: Malignancy, indeterminate/repeatedly non-diagnostic FNA, cosmetic concerns, obstructive symptoms.
• Thyroid Cancer: Total/hemi-thyroidectomy (needs experienced surgeon) -> I-131 ablation -> External beam radiation/chemo if advanced.

Past-Paper High Yield

• Nodule Workup: Euthyroid patient with a solid, hypoechoic, or complex thyroid nodule (e.g., 1.5 cm with microcalcifications) + normal TSH -> Next step: FNA. (Do not pick observe, levothyroxine, or scan).
• Low-Uptake Thyrotoxicosis: Commonly tested causes include subacute viral thyroiditis and factitious thyrotoxicosis (exogenous hormone abuse).
• Hyperemesis Gravidarum vs. Thyrotoxicosis: A pregnant woman (e.g., 11 weeks) with severe N/V, low TSH, and upper-limit-normal T3/T4 has hCG-induced hyperthyroidism. This is transient and cross-reactivity-driven. If severe sweating/palpitations occur at 8 weeks with a profoundly high T4, do an abdominal US to rule out molar pregnancy.
• Pregnancy Management:
  • Planning pregnancy / 1st trimester -> PTU.
  • 2nd/3rd trimester thyrotoxicosis -> Carbimazole/Methimazole.
  • Never use RAI uptake/scans or radioactive ablation in pregnancy.
• Levothyroxine Dosing: Elderly patients with a history of heart disease must start on a low dose of levothyroxine, unlike young healthy adults.
• Hypothyroidism + Hyperprolactinemia: Reassure the patient that correcting the hypothyroidism with levothyroxine will resolve the hyperprolactinemia.
• Central Hypothyroidism: Post-transsphenoidal surgery, monitor thyroid function by measuring T4, not TSH.
• Hyperparathyroidism Differential: A 70F with back pain, abdominal pain, constipation, High Ca, High PTH, Low PO4 -> Primary Hyperparathyroidism. An asymptomatic patient with mildly elevated Ca (e.g., 10.6), high PTH, and high urine Ca is typically managed with Observation if not meeting surgical criteria.

Memory Pearls

• Papillary vs. Follicular: Papillary has Projections (finger-like) and stays local (lymphatic). Follicular flows Far (hematogenous/blood vessel invasion).
• Graves' specific signs: Acropachy, Bruit, Exophthalmos, Pretibial myxedema. (Other hyperthyroid states only have adrenergic signs).
• PTU vs. Methimazole: PTU for Planning Pregnancy.

Calcium Disorders: Hypercalcemia

Core Concepts

Hypercalcemia occurs when calcium entry into the circulation (via accelerated bone resorption or excessive GI absorption) exceeds calcium excretion (urine) or deposition (bone). Primary hyperparathyroidism and malignancy account for >90% of cases.

Classification by PTH status:

• PTH-Mediated (High or Inappropriately Normal PTH):
  • Primary hyperparathyroidism (adenoma, hyperplasia, rare carcinoma)
  • Familial Hypocalciuric Hypercalcemia (FHH)
  • MEN Type I and IIa
  • Tertiary hyperparathyroidism (seen in advanced CKD)
  • Lithium-induced hyperparathyroidism
• PTH-Independent (Low/Suppressed PTH < 20 pg/mL):
  • Malignancy: PTHrP production (squamous cell, solid tumors), osteolysis (bone mets, multiple myeloma), ectopic PTH (rare).
  • Granulomatous diseases: Sarcoidosis, TB (macrophages have extrarenal 1-α-hydroxylase → ↑ 1,25-OH Vitamin D).
  • Medications: Thiazide diuretics, Vitamin D/A toxicity, Theophylline toxicity, Milk-alkali syndrome.
  • Endocrine/Other: Hyperthyroidism, Adrenal insufficiency, Pheochromocytoma, Immobilization, Paget disease (especially with bed rest).

Diagnosis / Clinical Features

• Presentation (Symptoms correlate with acuity and degree of elevation):
  • Bones: Bone pain.
  • Stones: Nephrolithiasis, polyuria, nocturia, dehydration, renal failure.
  • Groans (GI): Constipation, nausea, anorexia, pancreatitis, peptic ulcer disease.
  • Psychic Moans (CNS): Lethargy, weakness, confusion, coma.
  • Cardiac: Syncope, arrhythmias.
• Primary Hyperparathyroidism: Usually chronic, asymptomatic, mild hypercalcemia (< 12 mg/dL).
• Malignancy-associated: Usually acute, symptomatic, severe hypercalcemia (> 12–14 mg/dL). Often signifies advanced disease and a poor prognosis.

Investigations

1. Confirm Hypercalcemia: Repeat the test!
   • Rule out pseudohypercalcemia by correcting for albumin: Corrected Ca = Total Ca + [0.8 x (4.0 - Albumin)].
   • Alternatively, measure ionized calcium.
2. Measure Intact PTH: This is the critical branch point.
   • High or Upper-Normal PTH: Indicates a PTH-mediated cause (Primary HPT or FHH).
   • Low PTH (< 20 pg/mL): Indicates a PTH-independent cause (Malignancy, Granulomatous disease, Vitamin D toxicity).
3. Evaluate Urine Calcium (if PTH is normal/high):
   • High/Normal: Points to Primary hyperparathyroidism.
   • Low (< 100 mg/day or Fractional Excretion < 1%): Suspect FHH, Thiazides, or Milk-alkali syndrome.
4. Evaluate PTH-Independent Causes (if PTH < 20 pg/mL):
   • Measure PTHrP, 25-OH-Vit D (calcidiol), and 1,25-OH-Vit D (calcitriol).
   • If still unclear, consider TSH, SPEP/UPEP (for myeloma), and Vitamin A levels.

Management

Severity-Based Approach:

• Mild / Asymptomatic (< 12 mg/dL): Hydration (6–8 glasses of water/day). Avoid aggravating factors (thiazides, lithium, volume depletion, bed rest, high calcium diet >1000 mg/day).
• Severe (> 14 mg/dL) or Highly Symptomatic:
  1. Isotonic Saline (0.9% NaCl): First-line. Expands volume and promotes renal calcium excretion. Rate: 200–300 mL/h, monitoring urine output and for fluid overload.
  2. Calcitonin (IM/SC): Rapid onset (lowers Ca within 4–6 hrs) but subject to tachyphylaxis within 48 hours. Used as bridge therapy.
  3. Bisphosphonates (IV Zoledronic acid or Pamidronate): Highly effective for osteoclast-mediated resorption. Slow onset (days) but sustained effect. Preferred agents for malignancy.
  • Note on Loop Diuretics (Furosemide): Now reserved only for managing volume overload from IV saline. No longer routinely recommended for primary calcium reduction due to risks of electrolyte derangement and volume depletion.

Specific/Targeted Therapies:

• Glucocorticoids (Prednisone): Specifically for granulomatous diseases (e.g., sarcoidosis) or lymphomas. Decreases extrarenal calcitriol production (onset 2–5 days).
• Calcimimetics (Cinacalcet): Lowers PTH; used for parathyroid carcinoma or severe secondary HPT in dialysis patients.
• Gallium Nitrate: Inhibits osteoclastic resorption and PTH secretion; nephrotoxic, requires continuous infusion.
• Hemodialysis: Last resort for severe hypercalcemia with advanced CKD or heart failure where IV fluids cannot be safely given.
• Parathyroidectomy: Definitive treatment for Primary HPT. Indications in asymptomatic patients:
  • Age < 50 years.
  • Serum Ca > 1.0 mg/dL above the upper limit of normal.
  • Low Bone Mineral Density (BMD / osteoporosis).
  • CKD / Impaired renal function (due to hypercalcemia).

Complications / Prognosis

• Hypercalcemia of malignancy heavily portends a very poor prognosis.
• Milk-alkali syndrome can result in irreversible structural renal injury if prolonged.

Past-Paper High Yield

• FHH vs. Primary HPT: An asymptomatic patient with high calcium, high/normal PTH, and a family history of hypercalcemia requires a urine calcium-to-creatinine ratio to diagnose FHH. (FHH will show extremely low urine calcium).
• Diagnosing Primary HPT: An asymptomatic patient with high calcium, normal (or elevated) PTH, and normal creatinine most likely has Primary HPT. (Normal PTH is inappropriately unsuppressed in the face of high calcium).
• Sarcoidosis Mechanism: Hypercalcemia is driven by extrarenal 1-α-hydroxylase activity increasing 1,25-OH-Vit D. You will NOT find high PTH (PTH will be strongly suppressed).
• Malignancy Traps:
  • A male with prostate cancer presenting with hypercalcemia → best next step is to measure PTHrP.
  • A heavy smoker with a cavitary right upper lobe lesion (Squamous Cell Carcinoma) presenting with hypercalcemia (e.g., 11.9 mg/dL) → Hypercalcemia is due to PTHrP from the squamous cell lung cancer.
• Vitamin D Deficiency Traps:
  • Vitamin D deficiency causes low calcium and low phosphate, leading to secondary hyperparathyroidism (HIGH PTH).
  • A finding of "normal PTH" or "high phosphate and low calcium" is incorrect for Vitamin D deficiency.

Memory Pearls

• Causes of Hypocalciuric Hypercalcemia (Low urine Ca): Think FHH, Thiazides, Milk-alkali (Fewer Things Make urine Ca low).
• Albumin Correction Rule: For every 1.0 g/dL drop in albumin below 4.0, total calcium drops by 0.8 mg/dL.
• Calcitonin vs. Bisphosphonates: Calcitonin is fast but transient (tachyphylaxis); Bisphosphonates are slow but lasting. Use them together in severe hypercalcemic crises.

Reproductive Disorders

Core Concepts

• Hypogonadism Definition: Decreased function of the gonads.
  • Male: Decreased testosterone production and/or impaired spermatogenesis.
  • Female: Decreased estrogen production.
• Primary vs. Central Hypogonadism: Differentiated by LH levels.
  • Primary: Pathology in the gonads (Testes/Ovaries). LH is high (loss of negative feedback).
  • Central: Pathology in the pituitary or hypothalamus. LH is low or inappropriately normal.
• Note: Gynecomastia and Hirsutism are strictly self-reading topics for this module but frequently tested alongside these core concepts.

Diagnosis / Clinical Features

Symptoms of Testosterone Deficiency (Males)

• Mild-Moderate: Non-specific fatigue, weakness, depression, daytime sleepiness, reduced confidence, decreased libido, mild erectile dysfunction.
• Advanced: Loss of facial hair, loss of muscle mass, gynecomastia.
• Severe: Infertility.

Specific Syndromes causing Hypogonadism

• Klinefelter Syndrome (Primary): Chromosomal disorder (47, XXY). Characterized by tall stature, small firm testicles, gynecomastia, decreased libido, and infertility.
• Kallmann Syndrome (Central): Disordered migration of GnRH-producing neurons into the hypothalamus.
  • Features: Hypogonadism combined with anosmia.
  • Associated midline defects: Cleft lip/palate, sensorineural deafness, cerebellar ataxia, and renal agenesis.
  • Genetics: Low T, LH, and FSH. Can be X-linked, AD, or AR.
• Turner Syndrome (Primary): Chromosomal disorder affecting females (45, XO). Complete or partial absence of one X chromosome.

Congenital Adrenal Hyperplasia (CAH) Defect in adrenal hormone synthesis enzymes. 21-hydroxylase deficiency is the most common. Clinical presentation depends on the severity of the enzyme deficiency:

• Classical CAH (Severe deficiency): Presents at birth. Females have ambiguous genitalia.
  • Salt-losing form: Accompanied by severe clinical adrenal insufficiency (AI).
  • Non-salt-losing form: Ambiguous genitalia without clinical AI.
• Non-Classical CAH (Mild deficiency): Presents later (puberty/adolescence) with primary amenorrhea OR irregular periods and hirsutism.

Investigations

1. Confirming Testosterone Deficiency

• Initial Test: Suspected hypogonadism requires measuring testosterone.
• Ideal Test: Free testosterone by equilibrium dialysis or bioavailable testosterone (often unavailable locally).
• Practical Step: Measure Total Testosterone and SHBG, then use a calculator to determine free and bioavailable testosterone.

2. Localizing the Defect (Next Step)

• Measure LH:
  • High LH (Primary Hypogonadism): Investigate testicular causes (karyotype for Klinefelter, history of chemo/radiation, surgical removal, or infiltrative diseases like hemochromatosis).
  • Low/Normal LH (Central Hypogonadism): Next best step is a Pituitary MRI to rule out structural hypothalamic/pituitary pathology.

3. Congenital Adrenal Hyperplasia Workup

• Diagnostic marker: Measure 17-hydroxyprogesterone (elevated in 21-hydroxylase deficiency).
• Key differentiator: Patients with 21-hydroxylase deficiency are typically normotensive, in contrast to other forms of CAH (like 11β-hydroxylase deficiency, which presents with hypertension).

Past-Paper High Yield

• Infertility Workup Next Step: In a male patient presenting with decreased libido, fatigue, small firm testicles, family history of infertility, and tall stature (e.g., 1.92 meters), the diagnosis is Klinefelter Syndrome.
  • Exam Trap/Next Step: Do not immediately biopsy the testicle or order an MRI; the correct next step is Karyotyping (to confirm 47, XXY).

Memory Pearls

• Anosmia + Hypogonadism + Midline defects: Kallmann Syndrome (Failure of GnRH migration).
• Tall stature + Small firm testes + Infertility: Klinefelter Syndrome (47, XXY).
• High LH: The problem is in the gonads (Primary).
• Low/Normal LH: The problem is in the brain (Central) → get a Pituitary MRI.
• Elevated 17-OH Progesterone + Normotensive: 21-Hydroxylase Deficiency.

Diabetes Mellitus

Core Concepts

• Definition: A state of hyperglycemia resulting from a progressive loss of insulin secretion from beta cells, often superimposed on a background of insulin resistance.
• Classification by Etiology:
  • Type 1 Diabetes (Absolute insulin deficiency):
    • Type 1A: Autoimmune destruction. Associated with autoantibodies (GAD, insulin, IA-2, ZnT8).
    • Type 1B: Idiopathic/non-autoimmune beta-cell loss.
  • Type 2 Diabetes (Relative deficiency): Driven by peripheral insulin resistance and beta-cell dysfunction. Accounts for 90-95% of cases. Strongly linked to obesity (specifically visceral/intra-abdominal fat), sedentary lifestyle, and family history.
  • Monogenic Diabetes (formerly MODY): Autosomal dominant transmission, onset typically < 25 years, lack of autoantibodies. Associated with genetic mutations (e.g., HNF1A, GCK, HNF4A).
  • Latent Autoimmune Diabetes in Adults (LADA): Adult-onset, positive for ≥1 islet autoantibody, slow progression to insulin dependence. Clinically resembles T2DM initially but has a sub-therapeutic response to oral agents (like metformin or sulfonylureas).
  • Secondary Diabetes:
    • Conditions causing insulin resistance: Gestational DM, Cortisol-associated DM.
    • Conditions causing insulin deficiency (NOT resistance): Pancreatitis-associated DM, Cystic fibrosis-associated DM.

Diagnosis / Clinical Features

• Clinical Presentation:
  • The majority of T2DM patients are asymptomatic at presentation.
  • Classic symptoms (catabolic state): Polyuria, polydipsia, nocturia, blurred vision, and weight loss.
• Diagnostic Criteria:
  • Symptomatic patients: Random plasma glucose ≥ 200 mg/dL + classic symptoms.
  • Asymptomatic patients: Requires two abnormal test results (either concordant from the same sample or repeated on a separate day):
    • Fasting Plasma Glucose (FPG) ≥ 126 mg/dL.
    • 2-hour Plasma Glucose ≥ 200 mg/dL (during a 75g OGTT).
    • HbA1c ≥ 6.5%.

Investigations

• Islet Autoantibody Testing: Indicated when the diagnosis is uncertain, in young adults (<35), lean patients, or those with a sub-therapeutic response to oral medications.
• C-Peptide Level: Differentiates endogenous vs. exogenous hyperinsulinemia. Low C-peptide with high insulin in a hypoglycemic patient indicates exogenous insulin administration.
• Pre-Insulin Labs: Always check potassium (K) levels before initiating insulin, as insulin drives potassium into cells and can trigger severe hypokalemia.
• Insulin Tolerance Test: The gold standard test for confirming low Growth Hormone (GH) in a child presenting with short stature.

Management

• Treatment Goals: Achieve near-normoglycemia (typically HbA1c ≤ 7.0% for most), minimize cardiovascular risk factors, and avoid hypoglycemia.
• Lifestyle Modifications: Medical nutrition therapy, weight reduction, and exercise. A 3–6 month trial of strictly lifestyle changes is only appropriate for highly motivated patients with an HbA1c near target (< 7.5%).
• Metformin: First-line pharmacologic therapy for asymptomatic, non-catabolic T2DM.
  • Indications: Start immediately alongside lifestyle modifications if HbA1c > 7.5% or FBG is elevated but below the severe threshold (e.g., FBG 180–240 mg/dL).
  • Advantages: Highly efficacious, weight-neutral, low hypoglycemia risk.
  • Adverse Effects: Gastrointestinal upset (take with food to minimize), lactic acidosis (rare but high mortality), and Vitamin B12 deficiency (can present as macrocytic anemia or peripheral neuropathy).
• Insulin Therapy Initiation:
  • Indicated as initial therapy in T2DM if the patient is symptomatic/catabolic (weight loss, ketonuria) or has severe hyperglycemia (FBG > 250 mg/dL, Random BG > 300 mg/dL, or HbA1c > 10%).
• Drug Selection Based on Patient Profile:
  • Weight loss priority: GLP-1 receptor agonists or SGLT2 inhibitors.
  • Cardiovascular/Renal Comorbidities: GLP-1 receptor agonists or SGLT2 inhibitors.
  • Cost concerns: Sulfonylureas (e.g., glipizide) or pioglitazone.
• Hospitalized Patient Hyperglycemia:
  • Always use scheduled basal and pre-prandial insulin. Do not rely on a standalone insulin sliding scale.
• Diabetic Ketoacidosis (DKA) Management:
  • Mainstays are IV fluids, potassium replacement, and regular insulin.
  • Bicarbonate is generally not indicated (especially at pH levels like 7.25); it is strictly reserved for profoundly severe acidemia (pH < 6.9).
  • Address underlying precipitants (e.g., start antibiotics if the patient has signs of infection like fever and dysuria).

Complications / Prognosis

• Monitor HbA1c at least twice yearly in patients meeting glycemic goals, and quarterly in patients who are not at goal or whose therapy has changed.
• Reversing obesity can dramatically improve glycemic management and may even induce diabetes remission.

Past-Paper High Yield

• Diagnostic confirmation: If an asymptomatic patient has an HbA1c of 6.6% and an FBG of 127 mg/dL on the same day, they are definitively diagnosed with DM; no further testing is required.
• Insulin Resistance vs. Deficiency trap: Pancreatitis-associated DM and Cystic fibrosis-associated DM are due to structural destruction of the pancreas (deficiency), making them the least likely forms of diabetes to be associated with insulin resistance.
• Starting Insulin: A newly diagnosed patient with classic catabolic symptoms (e.g., random glucose 260 mg/dL, polyuria, weight loss) must be started on insulin as the next step, not oral agents.
• Starting Metformin: A patient with isolated polyuria, FBG 240 mg/dL, and HbA1c 7.5% (no weight loss or extreme elevations) should be started on lifestyle modifications and metformin.
• Metformin-induced Anemia: If a well-controlled diabetic on metformin, a sulfonylurea, and a statin develops new-onset anemia or neuropathy, it is most likely due to B12 deficiency from metformin.
• DKA Insulin Choice: For a patient in ketoacidosis, the specific type of insulin required is regular insulin.
• Weight loss add-on: For an obese patient (BMI 35) already on metformin who actively wants to lose weight, the best drug to add is a GLP-1 agonist.

Memory Pearls

• LADA: Think "Type 1.5" — autoimmune destruction presenting in adulthood. Suspect it when a non-obese adult fails metformin.
• MODY: Monogenic, Onset young (<25), Dominant inheritance, Yields negative autoantibodies.
• Metformin Side Effects (The 3 M's): Macrocytic anemia (B12 deficiency), Metallic taste (GI upset), Muscle pain (Lactic acidosis).
• Insulin pre-requisite: Check the K before you give the Key (insulin) to the cell.
• Hospital Glucose Management: Basal-bolus is best; sliding scale is a mess.

Diabetes Cases

Core Concepts

• Diagnosis Principles: A single abnormal glucose reading (fasting ≥ 126 mg/dL or random ≥ 200 mg/dL) is only diagnostic if accompanied by unequivocal classic symptoms (polyuria, polydipsia, unexplained weight loss). Otherwise, a second confirmatory test is required.
• DKA Sequence of Care: Intravenous fluids and electrolyte assessment always precede insulin administration to prevent fatal shifts in potassium.
• Glycemic Targets: Elderly patients with significant comorbidities (e.g., CKD, CAD) require relaxed HbA1c targets to avoid life-threatening hypoglycemia.

Diagnosis / Clinical Features

• Interpreting Random Glucose: A random glucose ≥ 200 mg/dL after a large meal in an asymptomatic patient is not sufficient for diagnosis. More testing (fasting glucose, HbA1c, or OGTT) is required.
• Clarifying Symptoms: If a patient presents with a single elevated fasting glucose (e.g., 136 mg/dL) and an isolated symptom like weight loss, you must clarify for other classic symptoms (polyuria, polydipsia) before making a definitive diagnosis without a second test.
• Adult-Onset Autoimmune Diabetes (LADA / T1DM): Suspect Type 1 DM or LADA in lean adults (e.g., BMI ~22) presenting with rapid-onset unintentional weight loss, polyuria, and severe hyperglycemia. Do not assume Type 2 DM based on age alone.
• Cystic Fibrosis-Related Diabetes (CFRD): A distinct clinical entity in patients with cystic fibrosis. It is neither classic Type 1 nor Type 2.

Investigations

• Differentiating T1 vs. T2 DM: In lean adults with severe symptomatic hyperglycemia, check serum C-peptide (inappropriately low in T1DM/LADA) and autoantibodies (e.g., GAD antibodies).
• Initial DKA Workup: Before starting targeted therapy, draw labs for Kidney Function Tests (KFTs - specifically potassium), serum ketones, ABG, Urinalysis (UA), and a CXR (to identify infectious triggers).

Management

• DKA Initial Step: The best first step in severe hyperglycemia/DKA (e.g., glucometer reads "Hi", accompanied by nausea/vomiting) is to start IV Normal Saline (0.9%) and draw baseline labs.
  • Exam Trap: Never start an insulin drip before knowing the serum potassium level, as insulin drives potassium intracellularly and can cause fatal arrhythmias if the patient is hypokalemic.
• CFRD Treatment: Patients diagnosed with Cystic Fibrosis-Related Diabetes require insulin therapy.
• Basal Insulin Adjustment (Somogyi Effect / Overbasalization):
  • Scenario: Elderly patient on basal-bolus insulin with a low/strict HbA1c (e.g., 6.1%), seemingly normal daytime sugars, but highly elevated morning fasting blood glucose (e.g., 180–250 mg/dL).
  • Action: Decrease the basal insulin dose (e.g., glargine/Lantus).
  • Rationale: A low HbA1c discordant with high morning fasting sugars strongly suggests undetected nocturnal hypoglycemia causing rebound morning hyperglycemia.
• Diabetic Neuropathy / Erectile Dysfunction (ED): ED is a common microvascular/autonomic complication. First-line therapy includes PDE-5 inhibitors (e.g., sildenafil).

Past-Paper High Yield

• Sildenafil Contraindications: In a diabetic patient prescribed sildenafil (Viagra) for ED, nitrates (e.g., isosorbide dinitrate) are absolutely contraindicated. Co-administration causes excessive cGMP accumulation, leading to profound, refractory vasodilation and life-threatening hypotension.

Memory Pearls

• DKA Priority: Fluids first, K+ second, Insulin third.
• Discordant A1c vs. Fasting: Low A1c + High Fasting = Hidden Lows. (Decrease the basal insulin).
• Lean + Hyperglycemia: Age does not rule out Type 1. Check C-peptide and GAD in lean adults with severe classic symptoms.
• The "NO" Rule: Nitrates + Sildenafil = NO (Nitric Oxide overload → severe hypotension).

GI

Exam Map

High-Yield Exam Themes & Revision Priorities:

• Esophageal Dysphagia Timelines: You must reflexively distinguish between mechanical obstruction (solids first, progressing to liquids) and motility disorders like Achalasia (simultaneous difficulty with solids and liquids).
• The Eosinophilic Esophagitis (EoE) Patient: Frequently tested as a young adult with a history of asthma/eczema presenting with a food bolus impaction. Look for "rings and furrows" on EGD and treat with topical/swallowed steroids.
• IBD Pathology & Extraintestinal Rules: Differentiating UC (continuous, crypt abscesses, rectal involvement) from CD (skip lesions, granulomas, transmural) is heavily tested. Exam Trap: UC patients who develop Primary Sclerosing Cholangitis (PSC) require annual colonoscopies immediately upon PSC diagnosis due to massive cancer risk.
• Acute GI Bleed Management: Hemodynamic stabilization is always the correct first step. Once stable, upper GI bleeds require EGD within 24 hours. Do not choose NGT lavage to rule out an upper GI bleed (high false-negative rate).
• Differentiating Lower GI Bleeds: Painless, brisk right-sided bleeding points to Diverticulosis. Painful, left-sided (LLQ) bleeding with "thumbprinting" on X-ray points to Ischemic Colitis.
• Autoimmune Liver Triads: Memorize the antibody associations: PBC = AMA positive (treat with UDCA); PSC = p-ANCA positive (strongly associated with Ulcerative Colitis, diagnose with MRCP); AIH = ANA/SMA or LKM-1 positive (treat with steroids).
• Cirrhosis Fluid Management: Calculate the SAAG ( ≥ 1.1 = portal hypertension). If performing a large-volume paracentesis, you must replace albumin (8 grams per liter removed) to prevent circulatory collapse.
• Wilson's Disease Lab Trap: Untreated Wilson's presents with low total serum copper and low ceruloplasmin, but highly elevated 24-hour urine copper. Do not pick "low urine copper" or "high serum copper" as correct statements.
• Liver Enzyme Ratios: Early NASH presents with AST/ALT < 1, whereas Alcoholic Hepatitis (ASH) presents with AST/ALT > 2.
• Malabsorption Localization: Use deficiency patterns to locate the disease: Iron = Duodenum (Celiac), Folate = Jejunum, B12/Bile Salts = Terminal Ileum (Crohn's). Use a high stool osmotic gap to identify carbohydrate malabsorption (e.g., lactose intolerance).
• Pancreatitis Decision Traps: Review drug-induced causes, amylase-vs-lipase interpretation, gallstone predictors, antibiotic pancreatic penetration, Ranson severity criteria, and pseudocyst intervention thresholds.

Esophageal Disorders

Core Concepts

• GERD Pathophysiology: Reflects an imbalance between injurious and defensive factors.
  • Primarily driven by Transient Lower Esophageal Sphincter Relaxations (TLESRs) or a hypotensive LES.
  • Aggravated by fat, chocolate, caffeine, smoking, alcohol, and drugs (e.g., anticholinergics, CCBs, nitrates, TCAs).
  • Anatomic disruption of the gastroesophageal junction (GEJ), such as a sliding hiatal hernia, contributes to incompetence.
• Achalasia: Results from the progressive degeneration of inhibitory ganglion cells (neurons) in the myenteric plexus -> failure of LES relaxation and aperistalsis in the esophageal body.
  • Pseudoachalasia (Secondary): Must be ruled out. Causes include gastric carcinoma, Chagas disease, amyloidosis, sarcoidosis, Eosinophilic Esophagitis (EoE), and neurofibromatosis.
• Eosinophilic Esophagitis (EoE): A chronic, immune/antigen-mediated disease heavily associated with atopic/allergic conditions (asthma, eczema).
• Esophageal Motility Disorders:
  • Diffuse Esophageal Spasm: Impaired inhibitory innervation leading to premature, simultaneous, and rapidly propagated contractions.
  • Nutcracker Esophagus: Smooth muscle hypertrophy or excessive excitation causing extremely high-pressure, yet sequential, contractions.
• Hiatal Hernias:
  • Sliding: Both the GEJ and part of the fundus herniate into the thorax (frequently contributes to GERD).
  • Para-esophageal: The fundus herniates beside a normally located GEJ (risk of incarceration, ulceration, or dysphagia).

Diagnosis / Clinical Features

• General Symptoms: Dysphagia (difficulty swallowing), odynophagia (painful swallowing), regurgitation, heartburn, non-cardiac chest pain.
• GERD: Classic heartburn and regurgitation.
  • Extra-esophageal manifestations: Hoarseness, chronic laryngitis, chronic cough, and exacerbation of asthma.
• Achalasia: Progressive dysphagia to both solids and liquids, chest pain, regurgitation, and difficulty belching.
• Eosinophilic Esophagitis (EoE): Dysphagia, food bolus impaction, refractory heartburn, and feeding difficulties.
• Zenker's Diverticulum: A false diverticulum in the posterior hypopharyngeal wall. Classically presents with dysphagia, halitosis (bad breath), and regurgitation of undigested food (often causing a nighttime cough).
• Esophageal Constrictions:
  • Schatzki Ring: Thin constriction at the squamocolumnar junction; a common cause of dysphagia and food bolus obstruction.
  • Esophageal Web: Congenital or inflammatory hypopharyngeal constrictions. Associated with iron deficiency anemia in Plummer-Vinson syndrome.
• Mallory-Weiss Tear: Upper GI bleeding preceded by severe vomiting and retching (mucosal tear at the GEJ).

Investigations

• Endoscopy (EGD):
  • Barrett's Esophagus: Visualizes metaplastic columnar epithelium replacing normal stratified squamous epithelium. Requires biopsy for diagnosis.
  • EoE: Classically reveals mucosal rings and furrows. Biopsy confirms >15 eosinophils/HPF.
  • Achalasia: Essential to perform to exclude secondary mechanical causes (pseudoachalasia).
• Esophageal Manometry (Gold Standard for Motility Disorders):
  • Achalasia: Failure of LES relaxation, elevated or normal resting LES pressure, aperistalsis, and simultaneous contractions (>40 mmHg).
  • Esophageal Spasm: >20% of swallows show premature, simultaneous contractions.
  • Nutcracker Esophagus: Sequential contractions but with abnormally high pressures.
• Barium Swallow:
  • Achalasia: Dilated esophagus, absent peristalsis, and a "bird-beak" narrowing at the lower end.
  • Esophageal Spasm: "Corkscrew" or "rosary bead" appearance.
• 24-Hour pH Monitoring / Impedance: Used to definitively diagnose GERD or quantify reflux.
• Chest X-Ray (Achalasia): May show an absent gastric bubble, an air-fluid level, and a widened mediastinum.

Management

• GERD: Lifestyle modifications -> H2 receptor blockers -> Proton Pump Inhibitors (PPIs). Surgical fundoplication is an option for refractory cases.
• Barrett's Esophagus: Aggressive GERD treatment (PPIs) and regular surveillance for dysplasia. Dysplasia is managed with endoscopic therapy (ablation/resection) or surgery (esophagectomy).
• Achalasia: Aimed at decreasing LES pressure.
  • Mechanical: Endoscopic balloon dilation, Peroral Endoscopic Myotomy (POEM), Heller myotomy.
  • Pharmacological: Botulinum toxin injection, oral nitrates, or Calcium Channel Blockers (CCBs).
• Eosinophilic Esophagitis: PPIs, topical (swallowed) glucocorticoids, dietary elimination, and endoscopic dilation for strictures.
• Zenker's Diverticulum: Cricopharyngeal myotomy + diverticulectomy.
• Esophageal Spasm & Nutcracker Esophagus: PPIs, peppermint oil, Calcium Channel Blockers (CCBs).
• Rings and Webs: Endoscopic dilation.

Complications / Prognosis

• GERD Complications: Esophageal stricture, Barrett's esophagus, esophageal adenocarcinoma, and exacerbated asthma.
• Barrett's Esophagus: Carries a >30-fold increased risk of esophageal adenocarcinoma (0.1–3% annual incidence).
• Caustic Ingestion: Severe ulceration can rapidly progress to profound fibrosis and intractable stricture formation.
• Mallory-Weiss Tear: Most cases resolve spontaneously without specific intervention.

Past-Paper High Yield

• Achalasia presentation: Highly tested as a patient (often middle-aged, normal physical exam) complaining of progressive dysphagia to both solids and liquids simultaneously. Manometry is required to confirm.
• Zenker's Diverticulum clues: Look for the classic triad of dysphagia, halitosis, and night-time coughing/regurgitation in an elderly patient.
• Eosinophilic Esophagitis indicators: Frequently tested as a young patient with a history of asthma or eczema presenting with a food bolus obstruction. Endoscopy showing "rings and furrows" is the diagnostic giveaway. The cornerstone of medical management is topical (swallowed) steroids.
• Nutcracker Esophagus vs. Spasm: Examiners differentiate Nutcracker esophagus by defining it as extremely forceful peristaltic activity causing chest pain/dysphagia, but crucially maintaining normal sequential peristalsis (unlike the simultaneous contractions of diffuse esophageal spasm).

Memory Pearls

• Dysphagia Timeline Rule:
  • Solids only (progressing to liquids) = Mechanical obstruction (Stricture, Schatzki ring, Web, Carcinoma).
  • Solids AND liquids (simultaneously) = Motility disorder (Achalasia, Spasm).
• Barium Buzzwords:
  • Achalasia = "Bird-beak"
  • Diffuse Esophageal Spasm = "Corkscrew"
• Plummer-Vinson Triad: Dysphagia + Esophageal Webs + Iron Deficiency Anemia.
• EoE Biopsy Cutoff: >15 Eosinophils/HPF with rings and furrows on EGD.
• Zenker's Location: A "false" diverticulum located in the posterior hypopharyngeal wall.

Upper Gastrointestinal Bleeding

Core Concepts

• Definition: Bleeding originating proximal to the Ampulla of Vater (Ligament of Treitz).
• Epidemiology: Accounts for 50% of all gastrointestinal bleeding.
• Major Etiologies:
  • Peptic Ulcer Disease (PUD): Most common. Risk factors include H. pylori, NSAIDs/COX-2 inhibitors, antithrombotics, smoking.
  • Varices/Portal Hypertensive Gastropathy: Suspect in chronic liver disease or heavy alcohol use.
  • Angiodysplasia (AVMs): Associated with renal disease, aortic stenosis (Heyde syndrome), or Hereditary Hemorrhagic Telangiectasia (HHT).
  • Aorto-enteric Fistula: Highly lethal; suspect in patients with a history of an abdominal aortic aneurysm (AAA) or aortic graft.
  • Marginal Ulcers: Occur at anastomotic sites (e.g., prior gastroenteric anastomosis).
  • Malignancy: Clues include dysphagia, early satiety, weight loss, and cachexia.

Diagnosis / Clinical Features

• Classic Presentation: Hematemesis, melena, upper abdominal pain, pallor, dizziness.
• Signs of Severe Bleeding: Orthostatic dizziness, confusion, angina, severe palpitations, cold/clammy extremities.
• Hemodynamic Correlation with Blood Loss:
  • <15% loss: Resting tachycardia.
  • ~20-40% loss: Orthostasis (The most accurate non-invasive indicator of blood loss severity). Defined as: ↓ Systolic BP > 20 mmHg, ↓ Diastolic BP > 10 mmHg, or ↑ HR > 15 bpm within 3 minutes of standing.
  • >40% loss: Supine hypotension/shock.
• Medication Mimickers: Bismuth, charcoal, licorice, and iron supplements can alter stool color (turning it black), resulting in false melena.

Investigations

• Risk Stratification Scores:
  • Blatchford Score: Pre-endoscopic risk assessment.
  • Rockall Score: Post-endoscopic risk assessment.
• Nasogastric Tube (NGT) Lavage: Has no proven benefit and carries a 15% false-negative rate. Do not rely on it to rule out UGIB.
• Endoscopy (EGD): The definitive diagnostic and therapeutic test.
• Small Bowel Capsule Endoscopy: Indicated for obscure GI bleeding (e.g., persistent melena/anemia with normal upper and lower endoscopies).

Management

1. Initial Resuscitation & Stabilization (Always Step 1)

• Obtain adequate IV access and initiate volume resuscitation.
• Keep the patient NPO.
• Airway protection: Intubate if there is ongoing hematemesis, altered mental status, or loss of the gag reflex to prevent aspiration.

2. Blood Transfusion Thresholds

• General target: Transfuse PRBCs if Hb ≤ 7 g/dL (Hematocrit <21%).
• High-risk target: Transfuse PRBCs if Hb ≤ 9–10 g/dL (Hematocrit <30%) in patients with CAD or shock.
• Platelets: Transfuse if < 50,000 in active/life-threatening bleeding. For stable EGD, a threshold of > 20,000 is acceptable.

3. Pharmacotherapy (Pre-Endoscopy)

• Prokinetics: Erythromycin 250mg IV (3 mg/kg) given 30–60 minutes before EGD to clear the stomach of blood/clots and improve visualization.
• Suspected Non-Variceal (PUD): Start IV PPI infusion (80 mg bolus → 8 mg/hr).
  • Note: PPIs decrease high-risk stigmata and the need for endoscopic intervention, but they do not decrease mortality, re-bleeding rates, or the need for surgery.
• Suspected Variceal Bleeding:
  • Vasoactive agents: Octreotide (50 mcg bolus → 50 mcg/hr infusion for 2–5 days) or Terlipressin to cause splanchnic vasoconstriction.
  • Antibiotic Prophylaxis: Mandatory in cirrhotic patients presenting with UGIB (preferably given before endoscopy).

4. Endoscopy (EGD) Timing

• Never perform EGD before hemodynamic stabilization.
• Routine: Within 24 hours of admission for stable patients (reduces transfusion needs, emergent surgery, re-bleeding, and hospital stay length).
• Urgent: Within 12 hours for high-risk features (tachycardia, hypotension, bloody emesis/NG aspirate, cirrhosis, Hb <8 g/dL).

5. Post-Hemostasis Management

• Antiplatelets (Secondary Prevention): Resume Aspirin/Clopidogrel in 1–3 days (no later than 7 days). If the patient had a stent placed within the last year or recent ACS, consult cardiology prior to stopping these drugs.
• Anticoagulation: Resume Warfarin the same afternoon. Resume LMWH after 12 hours in high-risk patients (e.g., mechanical valves, recent VTE <3mo, AFib + MS/Prosthesis).
• SSRIs: Consider switching to a non-SSRI antidepressant, ensuring a PPI is co-prescribed, and discontinuing NSAIDs.
• Repeat Endoscopy: Routine "second-look" EGD is not recommended unless there is clinical evidence of recurrent bleeding.
• Refractory Bleeding: If bleeding recurs after a second therapeutic EGD session, proceed to surgery or interventional radiology (transcatheter arterial embolization).

Past-Paper High Yield

• The initial step for Melena: In a stabilized patient presenting with melena and a drop in hemoglobin, the immediate next best step is Esophagogastroduodenoscopy (EGD).
• Timing of EGD in PUD: If a patient is stabilized in the ED with fluids and PPIs for a bleeding peptic ulcer, the next best step is to perform Endoscopy within 24 hours. Do not delay to observe, and do not place an NGT.
• Obscure GI Bleed Evaluation: For a patient with longstanding melena, anemia, and multiple normal upper and lower endoscopies, the next best step is a Small intestine capsule endoscopy.
• Cirrhosis Traps (New Ascites vs. Varices): In a patient with chronic hepatitis C presenting with new-onset ascites, the next best step is a diagnostic paracentesis to assess the fluid. Do not jump straight to initiating beta-blockers for variceal prophylaxis before working up the acute decompensation/fluid etiology.

Memory Pearls

• Orthostasis = Volume Loss: It is the single most accurate non-invasive indicator of significant (>20%) blood loss.
• PPI pre-EGD: Helps the endoscopist (less active bleeding/stigmata to treat) but does not save lives (no mortality benefit).
• NG Tubes: Useless for reliably ruling out an upper GI bleed (15% false-negative rate). Do not pick NGT lavage as a necessary diagnostic step.
• Forrest Classification: Used endoscopically to stage peptic ulcers based on their risk of re-bleeding (active spurting vs. clean base).

Lower Gastrointestinal Bleeding

Core Concepts

• Definition: Bleeding originating distal to the Ligament of Treitz (a fibromuscular band originating from the right diaphragmatic crus that fixes the duodenojejunal flexure).
• Lower GI Bleeding Sources:
  • Diverticula (30–40%) – Most common cause of acute massive colonic blood loss.
  • Colitis (15–20%) – Ischemic, infectious, or Inflammatory Bowel Disease (IBD).
  • Neoplasia (13%) – Carcinoma, polyps.
  • Upper GI Bleeding (10–13%) – Rapid transit UGIB can present as lower GI bleeding.
  • Anorectal Disease (10%) – Hemorrhoids, fissures.
  • Angiodysplasia (10%)
• Mid GI Bleeding Sources (Small Bowel):
  • Angiodysplasia (20–60%)
  • Ulcerations (10–40%) – IBD, NSAIDs.
  • Neoplasia (1–10%)
• Melena vs. Hematochezia:
  • Fresh blood usually implies a lower GI cause, unless there is massive/rapid bleeding from an upper GI source (indicated by hemodynamic instability + elevated blood urea).
  • Blood in the bowel for >14 hours converts to melena. Up to 35% of patients with melena have a bleeding source distal to the Ligament of Treitz.

Diagnosis / Clinical Features

History & Clues to Etiology:

• Blood Mixed vs. Separate: Bright red blood separate from stool strongly suggests a benign anorectal cause.
• Iatrogenic: Post-polypectomy bleeding can be delayed for up to 10 days.
• Medications: Always check for NSAIDs, Warfarin, and antiplatelet usage.
• Hidden Bleeding: Hypotension/shock without overt bleeding dictates an obligatory digital rectal examination (DRE).

Key Clinical Presentations by Etiology:

• Diverticular Bleeding: Painless, brisk, large-volume arterial bleeding (due to local trauma to the vasa recti). Often right-sided (despite most diverticula being left-sided).
• Ischemic Colitis: Sudden-onset cramping Left Lower Quadrant (LLQ) pain followed by bloody stools and mild-to-moderate tenderness. Due to low-flow states (most common) > embolization/thrombosis affecting watershed areas.
• Meckel's Diverticulum: Due to a persistent vitelline duct (fails to absorb by the 7th week of pregnancy). Ectopic gastric cells secrete acid, causing adjacent mucosal ulceration and bleeding.

Investigations

General Algorithm for Lower GI Bleeding:

• If bleeding stops spontaneously: Elective colonoscopy ± EGD.
• If continued bleeding: Urgent colonoscopy ± EGD.

Condition-Specific Diagnostics:

• Ischemic Colitis:
  • Plain X-Ray: Classic "thumbprinting" (representing submucosal hemorrhage and edema).
  • Further imaging: Contrast-enhanced CT scan and careful endoscopy.
• Meckel's Diverticulum:
  • Meckel's Scan: IV Technetium-99m is taken up by ectopic gastric mucosa and detected via a gamma camera.

Management

Medical Management:

• Ischemic Colitis:
  • Uncomplicated: Bowel rest, IV hydration, correct the underlying low-flow state ± IV antibiotics (>50% resolve conservatively).
  • Complicated (Infarction/Perforation): Urgent surgery is required if there is increasing tenderness, fever, or ileus.
• IBD Flare: IV hydration, IV steroids, and IV antibiotics.
• Infectious Colitis: IV hydration and IV antibiotics.

Endoscopic Intervention:

• Arterial Lesions (e.g., diverticula, post-polypectomy): Electrocoagulation (Heat Probe), Hemostatic clipping, Adrenaline injection, Snare polypectomy/Endoloop.
• Angiodysplasia & Radiation Colitis: Argon Plasma Coagulation (APC).

Radiologic & Surgical Intervention:

• Interventional Radiology: Angiography with selective embolization.
• Surgery: Accurate pre-operative localization is essential (associated with 5–10% mortality).

Diverticular Bleeding Algorithm:

1. Resuscitate → Diagnose and locate source.
2. Colonoscopy (first-line therapeutic and diagnostic tool).
3. If colonoscopy is unsuccessful AND bleeding is massive:
   • Hemodynamically Stable: Angiography (with embolization).
   • Hemodynamically Unstable: Surgery.

Past-Paper High Yield

• UGIB masquerading as LGIB: A patient presenting with fresh hematochezia, hemodynamic instability, and significantly elevated BUN has a massive Upper GI bleed, not a Lower GI bleed.
• Diverticular bleeding paradox: The majority of diverticula are left-sided, but diverticular bleeding more frequently originates from the right colon.
• Post-polypectomy timeline: Do not rule out iatrogenic bleeding just because the procedure wasn't yesterday; it can present up to 10 days post-procedure.
• Ischemic Colitis X-ray: "Thumbprinting" is the classic radiologic buzzword indicating submucosal edema/hemorrhage.
• Meckel's Pathophysiology: Bleeding is caused by acid secretion from ectopic gastric mucosa ulcerating the adjacent normal bowel wall.

Memory Pearls

• Treitz Landmark: Above Treitz = UGIB; Below Treitz = LGIB.
• Melena Rule: Melena does not absolutely rule out a lower GI bleed (35% are mid-to-lower, provided transit time is >14 hours).
• Pain vs. Painless: Ischemic Colitis = Painful (crampy LLQ). Diverticular Bleed = Painless (brisk, large volume).

Inflammatory Bowel Disease

Core Concepts

• Definition: Chronic, remitting, and relapsing inflammatory diseases of the gut, encompassing Ulcerative Colitis (UC) and Crohn’s Disease (CD).
• Epidemiology: Bimodal age distribution (peaks at 15–40 years and 50–80 years). Affects males and females equally; more common in white populations.
• Pathogenesis: Involves the IL-23–IL-17 axis and TNF-α. Associated with reduced gut microbiota diversity. CD is specifically linked to increased intestinal permeability.

Diagnosis / Clinical Features

Extra-Intestinal Manifestations (EIMs):

• Hepatobiliary: Primary Sclerosing Cholangitis (PSC) – highly associated with UC, gallstones (CD).
• Ocular: Uveitis, episcleritis, conjunctivitis. (Exam trap: Uveitis in CD can occur entirely independently of intestinal disease activity).
• Musculoskeletal: Peripheral arthritis, ankylosing spondylitis, sacroiliitis, metabolic bone disease.
• Dermatologic: Erythema nodosum, pyoderma gangrenosum.
• Hematologic/Vascular: Autoimmune hemolytic anemia, Venous Thromboembolism (VTE).
• Renal: Ureteric obstruction, fistulas, renal calculi (CD).

Investigations

• Endoscopy with Biopsy: Confirmatory test (differentiates UC from CD).
• Stool Studies: Fecal calprotectin (marks intestinal inflammation), culture, and Clostridium difficile toxins (must rule out infectious mimics in acute flares).
• Imaging: Capsule endoscopy (useful for small bowel CD), MRCP (if PSC is suspected).
• Labs: CBC (anemia), LFTs (cholestasis in PSC), CRP/ESR, B12 levels (often deficient in CD due to terminal ileum involvement).

Management

Ulcerative Colitis:

• Mild-to-Moderate (Induction & Maintenance): 5-ASA (Mesalamine) is the mainstay (oral and/or rectal).
• Severe/Fulminant Flare:
  • Admit, daily abdominal X-rays, NPO, monitor inflammatory markers.
  • Initiate IV Steroids (3–5 days) and VTE prophylaxis (LMWH).
  • Contraindication: Do NOT initiate Azathioprine during an acute flare (takes weeks to work).
  • If no response: Cyclosporine or Infliximab.
  • Surgical Consult: Must be done on Day 1 of admission. Colectomy if refractory or toxic megacolon develops.
• Maintenance: Azathioprine/6-MP, Biologics (Infliximab, Vedolizumab, etc.). Note: Methotrexate is generally NOT used for UC maintenance.
• Steroids: Used ONLY for induction. No role in maintenance.

Crohn's Disease:

• Induction: Corticosteroids (e.g., Prednisone, Budesonide for ileocecal disease).
• Maintenance: Azathioprine/6-MP, Methotrexate (MTX), Biologics.
• 5-ASA: Least effective in CD (high NNT of 17); mainly used for post-op colonic disease.
• Antibiotics: Metronidazole for perianal disease, abscesses, or fistulae.
• Surgery: Indicated for complications (obstruction, perforation, abscess) or medical failure. Surgery is not a cure for CD; the disease will recur.

Complications / Prognosis

• Colorectal Cancer (CRC) Risk: Increased in both UC and CD (if colonic involvement).
  • Pancolitis: Risk increases 8–10 years after onset.
  • Left-sided colitis: Risk increases 15–20 years after onset.
  • Proctitis: No significant increased risk.
• PSC and CRC Risk: A diagnosis of PSC in a UC patient drastically increases CRC risk. Surveillance colonoscopy must be performed annually starting from the time of PSC diagnosis.
• Crohn's Specific: Fistulae, bowel obstruction, acute perforation, B12 deficiency (terminal ileum destruction/resection).

Past-Paper High Yield

• Differentiating Mimics:
  • Pseudomembranous Colitis: Suspect in an older patient with recent antibiotics (e.g., treated for osteomyelitis) presenting with watery diarrhea and yellowish-white colonic plaques.
  • Ischemic Colitis: Suspect in elderly patients with vascular risk factors (HTN, DM) presenting with lower abdominal pain, bleeding, and focal ulceration strictly at the splenic flexure (watershed area).
• Upper GI CD: Crohn's can affect the entire GI tract. A patient with watery diarrhea and multiple duodenal ulcers that fail PPI therapy and test negative for H. pylori is a classic presentation for upper GI Crohn's.
• Physical Exam Clues: Anemia + per rectal bleeding + right lower quadrant (RLQ) mass + anal skin tags = Crohn’s disease.
• Diagnosing PSC: In an IBD patient presenting with painless jaundice, pruritus, elevated direct bilirubin, and markedly elevated ALP/GGT, the next best step is MRCP to diagnose Primary Sclerosing Cholangitis.
• Appropriate Maintenance Therapy: Steroids are strictly for induction. Do not choose steroids for maintaining remission. Methotrexate is highly effective for CD but is not standard maintenance for UC.
• Managing the Acute UC Flare: When a patient is admitted for a severe UC flare, initiate IV steroids, LMWH (pro-thrombotic state), and mesalamine enemas. Do NOT start Azathioprine acutely.

Memory Pearls

• UC = Ulcerative Colitis = Upward Continuous (starts in rectum, moves up).
• Crohn's = Cobblestone, Confirmed by non-caseating granulomas, Complete GI tract.
• Uveitis in CD: Follows its own rules (independent of gut inflammation).
• PSC + UC = 1 Year: If a UC patient gets PSC, scope them every 1 year for colon cancer.
• Biopsy distinctions: Crypt abscess = UC; Granuloma = CD.

Malabsorption and Celiac Disease

Core Concepts

Malabsorption broadly encompasses defects in the digestion and absorption of food nutrients along the 6-meter small intestine (amplified by villi and microvilli). It is divided into maldigestion and true malabsorption, mapped to the three phases of nutrient assimilation:

• Maldigestion (Luminal Phase Defect): Impaired breakdown of nutrients into absorbable units.
  • Pancreatic Exocrine Insufficiency: The most common cause. (e.g., chronic pancreatitis, cystic fibrosis). Leads to decreased lipase/protease and fat/protein malabsorption.
  • Inactivation of Pancreatic Enzymes: Hypersecretion of gastric acid (Zollinger-Ellison Syndrome) lowers pH, inactivating enzymes.
  • Inadequate Mixing: Post-gastrectomy.
  • Impaired Micelle Formation (Bile Salt Defect): Decreased synthesis (liver disease), impaired recycling (terminal ileum resection/Crohn's), or bile salt deconjugation (Small Intestinal Bacterial Overgrowth [SIBO] due to strictures, blind loops, or dysmotility).
  • Specific Enzyme Deficiencies: e.g., Lactase deficiency (Lactose intolerance).
• Malabsorption (Mucosal Phase Defect): Defective mucosal uptake/transport due to inadequate absorptive surface or mucosal damage (villous atrophy).
  • Causes: Celiac disease, extensive Crohn’s disease, Giardiasis, Whipple’s disease, intestinal lymphoma, Common Variable Immunodeficiency (CVID), and drug-induced (cholestyramine, neomycin, alcohol).
• Deranged Lymphatics (Post-Absorptive Phase Defect): Obstruction of the lymphatic system impairs the absorption of chylomicrons and lipoproteins.
  • Congenital: Intestinal Lymphangiectasia.
  • Acquired: Lymphoma, Whipple’s disease, tuberculosis, CHF, constrictive pericarditis, radiation, retroperitoneal fibrosis.

Diagnosis / Clinical Features

Diarrhea is the most common symptom (defined as stool mass >200 g/day). Clinical manifestations directly map to specific unabsorbed nutrients:

General Malabsorption Signs:

• Steatorrhea: Fat malabsorption resulting in pale, bulky, malodorous stools that float (oil droplets in the toilet) and are difficult to flush.
• Osmotic Diarrhea & Flatulence: Carbohydrate malabsorption leading to bacterial fermentation (hydrogen/methane gas), abdominal distention, and an increased stool osmotic gap.
• Edema / Ascites: Hypoalbuminemia from protein malabsorption or lymphatic loss (e.g., intestinal lymphangiectasia).
• Anemia:
  • Microcytic: Iron deficiency (often proximal bowel defect, classic for Celiac).
  • Macrocytic: Vitamin B12 deficiency (often terminal ileal defect, classic for Crohn's or resection).
• Metabolic Bone Disease: Vitamin D/Calcium malabsorption leading to osteopenia, osteomalacia, bone pain, and secondary hyperparathyroidism.
• Other Deficiencies: Bleeding (Vitamin K), Night blindness (Vitamin A), Peripheral neuropathy (Vitamin B12, thiamine), Tetany (Calcium, Magnesium), Glossitis/Cheilosis (Iron, B12, folate, Vit A).

Celiac Disease (Gluten-Sensitive Enteropathy): An immune disorder triggered by gliadin (a component of gluten) in genetically predisposed individuals (T-cell mediated mucosal damage).

• Classic Intestinal: Chronic diarrhea, weight loss, flatulence, aphthous stomatitis, angular cheilosis.
• Extra-Intestinal: Dermatitis herpetiformis, abnormal LFTs, hyposplenism, large-joint non-erosive symmetrical arthropathy, cerebellar ataxia, epilepsy (with bilateral parieto-occipital calcifications), peripheral neuropathy, and infertility.
• High-Risk Associations: Type 1 DM, autoimmune thyroid/liver diseases, Rheumatoid arthritis, Down syndrome, Turner syndrome, and IgA deficiency.

Investigations

Celiac Disease Diagnostic Pathway:

• Serology:
  • IgA anti-tissue transglutaminase (tTG) and IgA endomysial antibodies.
  • Critical Step: Must check total serum IgA levels (IgA deficiency is common; if low, check IgG tTG or IgG deamidated gliadin peptides).
• Small Intestinal Biopsy (Definitive):
  • Endoscopic biopsy of the proximal duodenum (maximally affected).
  • Histopathology: Subtotal or total villous atrophy with intraepithelial lymphocytic infiltration.
• Genetic Testing:
  • HLA-DQ2 (found in 98% of Northern European patients) and HLA-DQ8. Note: highly sensitive but non-specific (~25% of the normal population has HLA-DQ2). Excellent for excluding Celiac if negative.
• Testing Algorithm:
  • Low Probability (<2-5%): Start with serology + total IgA. If positive, proceed to biopsy.
  • High Probability (>2-5%): Proceed to simultaneous serology and biopsy (e.g., family history, Type 1 DM, unexplained iron-deficiency anemia).

General Malabsorption Tests:

• Stool Osmotic Gap: A significantly elevated stool osmotic gap (e.g., >100-150 mOsm/kg) in the setting of non-bloody diarrhea strongly indicates unabsorbed, osmotically active substances (e.g., carbohydrates in lactose intolerance).

Management

• Celiac Disease: Strict, lifelong adherence to a gluten-free diet (avoiding wheat, rye, and barley).
• Gluten Rechallenge (Diagnostic tool, rarely used): Involves consuming 10g of gluten/day for 4-6 weeks to document histologic/symptomatic return. Hazard: Risk of "gliadin shock" (fulminant diarrhea, dehydration, and acidosis).
• Pancreatic Insufficiency: Pancreatic enzyme replacement therapy (PERT).
• SIBO: Antibiotics and addressing the underlying anatomical/motility defect.

Complications / Prognosis

• Patients with untreated, long-term classical Celiac disease have a significantly increased risk of malignancies:
  • Enteropathy-associated T-cell lymphoma (EATL) / Non-Hodgkin’s lymphoma.
  • Small-bowel adenocarcinoma.
  • Esophageal and oropharyngeal squamous cell carcinoma.

Past-Paper High Yield

• Lactose Intolerance Diagnosis: A patient presenting with non-bloody diarrhea and a highly elevated stool osmotic gap (e.g., 150) points directly to an unabsorbed carbohydrate driving osmotic fluid shifts. Lactose intolerance is the most likely diagnosis.
• Intestinal Lymphangiectasia: Recognize this as a classic, direct cause of malabsorption via the post-absorptive (lymphatic) phase. It causes impaired chylomicron transport and protein-losing enteropathy. (Do not confuse it with intestinal telangiectasia or diverticulosis, which are not primary causes of classic malabsorption syndrome, though blind loops in diverticula can occasionally cause SIBO).
• Key Malabsorption Causes to differentiate: Celiac disease (mucosal), Crohn's disease (mucosal/bile salt recycling), Intestinal lymphangiectasia (post-absorptive).

Memory Pearls

• Anatomy of Absorption Deficits:
  • Iron is absorbed in the Duodenum (Classic deficiency in Celiac).
  • Folate is absorbed in the Jejunum.
  • B12 and Bile Salts are absorbed in the Terminal Ileum (Classic deficiency in Crohn's).
• Celiac Genetics: HLA-DQ2 and DQ8 ("I ate (8) too (2) much gluten").
• Maldigestion vs Malabsorption: If enzymes are missing (pancreas, lactase) or bile is poor (SIBO, liver), it is maldigestion. If the gut wall is damaged (Celiac, Crohn's) or lymph is blocked (Lymphangiectasia), it is malabsorption.

Functional Gastrointestinal Disorders (FGID)

Core Concepts

• Definition: A medical condition impairing the normal function of a bodily process (movement, nerve sensitivity, brain-gut axis) with completely normal anatomy on macroscopic (endoscopy, X-ray) and microscopic (biopsy, blood tests) evaluation.
• Prevalence: The most common GI disorders in the general population.
  • Affect ~25% of the US population (though 75% of these individuals are asymptomatic).
  • Account for ~40% of all GI problems seen by physicians.
• Classification: Exclusively defined by symptom-based diagnostic criteria categorized by the Rome Criteria.

Diagnosis / Clinical Features

1. Esophageal Disorders

• Functional Chest Pain: Esophageal-origin chest pain. Must rule out cardiac causes (angina) first.
• Globus: Sensation of a lump, tightness, or something "stuck" in the throat.
• Functional Heartburn: Persistent burning without evidence of GERD, motility disorders, or structural abnormalities.
• Functional Dysphagia: Subjective difficulty swallowing without organic obstruction/motility issue.
• Reflux Hypersensitivity.

2. Gastro-Duodenal Disorders

• Functional Dyspepsia (Non-Ulcer Dyspepsia - NUD)
  • Most common cause of dyspepsia overall (60% of all dyspepsia). Overlaps with IBS in 30% of cases.
  • Rome III Criteria: Onset ≥ 6 months + Duration ≥ 3 months. Must include ≥ 1 of: postprandial fullness, early satiety, epigastric pain, or epigastric burning.
  • Crucial Exclusions: Normal EGD (no structural cause) and symptoms are not exclusively relieved by defecation/stool changes (which would point to IBS).
  • Sub-Types:

• Cyclic Vomiting Syndrome (CVS)
  • Stereotypical episodes of N/V lasting < 1 week.
  • ≥ 3 episodes/year with completely asymptomatic periods in between.
  • Often associated with a personal/family history of migraines.
• Rumination Syndrome
  • Effortless, controlled vomiting without nausea.
  • Non-acidic; typically involves reswallowing or spitting.

3. Bowel Disorders: Irritable Bowel Syndrome (IBS)

• Rome III Criteria: Recurrent abdominal pain/discomfort ≥ 3 days/month for the last 3 months, with symptom onset ≥ 6 months prior to diagnosis. Must be associated with ≥ 2 of the following:
  1. Improvement with defecation.
  2. Onset associated with a change in stool frequency.
  3. Onset associated with a change in stool form/appearance.
• Etiologies / Pathophysiology:
  • Food intolerance: ↑ Mast cells + Food Antigens.
  • Post-infectious IBS (10% of cases): Risk factors include ↑ duration/severity of initial infection (strongest factor), cramping during infection, female gender, psychiatric disorders, and younger age.
  • Diarrhea-predominant (D-IBS): Often driven by rapid transit (45%), cholerheic diarrhea due to ↓ FGF-19 leading to ↑ colonic bile acids (25%), SIBO (10%), or ↑ serotonin enteroendocrine cells.
  • Constipation-predominant (C-IBS): Driven by slow colonic transit (only 25%; majority actually have normal transit).

Investigations

General Rule: FGIDs are diagnoses of exclusion. You must evaluate for and definitively rule out Alarm Symptoms ("Red Flags").

• Upper GI Alarm Symptoms (Esophageal / Dyspepsia): Age ≥ 50-55, typical symptoms lasting ≥ 5 years, dysphagia/odynophagia, persistent vomiting, GI bleed / hematemesis / melena / FOB+, iron deficiency anemia, unexplained weight loss, palpable mass or LNs (e.g., epigastric mass), jaundice, FHx of UGI cancer, poor response to medical Tx.
• Lower GI Alarm Symptoms (IBS): Age > 50, unexplained weight loss, rectal bleeding, recent change in bowel habits lasting ≥ 6 weeks (caliber/frequency/consistency), nocturnal symptoms, FHx of GI cancer or IBD, abnormal abdominal/rectal exam, unexplained anemia or biochemical abnormalities.

Specific Workup Pathways:

• Esophageal Chest Pain: R/O Angina first.
  • If Alarm Symptoms present: EGD ± Biopsy.
  • If NO Alarm Symptoms: Empiric PPI trial for 4–8 weeks → If failed, consider 24-hr pH monitoring and Manometry.
• IBS Workup: Mandates a completely normal baseline lab profile:
  • Normal CBC.
  • Normal inflammatory markers: CRP (<10), ESR (Males < 20, Females < 30).
  • Negative Celiac serology: Anti-tTG IgA & IgG.
  • Optional depending on clinical picture: TSH, routine stool analysis.

Management

Dyspepsia & Vomiting Disorders

• PDS Dyspepsia: Prokinetics.
• EPS Dyspepsia: PPIs.
• Refractory Dyspepsia: Antidepressants.
• Cyclic Vomiting Syndrome (CVS): Tricyclic Antidepressants (TCAs).
• Rumination Syndrome: Behavioral therapy (specifically diaphragmatic breathing).

Irritable Bowel Syndrome (IBS)

• Step 1: Lifestyle and Dietary Modification
  • FODMAP Restriction: Eliminate Fermentable Oligo-, Di-, Mono-saccharides And Polyols.
  • Gluten restriction: Can alleviate IBS symptoms even in the absence of Celiac disease.
  • Behavioral therapy and addressing psychosocial stressors.
• Step 2: Symptom-Directed Pharmacotherapy
  • Abdominal Pain: Spasmolytics (Anticholinergics, Peppermint Oil) → Low-dose TCAs → SSRIs (Note: Sertraline may worsen diarrhea).
  • Bloating: Probiotics (Bifidobacteria) ± Simethicone/Dimethicone.
  • Constipation (C-IBS): ↑ dietary fibers → Osmotic laxatives → Stimulant laxatives.
  • Diarrhea (D-IBS): Bulk-forming agents (Psyllium) or low-FODMAP rice. Opioids (Loperamide, Diphenoxylate). Note: Rifaximin may be used, but restrict strictly to those with confirmed SIBO.

Past-Paper High Yield

• Ischemic heart disease masquerading as GI issue: Always rule out cardiac ischemia first in patients presenting with functional chest pain.
• Differentiating Dyspepsia sub-types:
  • Pain related to meals (early satiety/fullness) = PDS → Treat with prokinetics.
  • Pain unrelated to meals (epigastric burning) = EPS → Treat with PPIs.
• Post-infectious IBS Risk Factors: The duration of the initial gastroenteritis infection is the single strongest predictor of developing post-infectious IBS.
• IBS Exclusions: Symptoms awaking the patient from sleep (nocturnal symptoms) are an alarm symptom and rule out functional IBS.
• Rumination Management: High-yield differentiator—treatment is explicitly behavioral (diaphragmatic breathing), not anti-emetics.

Memory Pearls

• PDS = Postprandial → give Prokinetics.
• EPS = Epigastric pain → give PPIs.
• Rome III Timeframes: 6 and 3 (Onset ≥ 6 months ago, symptomatic for at least the last 3 months).
• FODMAP: Fermentable Oligo-, Di-, Mono-saccharides And Polyols (sugar-free sweeteners). Avoid beans, apples, cabbage, wheat.

Pancreatitis

Core Concepts

• Pancreatic Cellular Overview:
  • Acinar cells (80%): Exocrine function.
  • Ductal cells (10%): Secretion modification.
  • Islet cells (10%): Endocrine function (Insulin, Glucagon, Somatostatin, Pancreatic polypeptides).
• Pathogenesis of Acute Pancreatitis (AP): Ductal obstruction, reflux, or increased ductal permeability (due to alcohol, drugs, or infections) leads to disruption of cell membranes and auto-digestion.
• Pathology Classifications: Interstitial (mild, lower risk) vs. Necrotizing (severe, high risk of infection and death).

Diagnosis / Clinical Features

• Acute Pancreatitis Presentation:
  • Severe abdominal pain, nausea, vomiting, fever, tachycardia.
  • Hemorrhagic signs (severe disease): Cullen's sign (periumbilical bruising), Grey-Turner's sign (flank bruising).
• Etiology of Acute Pancreatitis:
  • Major causes: Gallstones (most common) and Alcohol.
  • Other causes: Idiopathic, Drugs, Hyperlipidemia, Infections, Hypercalcemia, Ductal obstruction, Trauma, Ischemia/Hypotension, Post-operative.
• Drug-Induced Acute Pancreatitis:
  • Idiosyncratic: Azathioprine / 6-Mercaptopurine, Sulfonamides, Pentamidine, Valproic acid, Cimetidine.
  • Dose-dependent: Thiazides (high dose).
  • Secondary to Hypertriglyceridemia: Estrogens.
• Recurrent Pancreatitis Etiologies:
  • Pancreatic Divisum: Most common congenital abnormality (5-10% of population). Failure of major and minor duct fusion. Treatment: Minor duct sphincterotomy.
  • Hereditary Pancreatitis: Autosomal dominant, childhood onset. Calcifications develop by the second decade. High risk of pancreatic carcinoma.
• Chronic Pancreatitis (CP) Presentation:
  • Triad/Tetrad: Abdominal pain, Pancreatic calcifications, Steatorrhea, Diabetes.
  • Etiologies: Alcohol (most common), Idiopathic, Tropical, Hereditary, Hyperparathyroidism, Cystic Fibrosis, Pancreatic divisum.
  • Pancreatogenic Diabetes: "Brittle" diabetes occurring in severe disease. Involves loss of both Insulin and Glucagon. Insulin requirements are low, and Ketoacidosis is notably rare.

Investigations

• Laboratory Diagnosis of AP:
  • Leukocytosis, Elevated Amylase, Elevated Lipase.
  • Predictors of Gallstone Pancreatitis: Age > 50, Female, Amylase > 4,000 IU/L, AST > 100 U/L, Alkaline Phosphatase > 300 IU/L.
• Differentiating Causes of Hyperamylasemia:

• Imaging in AP:
  • Ultrasound: Useful for detecting gallstones (normal vs. bulky/inflamed pancreas).
  • CT Scan Indications: Ranson's score > 3, refractory hypoxemia/hypotension, persistent leukocytosis/fever, tender abdominal mass, hemodynamic deterioration, or presence of Cullen/Grey-Turner signs.
• Diagnosing Chronic Pancreatitis:
  • Most Sensitive: Endoscopic Ultrasound (EUS), ERCP (Structure); Secretin test (Function).
  • Less Sensitive: CT Scan, Transabdominal US; Bentiromide (PABA), Serum Trypsinogen, Fecal Chemotrypsin.
  • Least Sensitive: Abdominal X-Ray (shows calcifications); Fecal Fat.

Management

• Acute Pancreatitis:
  • Essential Supportive Care: NPO, IV fluid replacement, close clinical surveillance, nutritional support, adequate pain control.
  • Interventions to reduce inflammation: ERCP with papillotomy (for impacted gallstones), Peritoneal lavage (to remove toxic ascites).
  • Unproven/Ineffective therapies: Routine prophylactic antibiotics, reducing pancreatic secretions (via H2 blockers, NG suction, glucagon, or somatostatin).
• Antibiotic Selection (if infection is confirmed/suspected):
  • Excellent Penetration (Use these): Ciprofloxacin, Ofloxacin, Imipenem, Metronidazole.
  • Poor Penetration (Avoid): Aminoglycosides, Broad-spectrum penicillins, 3rd-generation cephalosporins.
• Chronic Pancreatitis Management: Discontinue alcohol, suppress pancreatic secretion (using oral Pancreatic Enzymes), modify neurotransmission (nerve block for pain), relieve obstruction (surgery, stenting).

Complications / Prognosis

• Ranson's Criteria for Severity (AP): Mortality risk correlates directly with the score.
  • At Admission: Age > 55, WBC > 16K, Glucose > 200 mg/dL, LDH > 350 IU/L, AST > 250 U/L.
  • During First 48 Hours: Hematocrit drop > 10%, BUN rise > 5 mg/dL, Calcium < 8 mg/dL, PaO2 < 60 mmHg, Base deficit > 4 mEq/L, Fluid sequestration > 6L.
• CT Criteria of Severity (AP):
  • Grade A: Normal.
  • Grade B: Enlargement.
  • Grade C: Peri-pancreatic inflammation.
  • Grade D: Single fluid collection.
  • Grade E: Multiple fluid collections / Phlegmon (ill-defined mass, sterile or infected).
• Infection & Mortality by AP Subtype:
  • Interstitial: Infection <1%, Mortality <1%.
  • Necrotizing: Infection 30-50%. Mortality is 10% if sterile, and up to 30% if infected.
• Specific Acute Complications:
  • Hypocalcemia: Loss of non-ionized calcium is common/asymptomatic (no tx needed). Loss of ionized calcium is rare, causes neuromuscular irritability, and requires treatment.
  • ARDS: Delayed onset, associated heavily with hyperlipidemia, characterized by progressive hypoxemia unresponsive to O2, increased lung stiffness, and diffuse opacities. Potentially reversible.
  • Pancreatic Pseudocyst: Complications include obstruction (CBD/Duodenum), bleeding, infection, leakage, rupture.
    • Indications for Intervention (Surgical, Percutaneous, or Endoscopic): Size > 5 cm, duration > 4-6 weeks, severe pain, rapid expansion, or structural complications.
• Chronic Pancreatitis Complications: CBD stenosis, duodenal obstruction, splenic vein thrombosis, pleural effusion, pseudocyst, pancreatic ascites.

Past-Paper High Yield

• Drug-induced Pancreatitis culprits: Differentiate idiosyncratic (Azathioprine, Valproate) from dose-dependent (Thiazides).
• Amylase vs. Lipase: Understand that parotitis, tubo-ovarian disease, and macroamylasemia elevate Amylase but leave Lipase normal.
• CP Diabetes unique features: Distinct from Type 1/Type 2 DM. Low insulin requirement, absence of glucagon, and DKA is very rare.
• Gallstone Pancreatitis Labs: Look for an Amylase > 4,000 IU/L combined with elevated liver enzymes (AST > 100, ALP > 300) as highly predictive for a biliary etiology.
• Antibiotic Choice in Necrotizing Pancreatitis: Imipenem, Fluoroquinolones, and Metronidazole have good pancreatic penetration; Aminoglycosides and 3rd-gen Cephalosporins do not.
• Pseudocyst intervention thresholds: Memorize the "5 and 5" rule approximation (Size > 5 cm, Duration > 4-6 weeks).

Memory Pearls

• Ranson's Criteria Mnemonic:
  • Admission ("GA LAW"): Glucose >200, Age >55, LDH >350, AST >250, WBC >16k.
  • 48 Hours ("C HOBBS"): Calcium <8, Hct drop >10%, pO2 <60, BUN rise >5, Base deficit >4, Sequestration >6L.
• Pancreatic Divisum: "Divided" ducts (major/minor failure to fuse) = treat the minor (minor duct sphincterotomy).

Autoimmune Liver Disease

Core Concepts

Autoimmune liver diseases are divided into three major pathologies based on the primary site of inflammation and the pattern of liver injury:

• Primary Sclerosing Cholangitis (PSC): Diffuse inflammation and fibrosis of the intrahepatic and extrahepatic biliary tree. Strongly associated with Inflammatory Bowel Disease (IBD).
• Primary Biliary Cirrhosis / Cholangitis (PBC): Non-suppurative destruction of small intrahepatic bile ducts. Primarily affects middle-aged women.
• Autoimmune Hepatitis (AIH): Intermittently progressive, cell-mediated inflammatory liver disease targeting hepatocytes, typically responding favorably to immunosuppression.

Diagnosis / Clinical Features

Primary Sclerosing Cholangitis (PSC)

• Clinical Presentation: Cholestatic pattern. Mostly asymptomatic initially (15-44%). Symptomatic patients present with fatigue (75%), pruritus (70%), jaundice, and hepatosplenomegaly.
• Associations: 60-80% of PSC patients have IBD (Ulcerative Colitis is twice as common as Crohn’s).

Primary Biliary Cirrhosis (PBC)

• Clinical Presentation: Insidious onset, heavily female predominant. Fatigue is the most common symptom (up to 80%), followed by pruritus (20-60%) and jaundice (late).
• Physical Exam: Hepatomegaly, hyperpigmentation, and xanthomata/xanthelasma (15-50% frequency, associated with high cholesterol).
• Associations: High rate of extrahepatic autoimmune diseases: Sicca syndrome (70%), autoimmune thyroid disease (40%), and scleroderma/CREST syndrome.

Autoimmune Hepatitis (AIH)

• Clinical Presentation: Typically a middle-aged (or teenage) woman presenting with fatigue, arthralgias/myalgias, oligomenorrhea, and jaundice.
• Classification:
  • Type 1: Any age (usually adults), ANA and SMA positive.
  • Type 2: Predominantly children/teens, LKM-1 positive, faster progression to cirrhosis.

Investigations

Laboratory & Serological Profile

Imaging & Histology

• PSC:
  • Imaging (Diagnostic): MRCP is the diagnostic modality of choice (non-invasive, no radiation, cost-effective). Shows typical "beaded" cholangiographic abnormalities (strictures/dilations).
  • Histology: Onion skin fibrosis (concentric fibrosis). Note: Small-duct PSC (5%) has a normal cholangiogram but positive biopsy.
• PBC:
  • Histology: Florid duct lesion (non-suppurative destructive cholangitis).
  • Note: 5-10% of cases are AMA-negative but have identical histology and prognosis.
• AIH:
  • Diagnosis: Requires a constellation of findings (International AIH Group Score).
  • Histology: Interface hepatitis with a lymphoplasmacytic infiltrate and rosetting of liver cells.

Management

Primary Sclerosing Cholangitis (PSC)

• Medical: No proven disease-specific medical therapy exists.
• Intervention: ERCP is used therapeutically for balloon dilation of dominant, symptomatic biliary strictures (stenting is less preferred due to complications).
• General Care: Screen for varices, manage osteoporosis, and treat ascending cholangitis with antibiotics.
• Surgical: Liver transplantation (85-88% 5-year survival).

Primary Biliary Cirrhosis (PBC)

• Disease-Modifying Therapy: Ursodeoxycholic Acid (UDCA). It is cytoprotective, modulates HLA expression, stabilizes bile canalicular membranes, and acts as a choleretic.
• Symptom Management:
  • Sicca syndrome: Increased fluid intake, oral sialogogues, artificial tears.
  • Xanthomata: May resolve with UDCA therapy.

Autoimmune Hepatitis (AIH)

• Indication to treat: AST ≥ 10x normal, or AST ≥ 5x normal with gamma-globulin ≥ 2x normal, or bridging necrosis on biopsy.
• Regimens:
  • Prednisone Monotherapy: Used in pregnancy, severe cytopenia, malignancy, or Azathioprine intolerance/TPMT deficiency.
  • Combination (Prednisone + Azathioprine): Preferred for maintenance to spare steroids. Ideal for postmenopausal women, diabetics, obese patients, and those with osteoporosis or hypertension.

Management of Chronic Cholestasis (Applicable to PSC & PBC)

• Metabolic Bone Disease: Osteoporosis is common (independent of menopause). Manage with Calcium + Vitamin D and Bisphosphonates. (Avoid steroids as they worsen bone disease).
• Malabsorption: Steatorrhea requires supplementation of fat-soluble vitamins (A, D, E, K).

Complications / Prognosis

• PSC Specific Risks: High risk of Cholangiocarcinoma (7-15% lifetime risk) and Colon Cancer (due to concurrent IBD). Annual cancer surveillance is critical.
• Portal Hypertension: Common in PBC/PSC as cirrhosis develops. Independent predictors of varices include serum albumin, bilirubin, and platelet count.
• Transplantation Outcomes: AIH has an 80-90% 5-year post-transplant survival but a 30-40% recurrence rate in the allograft. PSC also has good survival but recurrent issues with rejection, infection, and colon cancer.

Past-Paper High Yield

• Differentiating AIH vs. Wilson's Disease: A patient presenting with extreme transaminitis (ALT/AST > 1500), remarkably low Alkaline Phosphatase, and neurological signs (asterixis, choreiform movements) has fulminant Wilson's disease, not Autoimmune Hepatitis. AIH lacks choreiform movements.
• ERCP vs. MRCP Use: While MRCP is the preferred non-invasive test for diagnosing PSC, ERCP is the most appropriate next step for therapeutic management of acute biliary obstruction or ascending cholangitis (e.g., patient presenting with fever, highly elevated liver enzymes, and a dilated CBD).
• PBC Medical Therapy: Ursodeoxycholic acid (UDCA) is the highest-yield pharmacological intervention for PBC. It delays disease progression and can help resolve secondary signs like xanthomata.

Memory Pearls

• PSC: Primary Sclerosing Cholangitis = P-ANCA, Strictures (beading on MRCP), Colitis (Ulcerative Colitis).
• PBC: Primary Biliary Cirrhosis = Pruritus, Blood tests show AMA (Mitochondrial), CREST/Sjogren's association.
• AIH: AutoImmune Hepatitis = AST/ALT high, IgG high, Histology (Interface hepatitis). Types: 1 (ANA/SMA), 2 (LKM-1).

ASH and NASH

Core Concepts

• Nonalcoholic Fatty Liver Disease (NAFLD): The most common form of chronic liver disease (20–30% global prevalence) and the hepatic manifestation of metabolic syndrome.
• Nonalcoholic Steatohepatitis (NASH): A progressive subtype of NAFLD (~3% of the population) that carries a high risk of fibrosis, cirrhosis, and hepatocellular carcinoma (HCC).
• The Spectrum of NAFLD:
  • Simple Steatosis: Fat accumulation without significant inflammation.
  • NASH: Steatosis + lobular inflammation + hepatocellular ballooning injury ± fibrosis.
  • Cirrhosis: Fibrosis and nodular regeneration.
• Metabolic Syndrome (ATP III Criteria): Requires ≥ 3 of the following 5 features:
  1. Waist circumference ≥ 102 cm (men) or ≥ 88 cm (women)
  2. Triglycerides ≥ 150 mg/dL
  3. HDL < 40 mg/dL (men) or < 50 mg/dL (women)
  4. Blood Pressure ≥ 130/85 mm Hg
  5. Fasting Plasma Glucose ≥ 110 mg/dL
• Pathogenesis: Elevated free fatty acids (FFAs) → oxidative stress (ROS) → hepatocyte apoptosis (cytochrome c, caspase 3) → Kupffer cell activation → hepatic stellate cell (HSC) activation and fibrogenesis.

Diagnosis / Clinical Features

• Presentation:
  • Usually asymptomatic (45–100%) or presents with non-specific fatigue and RUQ discomfort.
  • Frequently an incidental finding (elevated LFTs, fatty liver on ultrasound, or hepatomegaly).
  • Hepatomegaly is detected in 60–80% of patients.
• Diagnostic Exclusions: Must exclude other causes to diagnose NAFLD:
  • Alcohol Consumption: Must be ≤ 1–2 drinks/day (greater amounts suggest Alcoholic Liver Disease/ASH).
  • Medications: Corticosteroids, amiodarone, methotrexate, calcium channel blockers, tamoxifen.
  • Other: Viral hepatitis, autoimmune hepatitis, Wilson disease, hemochromatosis, altered nutrition (TPN, rapid weight loss, starvation).

Investigations

• Biochemical Findings:
  • AST and ALT: Mildly elevated (2–5x upper limit of normal). Note: ALT level is NOT a reliable indicator of disease severity.
  • AST/ALT Ratio: Usually < 1 in early NAFLD (65–90% of patients).
  • Alkaline Phosphatase (ALP): Elevated (2–3x normal) in < 50% of patients.
  • Serum Ferritin: Elevated in ~50% of patients.
  • Liver synthetic function (Albumin, Bilirubin, INR) remains normal unless cirrhosis has developed.
• Imaging:
  • Ultrasound: Increased echogenicity ("bright" or radiopaque liver).
  • CT: Low attenuation of the liver.
• Liver Biopsy (Gold Standard):
  • Required to differentiate simple steatosis from NASH and to stage fibrosis.
  • Diagnostic Triad for NASH: Steatosis (≥ 5% of hepatic parenchyma) + Mixed lobular inflammation + Hepatocellular ballooning.

Management

• Lifestyle Modification (First-line):
  • Weight Loss Goal: ≥ 5% weight loss is required to improve steatosis; 7–10% weight loss is needed to improve necroinflammation. Aim for 0.5–1.0 kg/week.
  • Diet: Caloric restriction (600 kcal deficit), Mediterranean or Atkins diet. Low sodium, simple carbohydrates, and saturated/trans-fats.
  • Exercise: 5–7 sessions/week (30–45 mins each); aim for >10,000 steps/day.
• Pharmacotherapy (For NASH):
  • Pioglitazone: Consider for patients with biopsy-proven NASH and Type 2 Diabetes. (Warn about weight gain, bone loss, potential bladder cancer risk).
  • Vitamin E (800 IU/day): Consider for non-diabetic adults with biopsy-proven, non-cirrhotic NASH.
• Bariatric Surgery:
  • Indicated for severe obesity (BMI >40, or >35 with comorbidities).
  • Improves NASH but is contraindicated if portal hypertension or gastroesophageal varices are present.

Complications / Prognosis

• Fibrosis Progression: Averages 1 stage per 7 years, but 20% are "fast progressors" who can develop cirrhosis within 10 years.
• Risk Factors for Rapid Progression: Central obesity, HTN, T2DM, dyslipidemia, metabolic syndrome, and advancing age.
• Mortality: NASH is the 2nd most common reason for liver transplant and 3rd most common cause of HCC in Western countries. Leading cause of death is usually cardiovascular.

Past-Paper High Yield

• Typical Clinical Vignette: A middle-aged, obese patient with Type 2 Diabetes presenting with marked hepatomegaly, mildly elevated transaminases (2-5x normal), and an echogenic (radiopaque) liver on ultrasound. Diagnosis: NASH.
• Serum Ferritin: Know that ferritin is elevated in ~50% of NASH patients. (This is frequently tested as a standalone true/false statement).
• Transaminase Ratios and Levels (The Traps):
  • Early NASH: AST/ALT ratio is < 1.
  • Advanced Fibrosis in NASH: AST/ALT ratio flips to > 1.
  • Alcoholic Liver Disease (ASH): AST/ALT ratio is typically > 2 (rarely seen in NASH).
  • Enzyme degree: LFTs in NASH are usually only 2–5x normal. Watch out for distractor options claiming massive elevations (e.g., ALT/AST x10 normal or ALP x5 normal—these are false for NASH).

Memory Pearls

• Rule of 5s and 10s for NASH weight loss: 5% loss fixes the Fat (steatosis), 7–10% loss fixes the Fire (inflammation).
• NASH Biopsy Triad: Fat (≥5%), Fire (lobular inflammation), and Balloons (hepatocyte ballooning).
• AST/ALT Ratios: < 1 = simple NASH; > 1 = advanced fibrosis/cirrhosis; > 2 = alcoholic (ASH).

Liver Cirrhosis

Core Concepts

• Definition: The irreversible late stage of progressive hepatic fibrosis characterized by distortion of the hepatic architecture and the formation of regenerative nodules.
• Pathophysiology of Systemic Findings:
  • Loss of Synthetic Function: Decreased albumin (edema), decreased clotting factors (elevated PT/INR).
  • Impaired Detoxification / Breakdown: Hyperammonemia (hepatic encephalopathy), impaired estrogen breakdown (gynecomastia, testicular atrophy, spider angiomata, palmar erythema).
  • Portal Hypertension: Shunting of blood leads to varices, caput medusae, and splenomegaly (causing cytopenias).
• Definitive Treatment: Liver transplantation.

Diagnosis / Clinical Features

• Presentation: Often asymptomatic (diagnosed incidentally or at autopsy in 30-40% of cases). Can present acutely as decompensated cirrhosis with complications.
• Stigmata of Chronic Liver Disease (Physical Exam):
  • Skin/Nails: Spider angiomata, palmar erythema, Terry's nails, clubbing, jaundice.
  • Endocrine: Gynecomastia, testicular atrophy (due to altered estrogen metabolism).
  • Abdomen/GI: Hepatomegaly (or shrunken liver), splenomegaly, caput medusae (distended periumbilical veins), fetor hepaticus (musty breath odor).
  • Musculoskeletal: Dupuytren's contracture, hypertrophic osteoarthropathy.

Investigations

• Liver Enzymes:
  • AST and ALT moderately elevated (AST > ALT). Normal aminotransferases do not rule out cirrhosis.
  • Alkaline Phosphatase (ALP) usually elevated (<2–3x normal limit). Higher elevations suggest Primary Biliary Cirrhosis (PBC) or Primary Sclerosing Cholangitis (PSC).
  • GGT correlates with ALP; disproportionately high in alcohol-induced cirrhosis.
• Liver Function / Synthetic Tests:
  • Bilirubin: Normal early, progressive rise in advanced disease.
  • Albumin: Hypoalbuminemia reflects synthetic decline (though non-specific).
  • Prothrombin Time (PT/INR): Highly sensitive for liver synthetic dysfunction.
• Other Laboratory Findings:
  • Hyponatremia: Common with ascites; due to inability to excrete free water (high ADH secretion).
  • Thrombocytopenia: Primarily caused by portal hypertension -> congestive splenomegaly (spleen sequesters up to 90% of circulating platelets).
  • Anemia & Leukopenia: Multifactorial (GI loss, folate deficiency, hypersplenism).
  • Globulins: Increased due to shunting of bacterial antigens to lymphoid tissue.
    • Marked IgG elevation: Autoimmune hepatitis.
    • Marked IgM elevation: PBC (present in 90-95% of patients).
• Radiology:
  • Ultrasound (Initial): Shows small, nodular liver; detects portal hypertension (increased portal vein diameter, collateral veins).
  • Fibroscan: Uses shear wave propagation to assess tissue stiffness (faster wave = denser fibrosis).
• Histology: Liver biopsy (percutaneous, transjugular, laparoscopic) is the gold standard, particularly useful for diagnosing metabolic causes.

Management

• Ascites Management:
  • Sodium restriction: < 2 grams (88 mEq) daily.
  • Diuretics: Spironolactone (100–400 mg daily) +/- Furosemide (40–160 mg daily). Monitor kidney function and electrolytes closely.
  • Large Volume Paracentesis (LVP): If performing LVP, replace albumin to prevent circulatory dysfunction.
    • Rule: Give 8 grams of 25% albumin for each liter of ascitic fluid removed.
• Hepatic Encephalopathy (HE):
  • Lactulose (First-line): 30–45 mL PO 2–4 times/day; titrate to achieve 2–3 soft stools daily. Can be given as an enema if the patient cannot take PO.
  • Rifaximin: Used as add-on therapy for secondary prophylaxis, or if no improvement within 48 hours of starting lactulose.
  • Note on Ammonia Labs: High ammonia does not add diagnostic, staging, or prognostic value. However, a strictly normal ammonia level puts the diagnosis of HE in question.

Complications / Prognosis

• Spontaneous Bacterial Peritonitis (SBP):
  • Diagnosis: Ascites + Temp > 37.8°C (100°F), abdominal pain/tenderness, altered mental status, OR Ascitic fluid PMN count ≥ 250 cells/mm³.
  • Management Caveat: Permanently discontinue non-selective beta-blockers once SBP has developed.
  • High-Risk for SBP (Prophylaxis Indications):
    1. Cirrhosis with concurrent GI bleeding.
    2. History of 1+ prior SBP episodes.
    3. Ascitic fluid protein < 1.5 g/dL AND either:
       • Impaired renal function (Cr ≥ 1.2, BUN ≥ 25, or Na ≤ 130).
       • Liver failure (Child-Pugh ≥ 9 and Bilirubin ≥ 3).
• Child-Pugh Classification: Use to grade severity (A: <7, B: 7-10, C: >10).
  • Parameters evaluated: Bilirubin, INR, Albumin, Encephalopathy, Ascites (Mnemonic: "Pour Another Beer At Eleven" - PT/INR, Ascites, Bilirubin, Albumin, Encephalopathy).

Past-Paper High Yield

• First Presentation of Tense Ascites: A patient presenting with new tense ascites and asymptomatic hyponatremia should be treated with paracentesis, salt restriction, spironolactone, and furosemide. Do not isolate the hyponatremia and delay fluid offloading with just water restriction.
• Budd-Chiari Syndrome (Hepatic Vein Thrombosis): Suspect in young females on oral contraceptives presenting with abdominal pain, ascites, and jaundice. The key distinguishing physical finding from standard decompensated cirrhosis is a tender enlarged liver (due to acute hepatic congestion).
• Primary Biliary Cirrhosis (PBC) Serology: The most common serologic finding in PBC is the Anti-mitochondrial antibody (AMA) (associated with significantly elevated IgM levels).
• Ascitic Fluid Analysis (SAAG): Serum Ascites Albumin Gradient (SAAG) = Serum Albumin – Ascitic Albumin.
  • A SAAG ≥ 1.1 g/dL indicates portal hypertension (e.g., Cirrhosis, Right Heart Failure, Budd-Chiari).
  • Exam Trap: Do not diagnose SBP unless the absolute PMN count is ≥ 250 cells/mm³. If given WBCs and a neutrophil percentage, you must multiply them (e.g., WBC 230 x 30% PMNs = 69 PMNs = NOT SBP).

Memory Pearls

• Albumin Replacement Rule: 8 grams / 1 Liter removed during large-volume paracentesis.
• Cytopenia in Cirrhosis: Thrombocytopenia is usually the earliest and most profound cytopenia, driven directly by splenic sequestration (up to 90% stored).
• Enzyme Pattern: AST > ALT in cirrhosis (especially alcohol-related), whereas ALT > AST in most acute viral/toxic liver injuries.

Hereditary Liver Diseases and Wilson's Disease

Core Concepts

• Inherited Causes of Cirrhosis: Hemochromatosis, Wilson's disease, Alpha-1-antitrypsin deficiency, Cystic fibrosis, and Familial intrahepatic cholestasis.
• Hemochromatosis: An autosomal recessive iron overload disorder. Involves HFE gene mutations (most commonly C282Y homozygosity or C282Y/H63D compound heterozygosity) leading to increased intestinal iron absorption.
• Wilson's Disease: An autosomal recessive copper overload disorder (Chromosome 13 defect). A missense mutation in the ATP7B gene (a p-type ATPase) impairs copper excretion into bile and prevents incorporation into ceruloplasmin. Copper builds up in the liver, spills into the blood, and deposits in target organs (brain, cornea, kidneys).
• Iron vs. Copper Balance (Normal):
  • Iron: Ingest 10-20 mg/d; Absorb 1-2 mg/d. Total body iron is ~4g.
  • Copper: Ingest 1.5-4.0 mg/d. Excreted primarily in bile, with minimal urine output (<70 µg/day).

Diagnosis / Clinical Features

Hemochromatosis

• Demographics: Phenotypic expression is higher in men and increases with age (women are protected pre-menopause due to menstruation/pregnancy). Highly prevalent in Caucasians (Heterozygote 1:12, Homozygote 1:400).
• Classic Triad (Late): Cirrhosis, Diabetes Mellitus ("bronze diabetes"), and skin hyperpigmentation.
• Musculoskeletal: Arthropathy, arthritis, and pseudogout (calcium pyrophosphate deposition).
• Endocrine: Hypogonadism (due to pituitary gonadotropin deficiency leading to testicular atrophy), diabetes mellitus.
• Cardiac: Cardiomyopathy, conduction disorders.
• Hepatic: Hepatomegaly, cirrhosis, markedly increased risk of hepatocellular carcinoma (HCC).
• Infection: Increased susceptibility to bacteremia (e.g., Vibrio vulnificus, Listeria, Yersinia).

Wilson's Disease

• Demographics: Consider in children, adolescents, or young adults presenting with cryptogenic liver disease, hemolysis, or early-onset atypical neurologic/psychiatric symptoms.
• Hepatic: Acute hepatitis, fulminant hepatic failure, chronic hepatitis, cryptogenic cirrhosis.
• Neurologic/Psychiatric: Parkinson-like disorders (tremor, gait disturbance), psychosis, personality changes.
• Ophthalmologic: Kayser-Fleischer (KF) rings (copper in Descemet's membrane), sunflower cataracts.
• Hematologic: Coombs-negative hemolytic anemia (often presenting concurrently with acute liver disease).
• Renal: Fanconi syndrome (proximal renal tubular acidosis) with hypouricemia.
• Musculoskeletal: Osteoporosis, arthropathy.

Investigations

Hemochromatosis

• Initial Blood Tests:
  • Transferrin Saturation: Usually the earliest abnormality. >50% (often 55-100%).
  • Serum Ferritin: Markedly elevated (>300 ng/mL in males; >250 ng/mL in females; can be up to 3000).
  • Note on Ferritin Interpretation: If ferritin is high but iron/transferrin saturation is normal/low, suspect acute liver injury, acute phase reactant, or chronic disease rather than hemochromatosis.
• Genetic Testing: Check for HFE mutations (C282Y and H63D) in suspected patients or those with appropriate family history.
• Liver Biopsy: Used if diagnosis is uncertain or to stage disease/fibrosis.
  • Prussian Blue stain shows extensive iron deposition (3+ to 4+).
  • Hepatic iron index > 1.9 (mmol/g dry weight ÷ age).

Wilson's Disease

• Serum Labs:
  • Ceruloplasmin: Decreased (<20 mg/dL). Caveat: 5% of Wilson's patients have normal ceruloplasmin; it can also be low in protein-losing states or hepatic failure.
  • Total Serum Copper: Paradoxically decreased or normal. (Because 90% of serum copper is normally bound to ceruloplasmin, low ceruloplasmin drives total serum copper down, even though free/unbound serum copper is highly elevated).
• Urine Labs:
  • 24-hour Urine Copper: Markedly elevated (>100 µg/24 hr).
• Slit Lamp Examination: Confirms the presence of Kayser-Fleischer rings.
• Liver Biopsy: Gold standard/confirmatory. Quantitative hepatic copper > 250 µg/g dry weight.

Management

Hemochromatosis

• Phlebotomy: Mainstay of therapy.
  • Acute phase: Remove 1 unit (250 mg Fe) weekly or biweekly until mildly anemic.
  • Maintenance phase: Continue every 2-3 months. Target Ferritin < 50 ng/mL and Transferrin Saturation < 50%.
  • Improves survival and prevents disease progression.

Wilson's Disease

• Chelation Therapy: Penicillamine or Trientine (always give with Pyridoxine/B6 to prevent deficiency).
• Zinc: Blocks intestinal absorption of copper.
• Diet: Avoid high-copper foods (organ meats, shellfish, nuts, chocolate).
• Liver Transplantation: Curative in severe acute liver failure or decompensated cirrhosis.
• Monitoring: Follow 24-hour urine copper and non-ceruloplasmin (free) copper. Do NOT monitor Kayser-Fleischer rings to guide therapy.
• Screening: First-degree relatives must be screened.

Complications / Prognosis

Reversibility of Hemochromatosis with Phlebotomy:

• Reversible: Cardiac dysfunction, glucose intolerance (DM), hepatomegaly, skin pigmentation ("bronzing").
• Irreversible (Permanent): Cirrhosis, risk of Hepatocellular Carcinoma (HCC), arthropathy/pseudogout, and hypogonadism.

Past-Paper High Yield

• The Wilson's Disease Lab Trap: You must know the expected lab pattern in untreated Wilson's disease. Expect HIGH urinary copper, HIGH free/tissue copper, but REDUCED/NORMAL total serum copper (due to low ceruloplasmin). An exam option stating "low urinary copper" in untreated Wilson's is incorrect.
• Hemolysis + Liver Failure: Co-occurrence of Coombs-negative hemolytic anemia and liver disease strongly points to Wilson's disease.
• Hemochromatosis Arthropathy: A young-to-middle-aged male with known hemochromatosis presenting with an acutely swollen, painful joint (especially wrists or 2nd/3rd MCPs) has Pseudogout (calcium pyrophosphate crystal deposition disease). Do not confuse this with RA or gout.
• Irreversible features of Hemochromatosis: Remember that phlebotomy will not reverse joint pain (arthropathy) or the risk of HCC once cirrhosis has developed.

Memory Pearls

• Wilson's Labs: Low Ceruloplasmin, Low Total Serum Copper, HIGH Urine Copper, HIGH Free Serum Copper, HIGH Hepatic Copper.
• HFE Gene: High Ferritin Expression.
• C282Y: The most important mutation to look for in Hemochromatosis.
• Kayser-Fleischer Rings: Required for the diagnosis of Wilson's with neurologic symptoms, but absent in up to 50% of patients with purely hepatic presentations. Never use them to monitor treatment efficacy.

Viral Hepatitis A-E

Core Concepts

• Enterically Transmitted (Fecal-Oral): Hepatitis A (HAV) and E (HEV).
  • Primarily cause acute disease; no chronic state in immunocompetent patients.
• Parenterally Transmitted (Blood/Body Fluids): Hepatitis B (HBV), C (HCV), and D (HDV).
  • Can progress to chronic infection, cirrhosis, and hepatocellular carcinoma.
• Genomes: All hepatitis viruses are RNA viruses except HBV, which is a DNA virus (Hepadnaviridae).

Diagnosis / Clinical Features

• Hepatitis A (HAV):
  • Average incubation 21 days.
  • Symptomatic jaundice is age-dependent (<10% in children <6 years; 70–80% in adults >14 years).
  • Associated with contaminated food/water (e.g., raw shellfish, infected food handlers) and child day care centers.
• Hepatitis B (HBV):
  • Average incubation 60–90 days.
  • Perinatal transmission is the primary route in highly endemic regions (highest risk if mother is HBeAg+).
• Hepatitis C (HCV):
  • Average incubation 6–7 weeks.
  • Most acute infections are asymptomatic (jaundice in only 20–30%).
• Hepatitis D (HDV):
  • Requires HBV envelope (HBsAg) to replicate.
  • Coinfection (HBV + HDV simultaneously): Severe acute hepatitis, self-limited, low risk of chronicity.
  • Superinfection (HDV on top of chronic HBV): Presents as an acute flare/decompensation; very high risk of progressing to chronic HDV infection.
• Hepatitis E (HEV):
  • Average incubation 40 days.
  • Endemic in regions with poor sanitation; commonly affects travelers.

Investigations

1. Hepatitis B Serology (High-Yield for Exams):

• HBsAg (Surface Antigen): General marker of current active infection (acute or chronic).
• Anti-HBs (Surface Antibody): Marker of recovery and immunity (vaccination or resolved infection).
• Anti-HBc IgM (Core IgM): Marker of acute infection. Positive during the "window period" when HBsAg disappears but Anti-HBs has not yet appeared.
• Anti-HBc IgG (Core IgG): Marker of past or chronic infection (positive for life after natural exposure; negative in vaccinated individuals).
• HBeAg (e Antigen): Marker of active viral replication and high infectivity.
• Anti-HBe (e Antibody): Suggests virus is no longer replicating significantly (though HBsAg may still be positive from integrated HBV).
• HBV DNA: Indicates active replication. Most accurate marker, especially in "escape mutants" (where HBeAg is negative despite active replication). Used to monitor therapy.

2. Serology for Other Viruses:

• HAV: Acute = HAV-IgM via EIA. Immunity/Past exposure = HAV-IgG (total anti-HAV).
• HCV:
  • Screening: Anti-HCV (detectable 4–8 weeks post-exposure; remains positive even if cleared).
  • Confirmation: HCV RNA (qualitative/quantitative; positive within 1–3 weeks; indicates active viremia).
• HDV: Total anti-HDV / IgM anti-HDV + HDV RNA + HBsAg.
• HEV: IgM anti-HEV; HEV RNA in stool.

Management

• HAV & HEV: Generally self-limited; supportive care.
• HBV:
  • Acute: Supportive.
  • Chronic: Interferon OR Nucleos(t)ide analogs (First-line: Entecavir or Tenofovir).
• HCV: Direct-Acting Antivirals (DAAs).
• HDV:
  • Pegylated Interferon alpha (for 48–72 weeks).
  • Exam Trap: Nucleos(t)ide analogs (like Entecavir/Tenofovir) are NOT effective for HDV.
• Prophylaxis / Prevention:
  • HAV: Post-exposure prophylaxis with HAV vaccine or Immunoglobulin (IG) within 2 weeks of exposure.
  • HBV: Post-exposure HBIG (highly effective within 48h) + vaccination (e.g., neonates born to HBsAg+ mothers).
  • HCV: No vaccine; relies on blood screening and behavior modification.

Complications / Prognosis

• HAV: May cause fulminant hepatitis, cholestatic hepatitis, or relapsing hepatitis. No chronic sequelae.
• HBV Chronicity: Inversely related to age at infection.
  • Neonates (<1 yr): 90% become chronic.
  • Older children/Adults: 2–10% become chronic.
  • Complications: 15–25% premature mortality from chronic liver disease/cirrhosis/HCC.
• HCV Chronicity: Extremely high. ~70% develop chronic hepatitis; persistent infection in 85–100%. No protective antibody response is naturally generated.
• HEV Mortality: Case fatality is generally 1–3%, but skyrockets to 15–25% in pregnant women. Chronic sequelae only seen in immunosuppressed patients.

Past-Paper High Yield

• Diagnosis of Exclusion: Acute viral hepatitis (especially HAV) often presents with generic acute transaminitis. An exam question may present an acute liver injury patient with normal Ceruloplasmin, Iron studies, Alpha-1-antitrypsin, and negative Autoimmune markers (Anti-Smooth Muscle Antibody/ANA). In the absence of metabolic or autoimmune causes, select the acute viral etiology (e.g., Hepatitis A) as the most likely diagnosis.
• Vaccinated vs. Natural Immunity (HBV):
  • Vaccinated: Anti-HBs (+), Anti-HBc (–), HBsAg (–).
  • Natural Clearance: Anti-HBs (+), Anti-HBc IgG (+), HBsAg (–).
• Acute Flare in Chronic HBV: Differentiate a primary acute HBV infection (Anti-HBc IgM +) from an HDV superinfection (Anti-HDV IgM + with HBsAg + and Anti-HBc IgG +).

Memory Pearls

• A and E = Acute and Enteric (Fecal-oral).
• B, C, D = Blood-borne, Chronic potential, Deadly (cirrhosis/HCC).
• Hepatitis E is highly lethal in Expectant (pregnant) mothers.
• HDV Coinfection = Clears; HDV Superinfection = Severe (Chronic).
• HBV = DNA Virus. All others are RNA.

Hematology

Exam Map

High-Yield Exam Themes & Revision Priorities:

• The Anemia Algorithm: You must be able to instantly categorize anemia using MCV and Reticulocyte count. Differentiating Iron Deficiency (low ferritin, high RDW) from Thalassemia Trait (normal/high iron, normal RDW, target cells) is heavily tested.
• The "Aplastic" Traps: Distinguish strictly between true Aplastic Anemia (pancytopenia, hypocellular marrow, no splenomegaly) and a Parvovirus B19 Aplastic Crisis (sudden Hb drop and paradoxically low reticulocytes in a patient with a known hemolytic disease like Hereditary Spherocytosis or Sickle Cell).
• Coagulation Mixing Studies: A recurring exam favorite. Prolonged PTT that fully corrects with normal plasma = Factor Deficiency (e.g., Hemophilia). Failure to correct = Inhibitor (e.g., Acquired Hemophilia or Antiphospholipid Syndrome).
• The Thrombocytopenia Grid (ITP vs. TTP vs. HIT vs. DIC):
  • ITP: Isolated low platelets, treat with steroids, avoid transfusions.
  • TTP: Normal PT/PTT + schistocytes + severe ADAMTS13 deficiency + requires plasmapheresis.
  • DIC: Prolonged PT/PTT + low fibrinogen + high D-dimer.
  • HIT: Heparin use + platelet drop + paradoxical new thrombosis.
• Hemolysis Triggers & Smears: G6PD deficiency triggers (infections are highly tested, alongside fava beans and antimalarials) associated with bite cells and Heinz bodies. Autoimmune Hemolytic Anemia (Warm) is defined by spherocytes and a positive DAT/Coombs test.
• Leukemia Distinguishers:
  • CML: t(9;22) Philadelphia chromosome + basophilia.
  • CLL: Asymptomatic presentation = "watch and wait" (do not aggressively treat early stage).
  • AML M3 (APL): t(15;17) + Auer rods + treat with ATRA + extreme risk of DIC.
  • ALL: Tumor Lysis Syndrome labs + absolute requirement for CNS prophylaxis.
• Pharmacology & Bridging: The physiological requirement to bridge Warfarin with Heparin is a guaranteed exam concept (rapid Protein C/S depletion causes a transient hypercoagulable state, risking skin necrosis). Also, remember NOACs are absolutely contraindicated with mechanical valves.
• Transfusion Protocols: Know that returning the bag to the blood bank is the universal first step for any reaction. Differentiate TRALI (multiparous donor antibodies, non-cardiogenic edema, <6 hours) from TACO (fluid overload/hypertension).
• Multiple Myeloma Staging: Memorize the "CRAB" features. Elevated β2-microglobulin (> 5.5 mg/dL) is the specific marker for advanced Stage III disease.
• B12 vs. Folate: Differentiate purely by neurological symptoms (Subacute Combined Degeneration) and elevated Methylmalonic Acid (MMA) in B12 deficiency. Remember the "folate trap" of treating B12 deficiency with folate.

Approach to Anemia

Core Concepts

• Definition: Anemia is defined as a reduction in hemoglobin (Hb) concentration, hematocrit (Hct), or RBC count. The cut-off is typically defined as <-2 SD from the mean or the 2.5th percentile.
• WHO Hb Thresholds for Anemia:
  • Men (>15 years): < 13 g/dL
  • Women, non-pregnant (>15 years): < 12 g/dL
  • Women, pregnant: < 11 g/dL
• Severity Grading (Non-pregnant Women): Mild (11–11.9 g/dL) | Moderate (8–10.9 g/dL) | Severe (< 8 g/dL).
• Hepcidin-Ferroportin Axis (Key Iron Regulation):
  • Hepcidin: A 25 kDa peptide hormone that serves as the master iron regulator.
  • Mechanism: Hepcidin binds to ferroportin (the only cellular iron exporter on enterocytes, macrophages, and hepatocytes), leading to its degradation. This locks iron inside the cells, lowering serum iron.
  • Regulation:
    • Hypoxia/Anemia: Decreases hepcidin → allows iron release.
    • Inflammation (IL-6): Increases hepcidin → traps iron (pathophysiology of Anemia of Chronic Disease).
  • Disease States: Hepcidin deficiency = Hemochromatosis; Hepcidin excess = Anemia of Chronic Disease.

Diagnosis / Clinical Features

• The "Anemia Syndrome": Driven by tissue hypoxia. Symptoms include dizziness, fatigue, exertional shortness of breath, headaches, chest pain/palpitations, and secondary heart failure.
• Iron Deficiency Anemia (IDA) - Clinical Principles:
  • A Crucial Rule: "Iron deficiency anemia is not a final diagnosis per se." Always establish and document the underlying cause (e.g., "IDA secondary to colon cancer").
  • Causes to hunt for:
    • Nutritional (poor red meat intake)
    • Blood loss (GI/GU malignancies, heavy menses, hemosiderinuria)
    • Malabsorption (Celiac disease/gluten enteropathy)
    • Increased demand (Repeated pregnancies)

Investigations

• Kinetic Approach (Reticulocyte Count):
  • Corrected Reticulocyte % = Patient's Retic % × (Patient's Hct / 45)
  • Reticulocyte Production Index (RPI) = Corrected Retic / Maturation Time. (Maturation time: 1 for Hct 45%, 1.5 for 35%, 2 for 25%, 2.5 for 15%).
• Morphological Approach (MCV):
  • Microcytic (MCV < 78 fL, MCH < 26 pg): IDA, Thalassemia, Lead toxicity, Sideroblastic anemia, Anemia of chronic disease.
  • Normocytic: Acute blood loss, hemolysis, bone marrow failure, anemia of chronic disease.
  • Macrocytic (MCV > 98 fL): Megaloblastic anemias, Myelodysplastic Syndrome (MDS).
• Differentiating Microcytic Anemias:
  • Ferritin: The single best marker for iron deficiency in adults.
  • RDW (Red Cell Distribution Width):
    • IDA: High RDW (severe hypochromia, anisocytosis, and poikilocytosis).
    • Thalassemia Trait: Normal RDW (hypochromia with target cells, but uniform cell size).

Management

• Oral Iron: First-line therapy (ferrous gluconate/sulfate). Educate the patient on adherence and side effects.
• Monitoring Response: Check CBC monthly. Expected Hb rise is approximately 1 g/dL every 10 days. Check ferritin at 3 months.
• IV Iron: (e.g., iron sucrose, carboxymaltose) is indicated for patients who cannot absorb oral iron (e.g., severe malabsorption, previous bariatric surgery), or cannot tolerate oral preparations.

Past-Paper High Yield

Bone Marrow Failure & Aplastic Anemia

• Aplastic Anemia Diagnosis: A patient with fatigue, ecchymosis, pancytopenia (e.g., Hb 9, Plt 70K, WBC 2000), hypocellular bone marrow, and no fibrosis.
• Aplastic Anemia Treatment: Bone Marrow Transplant (BMT) is the definitive treatment for young patients with an HLA-matched family member (10-year survival > 80%).
• Febrile Neutropenia with Hypoplastic Marrow: Best initial management for a patient presenting with fever, profound pancytopenia, and hypoplastic marrow is Packed RBCs, Platelets, and IV Antibiotics.

Hemolysis & Blood Banking

• Acute Hemolytic Transfusion Reaction: The most common presentation in a young adult is back pain, red urine, and headache.
• ABO Incompatibility: It is false to state that ABO system antibodies frequently cross the placenta causing hemolysis. (Unlike Rh IgG antibodies, ABO antibodies are primarily IgM and do not readily cross the placenta).
• Hemolysis Labs: In active hemolysis (e.g., patient with anemia and 8% reticulocytes), finding a normal LDH is highly unexpected (LDH is typically elevated).

Thrombosis & Coagulation

• Heparin-Induced Thrombocytopenia (HIT): Classically presents with skin necrosis at the site of injection after ~10 days of heparin use. Next step in management: Stop heparin and start a direct thrombin inhibitor.
• Antiphospholipid Syndrome (APS): Characterized by a prolonged PTT that does not correct with a mixing study (due to an inhibitor, not a factor deficiency).
• TTP (Thrombotic Thrombocytopenic Purpura): Fundamentally caused by a lack of ADAMTS13.

Malignancy & Bone Marrow Infiltration

• Primary Myelofibrosis: Bone marrow findings characteristically show fibrosis and teardrop cells.
• Metastatic Infiltration: An older male with chronic lower back pain, enlarged prostate, elevated PSA, and pancytopenia with abnormal dysplastic cells in the BM has pancytopenia due to infiltration of the bone marrow by metastatic prostate cancer.
• Non-Hodgkin Lymphoma (NHL): The vast majority are of B-cell origin.
• Hodgkin Lymphoma Staging: Involvement of cervical and inguinal lymph nodes (both sides of the diaphragm) + B symptoms (sweating, weight loss, fever) = Stage IIIB.
• Chronic Lymphocytic Leukemia (CLL): Presents with progressive splenomegaly, treatment-refractory anemia, weight loss, night sweats, and a profoundly elevated lymphocyte count (e.g., 65 x 10^9/L).

Miscellaneous High-Yield Exam Differentiators

• Bariatric Surgery: A patient with a history of bariatric surgery presenting with severe microcytic anemia (MCV 69) and deeply low ferritin (e.g., 4) requires an IV iron transfusion (oral iron will not be absorbed).
• Pernicious Anemia Trap: Pernicious anemia causes pancytopenia/macrocytic anemia and is not associated with thrombocytosis.
• Takayasu Arteritis: A young Asian woman with syncope, severe fatigue, absent peripheral pulses, elevated ESR, and normocytic anemia. The most accurate diagnostic test is Aortic Arteriography.
• Drug-Drug Interaction: A patient on statins given antibiotics (e.g., macrolides) developing GI distress, fatigue, and foot drop (inability to plantar flex) is suffering from a statin-antibiotic drug-drug interaction (statin toxicity/myopathy).
• Meningococcal Infection: A teenager presenting with lethargy, fever, petechiae on lower limbs, and purulent CSF (high neutrophils, low glucose, high protein) has a meningococcal infection.
• Neuro/Exam Trap: A somnolent patient presenting with right-sided ptosis and a dilated right pupil likely has a Posterior Communicating Artery (P. comm) aneurysm compressing the oculomotor nerve.

Megaloblastic Anemia

Core Concepts

• Pathophysiology: Characterized by impaired DNA synthesis (arrest in S-phase) leading to delayed nuclear division. Cytoplasmic maturation (dependent on RNA/protein synthesis) remains intact, resulting in asynchronous maturation between the nucleus and cytoplasm and the formation of large precursor cells (megaloblasts).
• Ineffective Erythropoiesis: DNA replication errors trigger intramedullary apoptosis of hematopoietic precursors. This causes intramedullary hemolysis, manifesting peripherally as macrocytic anemia with a paradoxically low reticulocyte count.
• Etiologies:
  • Vitamin B12 (Cobalamin) Deficiency: Most commonly due to pernicious anemia (autoimmune destruction of gastric parietal cells/intrinsic factor). Other causes: gastrectomy, terminal ileum resection/disease (Crohn's), blind loop syndrome, Diphyllobothrium latum (fish tapeworm), and strictly vegan diets.
  • Folate (Folic Acid) Deficiency: Often due to decreased intake (alcohol use disorder, malnutrition, elderly), increased demand (pregnancy, hemolysis), or malabsorption (celiac, tropical sprue).
  • Copper Deficiency: Can cause macrocytic (or micro/normocytic) anemia, neutropenia, myelopathy, and peripheral neuropathy.
  • Drugs:
    • Impaired DNA synthesis: Methotrexate, Hydroxyurea, 5-Fluorouracil, Azathioprine, Trimethoprim, Zidovudine.
    • Impaired absorption/metabolism: Metformin, PPIs/Antacids, Oral Contraceptives, Phenytoin, Valproic acid.
  • Rare Inherited Syndromes:
    • Thiamine-responsive megaloblastic anemia (TRMA): Autosomal recessive (SLC19A2 mutation) presenting in infancy with megaloblastic anemia, diabetes mellitus, and early-onset sensorineural hearing loss.
    • Imerslund-Grasbeck syndrome: Biallelic mutation affecting the ileal receptor for the B12-IF complex; associated with proteinuria.

Diagnosis / Clinical Features

• General Anemia Symptoms: Weakness, exertional shortness of breath, palpitations, pallor, tachycardia, flow murmurs.
• Gastrointestinal: Hunter glossitis (beefy red, smooth tongue).
• Hemolysis Signs: Jaundice/icterus and splenomegaly secondary to intramedullary hemolysis.
• Neurological Manifestations (Vitamin B12 Deficiency ONLY):
  • Loss of vibratory sense and proprioception (positive Romberg test).
  • Paresthesias, peripheral neuropathy with lancinating pains.
  • Psychiatric disturbances (dementia-like presentation).
  • Note: Babinski reflex, hyporeflexia, clonus, and optic atrophy are less frequent.
  • Crucial: Neurological deficits may be incompletely reversible or permanent despite treatment.

Investigations

• Complete Blood Count & Peripheral Smear:
  • MCV > 100 fL (MCV > 115 fL is highly specific for B12 or Folate deficiency). Note: A normal MCV does not entirely rule out the disease (e.g., combined with iron deficiency).
  • Hypersegmented neutrophils (highly sensitive and specific).
  • Macro-ovalocytes and teardrop cells.
  • Low reticulocyte count (distinguishes it from hemolytic anemias/bleeding which also cause elevated MCV but have reticulocytosis).
• Diagnostic Biomarkers:
  • Vitamin B12 Level: < 200 pg/mL is deficient. (Spuriously low in multiple myeloma, HIV, pregnancy, OCPs; falsely elevated in myeloproliferative neoplasms, alcoholic liver disease, renal disease).
  • Folate Level: < 2 ng/mL is deficient. (Assay may be falsely negative/normal in patients with Intrinsic Factor autoantibodies).
• Metabolite Testing (The Definitive Differentiator):

• Bone Marrow Aspiration (if diagnosis is unclear): Hypercellular marrow, giant metamyelocytes, megaloblasts. Required primarily to rule out myelodysplastic syndrome (MDS) if vitamins are normal.

Management

• Rule Out B12 Deficiency First: B12 and folate levels must be checked simultaneously. Replacing folate in a B12-deficient patient will correct the anemia but allow irreversible neurological damage to rapidly progress.
• Vitamin B12 Supplementation:
  • Indications for Parenteral (IM): Neurologic symptoms, increased demand (pregnancy/infancy), or severe malabsorption.
  • Dosing: 1000 mcg IM weekly until corrected, then monthly.
  • Oral Alternative: 1000 mcg PO daily is equally effective if there is no intestinal malabsorption. Sublingual formulations are also available.
  • Duration: Indefinite/life-long for non-reversible causes (e.g., pernicious anemia, gastric bypass).
• Folate Supplementation:
  • Dosing: 1 mg PO daily. Continued indefinitely if the underlying cause is irreversible.
• Treatment Response Timeline:
  • Intramedullary hemolysis markers (LDH, bilirubin) improve within 1 week.
  • Hemoglobin/Hematocrit normalize within 1 to 2 months.
  • Neurological/psychiatric symptoms take 3 to 12 months to recover (may transiently worsen, or be permanently irreversible).
  • Transfusion: Reserved only for severe, highly symptomatic anemia.

Complications / Prognosis

• Gastric Malignancy: Patients with pernicious anemia have a 7-fold relative risk of gastric cancer (incidence ~0.27% per patient-year) due to chronic atrophic gastritis. Counsel patients to self-monitor and report GI symptoms immediately.
• Fetal Complications: Folate deficiency during pregnancy is strongly associated with neural tube defects (preventable with 600 mcg/day prenatal supplementation).
• Neurological Morbidity: Untreated or mismanaged B12 deficiency leads to permanent subacute combined degeneration of the spinal cord.

Past-Paper High Yield

• The "Folate Trap": Giving folate to a B12-deficient patient will improve the hematologic picture but exacerbate/unmask severe neurological deficits. Always check B12 before prescribing folate.
• Storage Timelines: Body stores of B12 (liver) last 2 to 4 years (a strict vegan takes years to develop anemia). Body stores of Folate last only 3 to 4 months (an alcoholic or malnourished patient develops anemia rapidly).
• Metabolite differentiation: The test of choice to confirm borderline B12 vs. Folate deficiency is Methylmalonic Acid (MMA). Elevated MMA = B12 deficiency.
• Reticulocyte Count: Megaloblastic anemia features intramedullary hemolysis and ineffective erythropoiesis, hence the reticulocyte count is low, contrasting with peripheral hemolytic anemias.

Memory Pearls

• B12 vs. Folate: B12 has Both (Hematologic + Neurologic symptoms); Folate just has hematologic.
• B12 Absorption Pathway:
  1. Salivary R-binder (mouth)
  2. Intrinsic Factor (stomach parietal cells)
  3. Cleavage of R-binder (pancreatic enzymes in duodenum)
  4. Absorption (Terminal Ileum).
     Any pathology along this tract (gastrectomy, pancreatitis, Crohn's in ileum) causes B12 deficiency.

Acquired Hemolytic Anemia

Core Concepts

• Hemolysis Definition: Shortened RBC survival leading to RBC destruction, with or without anemia (anemia occurs when destruction exceeds bone marrow compensation).
• Classification by Site of Destruction:
  • Extravascular: RBCs ingested by reticuloendothelial (RE) cells in the spleen and liver.
  • Intravascular: RBC destruction within the blood vessels.
• Evidence of Increased RBC Production (Compensation):
  • Peripheral Blood: Elevated reticulocytes (corrected/RPI), presence of circulating nucleated RBCs (NRBCs).
  • Bone Marrow: Erythroid hyperplasia, reduced myeloid/erythroid (M/E) ratio.
  • Bone (Chronic): Frontal bossing (deforming changes in skull/long bones due to marrow expansion).
• Bone Marrow Failure (Aplastic Anemia - AA): Life-threatening failure of erythrocyte, WBC, and platelet production. Characterized by peripheral pancytopenia and a hypocellular (empty) bone marrow. Primary defect is depletion/damage of hematopoietic precursor stem cells.

Diagnosis / Clinical Features

• General Hemolytic Anemia Features:
  • Anemia syndrome (fatigue, pallor, dyspnea).
  • Jaundice & Splenomegaly (typical of extravascular hemolysis).
  • Dark urine (tea-colored or red) and chronic ankle ulcers.
  • Increased requirement for folic acid.
• Autoimmune Hemolytic Anemia (Warm, IgG-mediated):
  • 45% Primary (Idiopathic).
  • 40% Secondary (Lymphoproliferative disease like NHL, Connective tissue disease, Infections).
  • 15% Drug-induced.
• Intravascular Hemolysis: Can present due to mechanical damage (MAHA), chemical damage (burns), severe infection (Malaria, Babesiosis), or ABO transfusion reactions.
• Aplastic Anemia Presentation:
  • Typically young adults or children (can affect any age).
  • Bleeding (thrombocytopenia) and Anemia (fatigue) are the most common presenting combination.
  • Infection (neutropenia).
  • Key Distinguisher: No splenomegaly (unlike hemolytic states or myeloproliferative disorders).

Investigations

• Autoimmune Hemolytic Anemia (AIHA):
  • Peripheral Smear: Normocytic/macrocytic anemia with densely hemoglobinated spherocytes and polychromasia (reticulocytes).
  • Hemolysis Labs: Elevated LDH, elevated unconjugated (indirect) bilirubin, elevated reticulocyte count.
  • Coombs Testing:
    • Direct Antiglobulin Test (DAT/Direct Coombs): Positive (detects IgG or C3d bound directly to the patient's RBCs).
    • Indirect Antiglobulin Test: Detects circulating anti-RBC antibodies in the patient's serum.
  • Bone Marrow: Erythroid hyperplasia with megaloblastoid changes (due to relative folate depletion from high turnover).
• Microangiopathic Hemolytic Anemia (MAHA):
  • Peripheral Smear: Schistocytes (fragmented RBCs).
  • Differential Diagnosis: TTP, HUS, DIC, Vasculitis, Malignant HTN, HELLP/Preeclampsia, Metastatic neoplasm with vascular invasion.
• Aplastic Anemia:
  • Peripheral Blood: Pancytopenia with reticulocytopenia (retics near 0%).
  • Bone Marrow Aspirate/Biopsy: Hypocellular/aplastic marrow.
  • Myelophthisic anemia (DDx): Peripheral pancytopenia but marrow is normocellular, hypercellular, or infiltrated (fibrotic, granulomatous, or neoplastic cells).

Management

• Warm Autoimmune Hemolytic Anemia (IgG):
  • 1st Line: Corticosteroids (Prednisone 1 mg/kg/day for 2 weeks, then taper) + Folic acid supplementation.
  • Treat underlying cause: (e.g., manage the lymphoproliferative disorder if secondary).
  • 2nd Line / Refractory: Splenectomy, Immunosuppressive agents, IVIG.
• Aplastic Anemia:
  • Remove causative agent (drugs, toxins) and provide supportive care (RBC transfusions, treat infections/bleeding).
  • Young patients (<40) + HLA-identical sibling: Bone Marrow Transplant (BMT) is the best first-line therapy.
  • Older adults or no sibling donor: Immunosuppressive therapy (IST) with Anti-thymocyte globulin (ATG) + Cyclosporine A (CSA).

Complications / Prognosis

• Aplastic Crisis: Triggered by Parvovirus B19 infection. The virus lyses RBC precursors causing a 7-10 day cessation of erythropoiesis. Normal patients tolerate this, but hemolytic patients (who rely on high reticulocyte production to compensate for shortened RBC lifespan) will acutely drop their hemoglobin and reticulocytes.
• Gallstones: Chronic hemolysis leads to high bilirubin excretion, causing pigment (biliary) stones.
• Secondary Malignancy: AIHA can precede or be the initial presentation of lymphoproliferative disorders like Non-Hodgkin Lymphoma (NHL).

Past-Paper High Yield

• Classic Presentation of Warm AIHA: A case featuring anemia, high LDH, high indirect bilirubin, and spherocytes on the peripheral blood smear should immediately point to Autoimmune Hemolytic Anemia.
• Diagnostic Peripheral Cell: The characteristic cell seen in the peripheral blood in patients with warm antibody AIHA is the densely hemoglobinated spherocyte.

Memory Pearls

• Spherocytes + Positive DAT (Coombs) = Autoimmune Hemolytic Anemia.
• Schistocytes + Negative DAT = Microangiopathic Hemolytic Anemia (think TTP, DIC, HUS).
• High Retics + Splenomegaly = Hemolysis (Marrow is working).
• Zero Retics + Pancytopenia + NO Splenomegaly = Aplastic Anemia (Marrow is empty).
• Hemolysis + Sudden drop in Retics = Parvovirus B19 Aplastic Crisis.

Congenital Hemolytic Anemia and Hemoglobinopathies

Core Concepts

• Classification of Congenital Hemolytic Anemias:
  • Membrane Defects: Hereditary Spherocytosis (HS).
  • Enzymopathies: G6PD Deficiency, Pyruvate Kinase (PK) Deficiency.
  • Hemoglobinopathies: Beta-Thalassemia, Sickle Cell Disease (SCD).
• Aplastic Crisis: A universal risk in chronic hemolytic anemias (especially tested in HS and SCD). It is triggered by Parvovirus B19 infection, which halts red blood cell production, leading to a sudden, severe drop in hemoglobin accompanied by a paradoxically low reticulocyte count.

Diagnosis / Clinical Features

• G6PD Deficiency:
  • Genetics: X-linked recessive (Xq28 mutation). G6PD Med (Mediterranean/Kurdish) is a severe variant (563 C->T mutation).
  • Pathophysiology: Defect in the Pentose Phosphate Pathway impairs NADPH production, leaving RBCs vulnerable to oxidative stress.
  • Clinical Syndromes: Ranges from asymptomatic to severe acute intravascular hemolysis (red urine, loin pain, jaundice).
  • Neonatal Jaundice: Occurs 1-3 days after birth; high risk for kernicterus.
  • Hemolytic Triggers:
    • Infections: A very common trigger (neutrophil/macrophage oxygen burst generates H₂O₂).
    • Favism: Exposure to fava (broad) beans; divicine produces free oxygen radicals.
    • Drugs: Antimalarials (Primaquine), Sulpha drugs, Dapsone, Nitrofurantoin, Methylene Blue, Nalidixic Acid, Pyridium.
    • Other: Diabetic Ketoacidosis (DKA), Henna (in infants).
• Hereditary Spherocytosis (HS):
  • Genetics: Mostly autosomal dominant.
  • Molecular Defect: Most commonly ankyrin mutations. Also spectrin, band 3, or protein 4.2 (Japanese) deficiency.
  • Clinical: "Anemia syndrome", splenomegaly, jaundice, pigment gallstones.
• Sickle Cell Disease (SCD):
  • Genetics: Autosomal recessive; point mutation in beta-globin gene (β6 Glu → Val).
  • Vaso-Occlusive Manifestations: Acute chest syndrome (ACS), hepatic/splenic crisis, priapism, stroke, avascular necrosis of the bone (e.g., hip).
  • Infectious Complications: Functional asplenia (auto-splenectomy) increases susceptibility to encapsulated organisms (Pneumococcus, H. influenzae). Tissue infarction predisposes to Staphylococcus osteomyelitis.
• Sickle Cell Trait:
  • Protective against malaria.
  • Genitourinary complications: Hyposthenuria (inability to concentrate urine), papillary sloughing, painless hematuria, and UTIs during pregnancy.
  • Other risks: Splenic infarction at high altitudes (hypoxia), rhabdomyolysis, sudden death.
• Beta-Thalassemia:
  • Clinical Effects: Severe anemia leading to extramedullary hematopoiesis (causes "tumor effect", skeletal changes, stunted growth), massive splenomegaly, and osteoporosis. Dilated cardiomyopathy can occur secondary to severe anemia.

Investigations

• G6PD Deficiency: Blood film shows Bite cells and Heinz bodies. High LDH, high indirect bilirubin, hemoglobinuria (intravascular hemolysis).
• Hereditary Spherocytosis: High reticulocytes, Negative DAT (Direct Antiglobulin Test, differentiates from autoimmune hemolysis), abnormal Osmotic Fragility Test.
• Sickle Cell Disease: Smear shows sickle cells and Howell-Jolly bodies (due to auto-splenectomy).
• Beta-Thalassemia Major: Severe microcytic hypochromic anemia (e.g., Hb 6, MCV 55), highly elevated serum ferritin (iron overload).

Management

• G6PD Deficiency:
  • Avoid precipitating factors (drugs, fava beans).
  • Supportive care during crisis: Folate, maintain good urine output, blood transfusion if severe. Exchange transfusion for severe neonatal jaundice.
• Sickle Cell Disease:
  • Painful Crisis: Correct fluid/electrolytes (use hypotonic fluid and avoid overhydration), treat underlying illness, use opioid analgesics (avoid meperidine), and use incentive spirometry. Transfusion is not indicated for uncomplicated pain.
  • Disease Modification: Hydroxyurea (increases HbF, reduces pain crises, ACS, and transfusion needs). Prophylactic penicillin in childhood prevents encapsulated infections.
  • Transfusion Indications: Stroke (decreases recurrence by 90%), Acute Chest Syndrome, Aplastic Crisis, Pre-operative optimization, symptomatic anemia, and splenic/hepatic sequestration.
• Beta-Thalassemia Major:
  • Chronic blood transfusions.
  • Iron Chelation Therapy: Required to prevent end-organ iron overload (skin, heart, liver, endocrine).
    • Oral Deferasirox: First-line, once-daily tridentate chelator, highly specific for iron, excreted mainly in feces.
    • Deferoxamine: Parenteral alternative.
  • Curative Therapy: Allogeneic Bone Marrow Transplantation (Allo-BMT).

Complications / Prognosis

• Acute Chest Syndrome (SCD): Indistinguishable from pneumonia (pleuritic chest pain, fever, cough, hypoxia, worsening anemia, new infiltrate). Multifactorial etiology (rib infarct causing splinting, fat embolism, atypical/viral infections). Treated with incentive spirometry, bronchodilators, O₂, and RBC transfusions.
• Iron Overload (Beta-Thalassemia): Constant transfusions lead to fatal iron deposition in the heart (cardiomyopathy), liver, and endocrine organs without chelation therapy.

Past-Paper High Yield

• Parvovirus B19 & HS: A patient with known hereditary spherocytosis presenting with a sudden drop in Hemoglobin AND a low reticulocyte count is experiencing an aplastic crisis caused by Parvovirus B19. (Tested multiple times as the key differentiator from a standard hemolytic crisis, which would have high reticulocytes).
• G6PD Triggers: Infections are a very common and highly tested trigger of hemolysis in G6PD deficiency, alongside classic triggers like antimalarials and fava beans.
• Heinz Bodies = G6PD: If a patient is given anti-malarial prophylaxis and develops anemia with Heinz bodies on the smear, the diagnosis is G6PD deficiency (not Hereditary Spherocytosis).
• Thalassemia Cure: The definitive, curative treatment for transfusion-dependent Beta-Thalassemia is Bone Marrow Transplantation (BMT).
• Thalassemia Chelation: Oral deferasirox is a primary, first-line treatment for iron chelation.
• SCD Complications: Stroke, Priapism, and Acute Chest Syndrome are classic complications of SCD. AML (Acute Myeloid Leukemia) is NOT associated with sickle cell disease.

Memory Pearls

• Bite & Heinz: Think G6PD. (The spleen bites out the Heinz bodies).
• Low Retics + Hemolytic Anemia = Parvovirus B19.
• Hyposthenuria & Hematuria: Think Sickle Cell Trait (sickling in the renal medulla due to hypoxia/hypertonicity).
• Glu → Val at position 6: The exact mutation for Sickle Cell.
• No Meperidine in SCD: Metabolite normeperidine causes seizures. Use other opioids.

Bleeding Disorders 1

Core Concepts

• Primary vs. Secondary Hemostasis:
  • Primary Hemostasis (Platelets/Vessel Wall): Characterized by mucocutaneous bleeding (epistaxis, GI/vaginal bleeding, gums), petechiae, superficial small ecchymoses. Bleeding after cuts/scratches is immediate and usually mild.
  • Secondary Hemostasis (Coagulation Factors): Characterized by deep soft tissue bleeding (joints, muscles/hemarthrosis), large/deep ecchymoses. Bleeding after cuts/scratches is rare. Bleeding after surgery/trauma is delayed (1–2 days) and often severe.
• Coagulation Screening:
  • Prothrombin Time (PT): Assesses the Extrinsic and Common pathways.
  • Activated Partial Thromboplastin Time (aPTT): Assesses the Intrinsic and Common pathways.
  • Thrombin Time (TT): Assesses the conversion of fibrinogen to fibrin.
  • Bleeding Time (BT): Assesses platelet function (platelet count must be normal for this to be valid).
• Mixing Studies: Differentiates factor deficiency from the presence of an inhibitor (e.g., autoantibodies).
  • Correction of prolonged aPTT/PT when patient plasma is mixed 1:1 with normal plasma = Factor Deficiency.
  • Failure to correct = Inhibitor (e.g., acquired hemophilia, lupus anticoagulant).

Diagnosis / Clinical Features

• Hemophilia A and B:
  • Inherited X-linked recessive bleeding disorders. Factor VIII deficiency (Hemophilia A; 1/10,000) and Factor IX deficiency (Hemophilia B; 1/50,000).
  • Severity depends on factor levels:
    • Severe (<1%): Spontaneous bleeding, hemarthrosis.
    • Moderate (1–5%): Bleeding with mild injury.
    • Mild (>5–25%): Bleeding with surgery or major trauma.
  • Genetics: The F8 gene is on Xq28. An intron 22 inversion is the most common mutation causing severe Hemophilia A (responsible for ~45% of cases).
• Von Willebrand Disease (VWD):
  • Most common inherited bleeding disorder (Autosomal Dominant).
  • vWF anchors platelets to the subendothelium and acts as a carrier protein for Factor VIII (prolonging its half-life).
  • Features primary hemostasis bleeding (mucocutaneous, prolonged bleeding from minor cuts).
• Disseminated Intravascular Coagulation (DIC):
  • Systemic activation of coagulation leading to intravascular fibrin deposition, causing both microvascular thrombosis (organ failure) and depletion of platelets/factors (severe bleeding).
  • Triggers: Sepsis (most common), major trauma (head injury, fat embolism), obstetric emergencies (amniotic fluid embolism, abruption), malignancies, severe allergic reactions, or snake venom.
• Immune Thrombocytopenia (ITP):
  • Autoimmune destruction of platelets. Presents with isolated thrombocytopenia, easy bruising, and petechiae in an otherwise healthy patient.
  • Key Negative Findings: No hepatosplenomegaly, no systemic symptoms, normal coagulation profile.
• Hemolytic Uremic Syndrome (HUS):
  • Characterized by the triad of Microangiopathic Hemolytic Anemia (MAHA), Thrombocytopenia, and Acute Kidney Injury (hematuria). Frequently preceded by bloody diarrhea (e.g., post-party/gathering infection).

Investigations

• VWD Laboratory Findings:
  • Type 1 (Partial quantitative): ↓ vWF antigen, ↓ vWF activity, Normal multimers.
  • Type 2 (Qualitative): ↓ vWF activity (out of proportion to antigen), Abnormal multimers.
  • Type 3 (Total quantitative): ↓↓ vWF antigen (absent), ↓↓ vWF activity, Absent multimers.
  • Note: aPTT may be normal or slightly prolonged (due to secondary FVIII clearance).
• DIC Laboratory Findings:
  • ↑ PT, ↑ aPTT, ↑ TT (consumption of coagulation factors).
  • ↓ Fibrinogen, ↓ Platelets.
  • ↑ Fibrin Degradation Products (FDPs) and ↑ D-Dimer (due to plasmin cleaving fibrin).
  • Peripheral smear: Schistocytes (fragmented RBCs due to intravascular fibrin strands).
• ITP vs. Aplastic Anemia (Bone Marrow differentiation):
  • ITP: Peripheral smear shows large platelets. Bone marrow shows normal or HIGH megakaryocytes (compensatory production).
  • Aplastic Anemia: Presents with pancytopenia (e.g., Hb 7, Plt 10k, WBC 1000). Bone marrow is severely hypocellular.
• Myeloproliferative Neoplasms (MPNs):
  • Patients with massively elevated cell lines require differentiation.
  • A pan-myelosis (↑ Hb, ↑ WBC, ↑ Platelets >800k) with increased neutrophils and basophils points to Polycythemia Vera (Rubra Vera), not just Essential Thrombocytosis.

Management

• Hemophilia:
  • Acute Bleeding: Replace missing factor (FVIII or FIX). Mild/Moderate bleeding target is 30% (25-40 U/kg). Major bleeding target is 80-100% (50 U/kg).
  • Prophylaxis: Scheduled factor replacement (e.g., 20 U/kg twice weekly) to prevent target joints.
  • Mild Hemophilia A Adjuncts: DDAVP (releases stored vWF and FVIII from endothelium) and Tranexamic Acid (stabilizes fibrin clot).
  • Inhibitor Management: Recombinant FVIIa, By-passing agents, high-dose FVIII (if low titer), or Immune Tolerance Induction (ITT).
  • Novel Therapies: Emicizumab (a bispecific antibody that bridges FIXa and FX, mimicking FVIII function).
• Von Willebrand Disease:
  • Type 1: DDAVP (Deamino-8-arginine vasopressin) 0.3 µg/kg IV.
  • Type 2 and 3: Factor VIII concentrate containing vWF (e.g., Humate-P). Cryoprecipitate can also be used as it contains vWF, FVIII, and fibrinogen.
• DIC:
  • First step: Treat the underlying cause vigorously (e.g., IV antibiotics for sepsis).
  • Supportive: FFP (replaces factors), Platelet transfusion, Coagulation inhibitor concentrates (ATIII).
• ITP:
  • First-line: Steroids (e.g., Prednisolone).
  • Contraindicated: Platelet transfusions are generally not used because the transfused platelets will just be rapidly destroyed by circulating autoantibodies.
• Aplastic Anemia (Severe):
  • Immediate priority in young, severe cases is to look for an HLA-matched sibling for Bone Marrow Transplant (BMT).

Complications / Prognosis

• Hemophilia Inhibitors: 10-15% of severe Hemophilia A patients develop alloantibodies (inhibitors) against exogenous FVIII, rendering standard replacement therapy ineffective.
• Transfusion-transmitted infections: Historically, plasma-derived factors caused Hepatitis B, Hepatitis C, and HIV infections. Modern recombinant products eliminate this risk.

Past-Paper High Yield

• Mixing Study Trap: A patient (e.g., 25 y/o male) presenting with acute hemarthrosis and a massively prolonged aPTT (e.g., 112 sec) that does NOT improve with a mixing study has Acquired Hemophilia with Inhibitor Development, not an inherited factor deficiency.
• ITP Presentation & Management:
  • Classic stem: Young female, easy bruising, petechiae, isolated severe thrombocytopenia (e.g., 12k), large platelets on smear, no splenomegaly.
  • Exam focus: Steroids are the best first-line treatment. Platelet transfusion is explicitly not used.
  • Pathology core: Bone marrow will have normal or HIGH megakaryocytes. Primary ITP has no association with systemic disorders.
• Aplastic Anemia differentiation: A young patient with acute bleeding (menorrhagia), fever, NO splenomegaly, and pancytopenia. The definitive diagnostic finding is a severely hypocellular bone marrow, and the primary curative step is HLA-matched BMT.
• HUS Diagnosis: A patient with a recent history of bloody diarrhea (e.g., "went to a party 3 days ago") presenting with acute renal failure (hematuria) and thrombocytopenia. The best next step to confirm the diagnosis is to look for schistocytes in the blood film.
• Polycythemia Vera: A patient with elevated Hb (>14.5), extremely high platelets (>800,000), leukocytosis, and basophilia is diagnosed with Polycythemia Rubra Vera, distinguishing it from Essential Thrombocytosis (which features isolated platelet elevation).

Memory Pearls

• DIC vs. Liver Disease: Both have high PT/aPTT and low platelets, but DIC has low fibrinogen and high D-dimers, whereas factor VIII is normal or high in liver disease (it is made in endothelial cells, not just the liver) but consumed in DIC.
• DDAVP works on the Endothelium: Releases stored vWF (and therefore FVIII). Useful in mild Hemophilia A and Type 1 VWD, but useless in severe cases where stores are absent.
• Type 3 VWD mimics Hemophilia A: Because vWF is entirely absent, FVIII has no carrier and gets degraded rapidly, leading to prolonged aPTT and deep tissue bleeding.

Bleeding Disorders 2

Core Concepts

• Platelet Physiology: Lifespan is 7–10 days. The adult body produces 10^11 platelets/day (3000 platelets per megakaryocyte). 20–30% are pooled in the spleen.
• Classification of Platelet Disorders:
  • Quantitative: Abnormal distribution (splenomegaly), dilution effect, decreased production, increased destruction (immune vs. non-immune).
  • Qualitative: Inherited (rare, e.g., Glanzmann Thrombasthenia) vs. Acquired (medications, chronic renal failure, cardiopulmonary bypass).
• Platelet Destruction Syndromes:
  • Immune: ITP, Drug-induced, HIT.
  • Non-immune / Consumptive: DIC, TTP, Sepsis.
• Clinical Bleeding Pattern: Cutaneous/mucosal (petechiae, ecchymoses, epistaxis, menorrhagia, GI, intracranial) is characteristic of platelet-type bleeding. Bleeding manifestations generally correlate with the platelet count (e.g., life-threatening if <10k, minor trauma bleeds if 10k–30k).

Diagnosis / Clinical Features

• Glanzmann Thrombasthenia (GT): Inherited qualitative platelet disorder. Presents with life-long mucosal bleeding, prolonged bleeding from cuts, purpura, and menorrhagia. Parents are often consanguineous (e.g., 1st-degree relatives).
• Immune Thrombocytopenia (ITP): Autoimmune destruction of platelets mediated by autoantibodies against major platelet membrane glycoproteins. Megakaryocytes in the bone marrow are increased, but production remains decreased. Presents with isolated sudden-onset purpura, petechiae, and mucosal bleeding in an otherwise healthy patient without splenomegaly or lymphadenopathy.
• Heparin-Induced Thrombocytopenia (HIT): Typically occurs 4–14 days after heparin exposure (or rapidly if previously exposed). Suspect if platelet count drops >50% or falls <100k. Characterized by paradoxical thrombosis (arterial or venous limb gangrene) and skin necrosis at the injection site.
• Thrombotic Thrombocytopenic Purpura (TTP): Caused by severely deficient ADAMTS13 (VWF-cleaving protease), leading to ultra-large VWF multimers that cause microvascular thrombosis.
  • Classic Pentad:
    1. Microangiopathic hemolytic anemia (MAHA)
    2. Thrombocytopenia
    3. Neurologic dysfunction (confusion, seizures, leukoencephalopathy on MRI)
    4. Renal disease
    5. Fever.
• Acquired Hemophilia: Sudden onset of severe, unprovoked bleeding (e.g., joint effusion, soft tissue bleeding) in a patient with no prior bleeding history. Due to the development of autoantibodies (inhibitors) against clotting factors (most commonly Factor VIII).

Investigations

• Glanzmann Thrombasthenia:
  • Platelet count and morphology: Normal.
  • PT/PTT/TT: Normal.
  • Hallmarks: Prolonged bleeding time (>15 mins), absent or impaired clot retraction, absent/reduced platelet fibrinogen.
  • Flow cytometry: Absent or reduced GPIIb-IIIa receptors. No aggregation with physiological aggregating agents.
• Immune Thrombocytopenia (ITP): Isolated severe thrombocytopenia. PT, PTT, TT are normal. Rule out secondary immune causes (DAT, ANA, anti-DNA).
• Thrombotic Thrombocytopenic Purpura (TTP):
  • Hallmark: High LDH, indirect hyperbilirubinemia, reticulocytosis, and schistocytes on blood smear.
  • Coagulation: PT, PTT, and TT are normal (differentiates TTP from DIC).
  • Specific testing: Severely deficient ADAMTS13.
• Evaluating Prolonged PTT (Mixing Study):
  • If a patient has a prolonged PTT, mix their plasma 1:1 with normal plasma.
  • Full correction: Indicates a factor deficiency (e.g., Hemophilia).
  • Partial / No correction: Indicates the presence of an inhibitor (e.g., Acquired hemophilia with inhibitor, or Antiphospholipid antibody/Lupus anticoagulant).

Management

• Glanzmann Thrombasthenia: Supportive care.
• Immune Thrombocytopenia (ITP):
  • Observation: If PLT >50k and no bleeding.
  • Initial Therapy: If PLT <30k or bleeding -> Oral Prednisolone (1 mg/kg/day for ~4 weeks, then taper).
  • Curative/2nd line: Splenectomy, Rituximab.
  • Rescue Therapy: IVIG, High-dose glucocorticoids.
  • Chronic Therapy: Thrombopoietin (TPO) receptor agonists (see comparison below).
• Thrombotic Thrombocytopenic Purpura (TTP):
  • Primary: Daily plasma exchange (plasmapheresis) until recovery (reduces mortality from >90% to <20%). Monitor LDH and PLT count.
  • Relapsed/Refractory: Rituximab, Vincristine, Splenectomy.
  • Note: Glucocorticoids and aspirin have an unproven adjunctive role.
• Heparin-Induced Thrombocytopenia (HIT):
  • Two Do's: STOP heparin immediately, START an alternative anticoagulant.
  • Two Don'ts: NO warfarin until substantial platelet recovery (prevents venous limb gangrene); NO platelet transfusions (worsens thrombosis).
  • Two Diagnostics: Send HIT functional testing, order bilateral lower limb duplex ultrasounds.
• Platelet Transfusion Complications:
  • Transfusion Reactions: Higher incidence than RBCs; related to storage length, leukocytes, and especially bacterial contamination.
  • Refractoriness: Alloimmune destruction (HLA antigens) or Non-immune (MAHA, DIC, fever, sepsis, splenomegaly, medications like Amphotericin, Vancomycin).

Complications / Prognosis

• HIT Complications: High risk of new thrombosis (up to 50%), amputation (~10%) due to arterial thrombosis or venous limb gangrene, and death (10–20%).
• TTP Prognosis: Untreated mortality >90%; treated with plasma exchange mortality <20%. Monitor ADAMTS13 post-recovery for relapse.
• ITP in Pregnancy: Requires careful monitoring during pregnancy and post-delivery care of the newborn due to maternal IgG crossing the placenta.

Past-Paper High Yield

• Prolonged PTT + Venous Thrombosis: A patient with bilateral lower limb swelling (DVT), PE, and prolonged PTT most likely has Antiphospholipid Syndrome (Lupus Anticoagulant).
• Hemophilia A vs B Diagnosis: The definitive test to distinguish Hemophilia A from B is a Factor Assay.
• Hemophilia A Genetics: The most common cause of severe Hemophilia A in Jordan is the Intron 22 inversion.
• Mixing Studies & Acquired Hemophilia: A middle-aged/elderly patient with new-onset severe bleeding (e.g., joint effusion, large joints) and prolonged PTT that only partially corrects on a mixing study is diagnostic of Acquired hemophilia with an inhibitor.
• Cirrhotic Variceal Bleed Prophylaxis: (General clinical crossover) A patient presenting with an upper GI bleed and stigmata of cirrhosis (telangiectasias, ascites) should receive prophylactic antibiotics; the preferred agent is Ceftriaxone.

Memory Pearls

• HIT Management Rules: 2 Do's (Stop Heparin, Start Non-Heparin AC), 2 Don'ts (No Warfarin yet, No Platelets), 2 Diagnostics (HIT assay, Venous Dopplers).
• TTP vs DIC: TTP has normal coagulation times (PT/PTT), while DIC has prolonged PT/PTT and elevated D-dimers. Both have thrombocytopenia and schistocytes.
• ITP Treatment Thresholds: PLT >50k = None; PLT <30k or bleeding = Glucocorticoids.

Acute Leukemia

Core Concepts

• Pathogenesis of AML: A disease strongly associated with aging. Hematopoietic stem cells acquire mutations over their lifetime → clonal hematopoiesis → subclonal evolution → MPD / MDS / AML.
• Mechanisms of Clinical Manifestations:
  • Bone Marrow Replacement: Anemia, thrombocytopenia, neutropenia.
  • Extramedullary Infiltration: Lymph nodes, gums (gingival hyperplasia), skin (leukemia cutis), and CNS.
  • Release of Granules/Metabolites: DIC, Tumor Lysis Syndrome (hyperuricemia/gout, acute renal failure).
  • Hyperviscosity: Due to extreme leukocytosis (e.g., WBC > 50,000–100,000).

Diagnosis / Clinical Features

• AML Presentations:
  • Bleeding diathesis (easy bruising, hemorrhagic spots) and systemic infections (fever).
  • Promyelocytic (M3): High risk of DIC (elevated PT/PTT, active bleeding).
  • Myelomonocytic (M4): Associated with painful gums (gingival hyperplasia), leukemia cutis, and potential CNS disease.
• ALL Presentations:
  • More common in younger patients (e.g., teens/young adults).
  • Fatigue, joint pain, bone pain, high fever, severe tonsillar/throat infections.
  • Prominent generalized lymphadenopathy and hepatosplenomegaly.
  • Frequent baseline presentation with Tumor Lysis Syndrome (TLS).

Investigations

• Laboratory Findings:
  • Pancytopenia or extreme leukocytosis with circulating blasts.
  • Tumor Lysis Labs (classic in ALL): ↑ LDH, ↑ Uric Acid, ↑ Potassium, ↑ Phosphate, ↓ Calcium.
  • Coagulation: Prolonged PT/PTT (evaluate for DIC, especially in AML M3).
• Morphology & Staining:
  • AML: Prominent Auer rods (especially in M3).
  • ALL: PAS strongly positive (+++).
• ALL FAB Morphologic Subtypes:
  • L1 (75%): Small round blasts, clumped chromatin.
  • L2 (20%): Pleomorphic, larger blasts, clefted nuclei, fine chromatin.
  • L3 (5%): Large blasts, prominent nucleoli, vacuolated cytoplasm.
• ALL Immunophenotyping:
  • B-Lineage (80%): CD19(+), Tdt(+).
    • Pro-B: CD10(–), CyIg(–)
    • Common: CD10(+), CyIg(–)
    • Pre-B: CD10(+), CyIg(+), SmIg(–)
    • Mature-B: SmIg(+)
  • T-Lineage (20%): CD7(+), Tdt(+).
    • Pre-T: CD2(–)
    • Mature-T: CD2(+)

Management

• AML M3 (APL):
  • Treated with ATRA (all-trans retinoic acid) to induce differentiation of leukemic cells.
  • Responsive to cytarabine/daunorubicin, but chemotherapy causes rapid tumor lysis; ~10% die from DIC induced by granule release from dying cells.
• ALL Treatment Phasing: Choice depends on risk, immunophenotype, age, and biological condition.
  • Induction (1 month): Goal is rapid restoration of normal marrow. Regimen includes Anthracycline, Vincristine, Cyclophosphamide, L-asparaginase, MTX, Ara-C, Steroids.
  • Consolidation (4-8 months): Goal is to prevent resistant clones and eliminate residual disease. Options: Chemotherapy or Allogeneic Stem Cell Transplant.
  • Maintenance (2-3 years): 6-MP, Methotrexate, Vincristine, Steroids.
  • CNS Prophylaxis (Crucial): Intrathecal Methotrexate, Ara-C, Steroids, or Craniospinal irradiation.
• Allogeneic BMT Indications in ALL: High-risk disease, unacceptable minimal residual disease, good performance status, and donor availability. Curative intent.

Complications / Prognosis

• ATRA Syndrome (Retinoic Acid Syndrome):
  • Timing/Cause: Occurs within the first 3 weeks of ATRA therapy. Caused by adhesion of newly differentiated neoplastic cells to the pulmonary vasculature endothelium.
  • Features: Fever, dyspnea, chest pain, pulmonary infiltrates, pleural/pericardial effusions, and hypoxia. Does not cause DIC.
  • Treatment: Glucocorticoids, chemotherapy, supportive care. Mortality is ~10%.
• Prognostic Categories in ALL (Cytogenetics):
  • Better: Normal karyotype, Hyperdiploidy.
  • Poor: t(8;14), t(4;11).
  • Very Poor: t(9;22) → BCR/ABL(+).
• High/Very High-Risk Features in ALL:
  • Pre-T or Pro-B immunophenotypes.
  • Age > 35 years.
  • WBC > 30k (B-ALL) or > 100k (T-ALL).
  • No remission after 4 weeks of induction therapy.
  • Philadelphia chromosome positive / BCR-ABL(+).
• Prognostic Categories in AML:
  • Good Prognosis: t(15;17) [M3], inv(16) [M4].

Past-Paper High Yield

• Polycythemia Vera to AML Transformation Trap: Exam questions often test the natural history of myeloproliferative disorders. It is false to state that 50% of Polycythemia Vera cases transform into AML. (The actual transformation rate is much lower, typically <10%).
• CNS Staging and Prophylaxis (ALL vs. Lymphoma): Unlike typical Hodgkin Lymphoma (where brain CT is not routine for staging unless symptomatic), ALL has a high propensity for CNS involvement. CNS prophylaxis (intrathecal chemo/radiation) is a mandatory component of ALL management.
• Tumor Lysis Syndrome Labs: Be prepared to identify TLS in ALL case vignettes: markedly elevated LDH and Uric Acid, hyperkalemia, hyperphosphatemia, and hypocalcemia.
• M4 AML Distinguishers: Look for an inverted 16 chromosome, eosinophilia, painful/swollen gums, and leukemia cutis (skin infiltration).

Memory Pearls

• M3 / APL Triad: t(15;17) + prominent Auer rods + high DIC risk. Treatment = ATRA.
• ATRA Syndrome vs. DIC: ATRA causes pulmonary infiltrates/effusions (ATRA syndrome) but does not cause DIC. Traditional chemotherapy in M3 does cause DIC due to granule release.
• B-cell ALL progression (Surface markers): Starts with CD19+/CD10- (Pro-B) → gains CD10+ (Common) → gains Cytoplasmic Ig (Pre-B) → gains Surface Ig (Mature-B).

Chronic Leukemia

Core Concepts

• Chronic Lymphocytic Leukemia (CLL): Accumulation of morphologically mature but immunologically immature B-lymphocytes in peripheral blood, bone marrow, and lymphatic tissues.
• Chronic Myeloid Leukemia (CML): Clonal expansion of a hematopoietic stem cell driven by a reciprocal translocation between chromosomes 9 and 22, resulting in the BCR-ABL fusion gene. Accounts for 20% of adult leukemias; primarily affects middle-aged individuals.

Diagnosis / Clinical Features

Chronic Lymphocytic Leukemia (CLL)

• Presentation: Often asymptomatic. May present with recurrent infections (due to hypogammaglobulinemia), fever, pallor.
• Physical Exam: Lymphadenopathy (cervical, axillary) and Splenomegaly.
• Key Distinction: Recurrent infections and bulky lymphadenopathy are prominent.

Chronic Myeloid Leukemia (CML)

• Presentation: Insidious onset (often accidental discovery). Hypermetabolic symptoms (fatigue, malaise, sweating, weight loss).
• Physical Exam: Minimal to massive splenomegaly (causes LUQ pain, early satiety, mass effect). Mild hepatomegaly.
• Key Distinction: Lymphadenopathy is rare in CML unless in terminal stages.

Investigations

Chronic Lymphocytic Leukemia (CLL)

• CBC: Lymphocytosis. May show anemia and thrombocytopenia.
• Immunophenotyping (Flow Cytometry): CD5(+), CD19(++), CD20(++), surface Ig(+).
• Hemolysis markers: Direct Antiglobulin Test (DAT) may be strongly positive, indicating secondary Autoimmune Hemolytic Anemia (AIHA), with elevated reticulocytes and LDH.
• Cytogenetics: +12 (Trisomy 12) is a noted abnormality.

Chronic Myeloid Leukemia (CML)

• CBC & Smear: Elevated WBC count (<5% blasts in chronic phase). Elevated platelets. Normochromic normocytic anemia. Basophilia is a hallmark finding.
• Uric Acid: Often elevated (hyperuricemia/gout risk) due to high cell turnover.
• Diagnostic Confirmation (Gold Standard):
  • Cytogenetics/Karyotyping: Identifies t(9;22)(q34;q11.2) — the Philadelphia chromosome.
  • FISH (Fluorescence In Situ Hybridization): Locates the BCR-ABL translocation (Locus Specific Identifier).

Management

Chronic Lymphocytic Leukemia (CLL)

• Indications for Treatment: Symptoms, decline in Hb or platelets, massive/progressive lymphadenopathy or hepatosplenomegaly, recurrent infections.
• Asymptomatic/Early Stage: Watchful waiting.
• Pharmacologic Options:
  • Alkylating Agents: Chlorambucil, Cyclophosphamide.
  • Purine Nucleosides: Fludarabine, Pentostatin, Cladribine.
  • Chemoimmunotherapy.

Chronic Myeloid Leukemia (CML)

• Primary Therapy: Imatinib mesylate (Tyrosine Kinase Inhibitor).
  • Mechanism: Competitive inhibition at the ATP binding site of the Abl kinase.
  • Side Effects: Fluid retention, nausea, muscle cramps, diarrhea, skin rashes. Myelosuppression is the most common hematologic side effect.
• Resistance to Imatinib: Caused by kinase site mutations, gene amplification, alternative signaling pathways, or multi-drug efflux proteins (manage with 2nd generation TKIs).
• Definitive Therapy: Allogeneic Stem Cell Transplant (SCT). Recommended for selected patients or in blast crisis.

Complications / Prognosis

CLL Prognostic Markers

• Clinical Staging: Rai (Stage 0-IV) and Binet (Stage A-C). Median survival ranges from >10 years (Early) to 1-3 years (Advanced).
• IgHV Mutation Status:
  • Mutated (Post-germinal center): Slow progression, better prognosis.
  • Unmutated (Pre-germinal center): Rapid progression, worse prognosis.
• Surrogate Markers: ZAP 70 and CD38 presence indicates poorer prognosis.

CML Disease Phases

1. Chronic Phase: <5% blasts. 95% of patients achieve complete hematologic remission with Imatinib in this phase.
2. Accelerated Phase: Blasts 10–20% in blood/marrow, Basophils ≥20%, Platelets <100k, cytogenetic clonal evolution.
3. Blastic Phase (Crisis): Acute leukemia presentation. Blasts ≥20% in blood/marrow. Hyposegmented neutrophils (Pelger-Huet anomaly) may appear. Blasts can be myeloid, lymphoid, or erythroid.

Past-Paper High Yield

• CLL vs. CML differentiating feature: The t(9;22) translocation is exclusively a hallmark of CML and is never expected in a patient with CLL.
• CML Genetic Abnormality: Always identify t(9;22) (Philadelphia chromosome) for CML.
• Next step for suspected CML: Order FISH looking for BCR-ABL translocation.
• Best diagnostic indicator for CML: The presence of t(9;22) alongside basophilia confirms the diagnosis (better and more specific than relying solely on a bone marrow biopsy).
• CLL Prognosis & Management: A patient diagnosed with CLL in the early/chronic phase will generally live for a long time without treatment (watchful waiting is the correct approach for asymptomatic early-stage disease).

Memory Pearls

• CML Triad: Middle-aged + Massive Spleen + Basophilia = think CML. Confirm with FISH for t(9;22).
• CLL Flow: B-cell disease that aberrantly expresses T-cell marker CD5.
• CLL = Watch and Wait: Do not treat CLL just for an elevated WBC; wait for cytopenias, bulky lymphadenopathy, or B-symptoms.

Chronic Myeloproliferative Disorders and VTE

Core Concepts

Venous Thromboembolism (VTE)

• Multifactorial Disease: Caused by combined inherited and acquired risk factors (Virchow’s Triad: Stasis, Hypercoagulability, Endothelial Damage).
• Burden of Disease: Preventable, highly common in hospitalized patients (most have ≥1 risk factor), and carries significant mortality and morbidity.
• Important Genetic Factors (Thrombophilias): Protein C deficiency, Protein S deficiency, Antithrombin III (ATIII) deficiency, Factor V Leiden mutation, Prothrombin (Factor II) mutation.

Myeloproliferative Neoplasms (MPNs)

• Definition: Clonal bone marrow stem cell disorders causing hyperproliferation of one or more myeloid lineages without dysplasia.
• Key Pathogenesis: Gain-of-function JAK2-V617F mutation. Present in:
  • ~95% of Polycythemia Vera (PV)
  • 43–57% of Primary Myelofibrosis (MF)
  • 23–57% of Essential Thrombocythemia (ET)
• Common MPN Features: Splenomegaly, hypercatabolism (weight loss, acute gouty arthritis), unusual thromboses (e.g., Budd-Chiari syndrome), and generalized pruritus (classically aquagenic/after bathing).

Diagnosis / Clinical Features

• VTE Presentation:
  • DVT: Painful, swollen, hot limb.
  • PE: Repeated attacks of cough, hemoptysis, shortness of breath.
• Polycythemia Vera (PV): Often presents with plethoric "hot" face, severe aquagenic pruritus, gout (due to high cell turnover/hyperuricemia), and unusual thrombosis. Labs show polycythemia (high Hb/RBC mass) alongside normal O2 saturation, leukocytosis, thrombocytosis, and notably low serum erythropoietin (EPO).

Investigations

WHO Diagnostic Criteria for Polycythemia Vera (PV) Requires BOTH Major criteria OR 1 Major + 2 Minor criteria:

• Major Criteria:
  1. Elevated RBC mass >25% above mean normal OR Hemoglobin >18.5 g/dL (male) / >16.5 g/dL (female).
  2. Presence of JAK2 V617F mutation.
• Minor Criteria:
  1. Bone marrow showing trilineage myeloproliferation (panmyelosis).
  2. Low serum erythropoietin (EPO) levels.
  3. Endogenous erythroid colony formation in vitro.

WHO Diagnostic Criteria for Essential Thrombocythemia (ET) Requires ALL FOUR criteria:

1. Platelet count ≥ 450,000/μL.
2. JAK2 V617F positive OR no evidence of reactive thrombocytosis.
3. Does not meet WHO criteria for other MPNs (e.g., PV, CML, MF).
4. Bone marrow shows marked megakaryocytic hyperplasia (large, mature morphology) with little to no granulocytic or erythroid proliferation.

Management

VTE Treatment Modalities

• Initial: Thrombolytic therapy, Heparin (UFH or LMWH), Oral Anticoagulant Therapy (Warfarin/NOACs). Overlap required if starting Warfarin.
• Other Modalities: Venous thrombectomy, IVC filters, Pulmonary embolectomy (for severe/refractory cases).

Anticoagulant Pharmacology Overview

NOAC Contraindications: Prosthetic heart valves, severe renal impairment (requires dose reduction in moderate impairment), significant active bleeding/haemostasis disorders, liver disease, pregnant/breastfeeding women, children <18 years.

MPN Management

• Ruxolitinib: Selective JAK1 & JAK2 inhibitor.
  • Indication: Second-line treatment for MPNs (after hydroxyurea).
  • Efficacy: Improves systemic symptoms (pruritus, constitutional symptoms) and reduces transfusion requirements/splenomegaly.
  • Limitation: No demonstrated survival benefit as yet.

Complications / Prognosis

• VTE Complications:
  • Post-thrombotic syndrome (venous stasis/ulceration) occurs in ~40% of DVT patients.
  • Pulmonary hypertension develops in ~5% of PE patients.
  • Death occurs in 3% (DVT) to 30% (PE) of cases.
• Warfarin-Induced Skin Necrosis / Microvascular Thrombosis: Occurs due to the rapid depletion of Protein C (an endogenous anticoagulant with a short half-life) before procoagulant factors (II, IX, X) deplete. Risk is highest in patients with heterozygous Protein C or S deficiency, high initial Warfarin doses, or inadequate heparin overlap.
• MPN Progression: MPNs carry a significant predisposition to evolve into acute leukemias or fibrosis.
  • PRV: ~70% progress to Myelofibrosis (MF); ~10% transform to Acute Myeloid Leukemia (AML).
  • ET: ~10% transform to AML.
  • CML: ~30% transform to AML.

Past-Paper High Yield

• Warfarin + Heparin Overlap: Always tested. Warfarin causes a transient prothrombotic state due to the rapid clearance of Protein C and S (short half-lives compared to Factor II and X). You must bridge with Heparin until INR is therapeutic.
• Diagnostic Trap (PV vs. Secondary Polycythemia): Suspect PV in a patient with high Hemoglobin/RBC mass, splenomegaly, gout, and aquagenic pruritus. The differentiator is low EPO levels and JAK2+ status (Secondary causes like COPD or high altitude will have high EPO).
• NOACs vs. Warfarin: NOACs are absolutely contraindicated in patients with mechanical/prosthetic heart valves, moderate/severe liver disease, and pregnancy. Use Warfarin for mechanical valves; use LMWH in pregnancy.
• MPN Classic Triad of Complications: Expect questions linking MPNs to 1) Gout (hyperuricemia from cell turnover), 2) Budd-Chiari syndrome (hepatic vein thrombosis), and 3) Progression to Myelofibrosis or AML.

Memory Pearls

• Virchow's Triad for VTE: SHE (Stasis, Hypercoagulability, Endothelial damage).
• Warfarin targets: "DiXon" factors (IX, X, VII, II).
• NOAC targets: "Xa" is in the name for Factor Xa inhibitors (Apixaban, Rivaroxaban). Dabigatran targets ThRombin (IIa).
• MPN Mutations: JAK2 = "Just A Kinase 2". Present in almost all PV (95%), half of ET and MF. (Mnemonic: PV is the Principal Victim of JAK2).

Lymphoma and Myeloma

Core Concepts

• Lymphoma (NHL & Hodgkin's): Malignancies arising from lymphocytes. 85% of Non-Hodgkin Lymphomas (NHL) are of B-cell origin; the rest are T-cell or null cell. Each type reflects a lymphocyte arrested at a specific developmental stage.
• Multiple Myeloma (MM): A plasma cell dyscrasia characterized by bone marrow infiltration, secretion of abnormal monoclonal proteins, and end-organ damage.
• Key Etiological Associations (NHL):
  • Viral: EBV (Burkitt’s), HTLV-I (T-cell leukemia-lymphoma), Hepatitis C.
  • Chronic Inflammation: Helicobacter pylori (Gastric MALT lymphoma), Chlamydia psittaci (Ocular adnexal lymphoma), Sjögren’s syndrome.
  • Immunosuppression: AIDS, Organ transplant (cyclosporine), Congenital (Wiskott-Aldrich).
  • DNA Repair Defects: Ataxia telangiectasia, Xeroderma pigmentosum.

Diagnosis / Clinical Features

Lymphomas (General):

• Lymphadenopathy: Painless enlargement (extent dictates the stage).
• B-Symptoms: Fever, night sweats, significant weight loss.
• Other features: Extra-nodal involvement, local compression symptoms.

Multiple Myeloma: Clinical presentation is driven by bone marrow infiltration and abnormal protein secretion.

• Bone pain: Especially in the back; osteolytic lesions and pathological fractures (driven by osteoclast activation, not osteoblasts).
• Renal impairment: Due to light chain toxicity to renal tubules (occurs in ~50% of patients).
• Infections: Recurrent bacterial infections (>2 episodes) due to hypogammaglobulinemia of normal functioning antibodies.
• Hyperviscosity syndrome: Especially common in rare IgM-secreting myeloma.
• Amyloidosis: Deposition of light chains.

Investigations

Lymphomas:

• Excisional LN Biopsy: Absolute requirement for definitive diagnosis and subtyping (FNA is insufficient).
• Ann Arbor Staging:
  • Stage I: 1 lymph node region.
  • Stage II: >1 lymph node region, same side of diaphragm.
  • Stage III: Lymph node regions on both sides of diaphragm.
  • Stage IV: Diffuse extra-nodal sites.

Multiple Myeloma:

• Diagnosis of Active MM requires BOTH:
  1. Clonal bone marrow plasma cells ≥10% OR biopsy-proven bony/extramedullary plasmacytoma.
  2. ≥1 CRAB feature (Calcium ↑, Renal failure, Anemia, Bone lesions).
• Smouldering MM: Serum monoclonal protein ≥3 g/dL OR urinary monoclonal protein ≥500 mg/24h AND/OR bone marrow plasma cells 10%–60%. Crucially, there is an absence of CRAB criteria (no end-organ damage).
• Imaging: Plain X-rays (Skeletal Survey), MRI, or PET scan. Trap: Lytic lesions do not show up well on standard radionuclide bone scans because there is no osteoblastic activity.
• Labs: Serum protein electrophoresis (SPEP) and immunofixation, Quantitative immunoglobulins, Serum β2-microglobulin.

Management

Lymphoma:

• Indolent NHL (e.g., Follicular, CLL/SLL, MALT): Observation only until symptomatic (constitutional symptoms, anatomical obstruction, painful LNs, cytopenias). Treatments include Oral/IV chemo (chlorambucil, CHOP), Rituximab (anti-CD20).
• Aggressive NHL (e.g., DLBCL): Disseminates via bloodstream early. Must use systemic chemotherapy (CHOP-R x 8 cycles, or CHOP-R x 3 + radiotherapy). Note: Highly responsive to chemo and potentially curable.
• Very Aggressive (e.g., Burkitt’s): Multidrug pediatric leukemia regimens + BMT.
• Hodgkin's Lymphoma: ~85% curable. Regimens include ABVD, MOPP, BEACOPP.

Multiple Myeloma:

• Standard chemotherapy combos: Dexamethasone + Thalidomide OR Bortezomib/Lenalidomide; Melphalan + Prednisone.
• High-Dose Chemotherapy with Autologous Bone Marrow Transplant.

Complications / Prognosis

Multiple Myeloma - International Staging System (ISS):

• Stage I: Serum albumin > 3.5 g/dL AND serum β2-microglobulin < 3.5 mg/dL.
• Stage II: Fits neither I nor III.
• Stage III: Serum β2-microglobulin > 5.5 mg/dL (Indicates poor prognosis).
• Adverse Prognostic Genetics: Deletion 13, t(4;14).

Lymphoma Adverse Prognostic Factors:

• Age > 60 years.
• Stage III or IV (advanced disease).
• High serum Lactate Dehydrogenase (LDH).
• Performance status (ECOG ≥ 2).
• > 1 extranodal site involved.

Past-Paper High Yield

• Myeloma Staging Marker: A patient with multiple myeloma is categorized as Stage 3 if their β2-microglobulin is > 5.5 mg/dL.
• Advanced Myeloma Labs: An elevated β2-microglobulin is a hallmark laboratory finding specifically indicating advanced, extensive multiple myeloma. (Note: Past papers may contain a typo referring to "B2 macroglobulin"; recognize this as β2-microglobulin).
• Curability of Lymphomas: Diffuse Large B-Cell Lymphoma (DLBCL) is the classic example of an aggressive, yet highly curable non-Hodgkin lymphoma. Contrast this with Follicular lymphoma, which is indolent (patients live a long time) but generally incurable with standard therapy.
• Myeloma Clinical Traps: For questions asking "Which of the following is NOT seen in multiple myeloma," you must rely on standard inclusion criteria. Expect to see: CRAB features (Hypercalcemia, Renal failure, Anemia, Bone lytic lesions), elevated total protein/globulin gap, elevated ESR, hyperviscosity, amyloidosis, and recurrent infections. Look for an option that clearly violates these (e.g., osteoblastic lesions, normal ESR, or a feature of a completely different disease like prominent painless lymphadenopathy, which points to lymphoma instead).

Memory Pearls

• Myeloma End-Organ Damage (Buy CAVIAR):
  • Buy = Lytic bone lesions (visible on plain x-ray)
  • C = hyperCalcemia
  • A = Anemia
  • V = HyperViscosity
  • I = Bacterial Infections
  • A = Amyloidosis
  • R = Renal failure (light chain cast nephropathy)
• Lymphoma Translocations (Must Know for Exams):
  • t(14;18): Follicular Lymphoma (bcl-2 oncogene)
  • t(8;14): Burkitt’s Lymphoma (c-myc oncogene)
  • t(11;14): Mantle Cell Lymphoma (cyclin D1 gene)

Blood Transfusion

Core Concepts

• Blood Component Shelf Life & Storage:
  • Packed Red Blood Cells (pRBCs): Shelf life 35–42 days at 1–6°C.
  • Platelets: Shelf life 5 days at 20–24°C (room temperature). Because they are kept at room temperature, platelets have the highest risk of bacterial contamination (1 in 250 transfusions).
  • Fresh Frozen Plasma (FFP): Shelf life 1 year at -18°C. Must be ABO compatible. Dose: 10–15 mL/kg. Indicated for multiple coagulation factor deficiencies (liver disease, trauma, DIC) and rapid warfarin reversal.
• Special Red Blood Cell Preparations:

Diagnosis / Clinical Features

• Categories of Acute Transfusion Reactions (< 24 hours):
  • Immunologic: Hemolytic (ABO incompatibility), Febrile non-hemolytic, Allergic, Anaphylactic, TRALI.
  • Non-immunologic: Transfusion-Associated Circulatory Overload (TACO), Bacterial contamination, Air embolus, Metabolic reactions.
• Categories of Delayed Transfusion Reactions (> 24 hours):
  • Immunologic: Alloimmunization (HLA, RBC), Delayed hemolytic, GVHD, Post-transfusion purpura.
  • Non-immunologic: Iron overload, Viral transmission (HCV, HBV, HIV).
• Transfusion-Related Acute Lung Injury (TRALI):
  • Onset: Typically occurs within 1–4 hours (and strictly within the first 6 hours) of starting the transfusion.
  • Pathophysiology:
    • Immune (Classical) Theory: Donor anti-leukocyte/HLA antibodies (often from multiparous female donors who were alloimmunized during pregnancy) react with recipient neutrophils.
    • Neutrophils sequester in the pulmonary vasculature → release cytokines/complement → endothelial damage and capillary leak.
  • Clinical Presentation: Rapid onset of non-cardiogenic pulmonary edema, acute respiratory distress (ARDS), fever with chills, non-productive cough, cyanosis, and hypotension.
  • Prevention: Avoid using multiparous women as plasma/blood donors.

Investigations

• Acute Transfusion Reaction Workup:
  • Send the remaining blood unit and post-transfusion patient blood/urine samples back to the blood bank for Coombs testing, hemolysis check, and potential bacterial culture.
• TRALI Imaging:
  • Chest X-ray: Bilateral pulmonary infiltrates classically in the hilar region.
  • Key Differentiator: Physiologic/radiographic features will show no clinical evidence of left atrial hypertension (PAWP < 18 mm Hg), differentiating TRALI from TACO.

Management

• Universal Protocol for ALL Acute Transfusion Reactions:
  1. STOP THE TRANSFUSION IMMEDIATELY.
  2. Maintain IV access with 0.9% Normal Saline (NaCl).
  3. Check blood component label and patient ID for mismatch.
  4. Monitor patient vitals, blood pressure, and urine output closely.
  5. Notify the Blood Bank.
  6. Do NOT discard the transfused unit; keep it and send it to the blood bank along with fresh patient blood/urine samples for investigation.
  7. Provide necessary supportive care.
• TRALI Management:
  • No specific targeted treatment; care is largely supportive.
  • Provide respiratory support with supplemental O2. Most cases require mechanical ventilation.
  • Steroids may be used in some cases.
• Iron Overload Management (Frequent Transfusions):
  • Oral deferasirox is the first-line treatment for iron chelation in patients undergoing frequent transfusions (e.g., thalassemia). Note: Organ damage from iron overload can often be halted or partially reversed with effective chelation.

Complications / Prognosis

• Metabolic Complications of Massive Transfusion:
  • Hypocalcemia: Due to systemic chelation of calcium by the citrate anticoagulant used in stored blood bags.
  • Hyperkalemia: Due to progressive RBC lysis and leakage of intracellular potassium during storage. (Hypokalemia is not a complication of transfusion).
• Platelet Transfusion Refractoriness:
  • Failure to achieve the expected platelet bump.
  • Immune causes: HLA alloimmunization (most common).
  • Non-immune causes: Splenic sequestration, DIC / microangiopathic hemolytic anemia, active bleeding, severe infection/fever, or medications (Amphotericin, Vancomycin, ATG, Interferons).

Past-Paper High Yield

• Suspected Reaction Protocol Trap: In a suspected transfusion reaction, it is fundamentally WRONG to discard the transfused units. You must stop the transfusion, secure the IV with saline, check vitals, and return the bag to the blood bank.
• TRALI Timing: Classic exam presentation specifies that TRALI occurs strictly within the first 6 hours following a transfusion.
• Metabolic Derangements: Blood transfusions do NOT cause hypokalemia. Stored blood actually causes hyperkalemia (RBC lysis) and hypocalcemia (citrate toxicity).
• Iron Chelation: With advancements in care for patients requiring frequent transfusions, oral deferasirox is now the first-line treatment for iron overload. It is a misconception that established organ damage can never be improved.

Memory Pearls

• "Washed prevents Washout" (Anaphylaxis): Use washed RBCs for IgA deficiency to prevent severe anaphylactic shock.
• "Irradiation kills the Invaders": Irradiated RBCs destroy donor T-cells, preventing Graft-Versus-Host Disease (GVHD).
• "Leuko-poor stops the fever": Leukodepletion removes donor WBCs, heavily reducing febrile non-hemolytic reactions.
• TRALI vs. TACO:
  • TRALI: Multiparous donor antibodies → Hypotension, Normal left atrial pressure (non-cardiogenic).
  • TACO: Fluid overload → Hypertension, Elevated left atrial pressure, BNP elevation.

Megaloblastic Anemia and Pernicious Anemia

Core Concepts

• Macrocytic Anemias: Defined by an elevated MCV (>100 fL). Major causes include:
  • Megaloblastic: Vitamin B12 (cobalamin) deficiency, Folate deficiency, Drugs (methotrexate, azathioprine, 6-mercaptopurine).
  • Non-megaloblastic: Liver disease (alcohol, cirrhosis), increased erythropoiesis (hemolysis, hemorrhage response), hypothyroidism.
  • Bone Marrow Disorders: Myelodysplastic Syndrome (MDS), hypoplastic anemia.
• Pernicious Anemia (PA): An autoimmune disorder and the end-stage of Atrophic Body Gastritis (ABG).
  • Pathophysiology: Autoimmune destruction of the oxyntic gastric mucosa leads to achlorhydria and lack of Intrinsic Factor (IF), preventing B12 absorption in the terminal ileum.
  • Associations: Highly associated with other autoimmune diseases (Autoimmune thyroid disease, Type 1 Diabetes, Vitiligo).
• Myelodysplastic Syndrome (MDS): A heterogeneous group of clonal malignant hematopoietic stem cell disorders characterized by ineffective, dysplastic hematopoiesis.
  • Results in variable cytopenias and carries a high risk of transformation to Acute Myeloid Leukemia (AML).

Diagnosis / Clinical Features

Vitamin B12 Deficiency

• Neurological symptoms (Hallmark): Subacute Combined Degeneration of the Spinal Cord (degeneration of the posterior and lateral columns).
  • Presents with loss of vibration and proprioception in lower limbs, imbalanced gait, paresthesia in hands/feet.
  • Psychiatric features: "Odd" behavior, irritability, psychosis.
• Physical Exam: Beefy red tongue (glossitis), vitiligo (if autoimmune PA).

Folate Deficiency

• Presentation: "Anemia syndrome" (fatigue, pallor, weight loss) without neurological symptoms.
• Causes:
  • Inadequate intake: Lack of fresh/uncooked food, chronic alcoholism, TPN.
  • Malabsorption: Celiac disease, sprue, alcoholism.
  • Increased requirement: Pregnancy/lactation, chronic hemolysis, malignancy.
  • Defective utilization: Folate antagonists (methotrexate, trimethoprim), purine/pyrimidine analogs.

Myelodysplastic Syndrome (MDS)

• Epidemiology: Typical patient is elderly (60–90 years old) with a slight male preponderance.
• Clinical: >80% present with anemia (chronic low Hb leading to cardiac remodeling/heart failure). 50–70% have granulocytopenia (frequent infections), 30% have thrombocytopenia.

Investigations

• Peripheral Blood Smear:
  • B12/Folate Deficiency: Shows Macro-ovalocytes and Hypersegmented neutrophils (>5 lobes).
  • Note on Nucleated RBCs/Blasts: Nucleated RBCs can occasionally be seen in the periphery in severe anemia. Blasts are not seen in simple B12/folate deficiency; their presence strongly suggests MDS or leukemia.
• Bone Marrow:
  • B12/Folate: Hypercellular with Megaloblasts (these reside in the marrow, not the peripheral blood).
  • MDS: Dysmorphic cells, ringed sideroblasts (e.g., ≥15% in RARS), and varying percentages of blasts (<20%; if ≥20%, it is AML).
• Laboratory Tests (Megaloblastic Anemia):
  • Elevated LDH (often dramatically high, e.g., >1000) due to ineffective erythropoiesis (intramedullary hemolysis).
  • Low corrected reticulocyte count.
  • PA specific: Anti-Intrinsic Factor (IF) antibodies and Anti-Parietal Cell (PCA) antibodies.
• MDS Diagnostics:
  • Diagnosis requires bone marrow aspirate (with iron stain for sideroblasts) + biopsy + cytogenetics.
  • Common cytogenetic anomalies: del(5q), -7/del(7q), +8.
  • Prognosis scoring (WPSS) incorporates WHO category, karyotype, and transfusion requirement.

Management

Vitamin B12 Deficiency (Pernicious Anemia)

• Avoid Blood Transfusions: Generally not required, even with very low Hb.
• Replacement: Vitamin B12 IM injections daily for 7–10 days, followed by monthly lifelong injections.
• Monitoring Timeline:
  • 2 days: LDH falls; bone marrow megaloblastic changes disappear.
  • 3–4 days: Reticulocytosis begins (peaks at 5–10 days).
  • 10–14 days: Rise in Hb begins; hypersegmented PMNs disappear.
  • 8–10 weeks: Hb and MCV normalize.
• Treatment Risk: Watch closely for severe hypokalemia during the early response (due to massive cellular uptake of potassium during new RBC synthesis).

Folate Deficiency

• Treat the underlying cause.
• Administer oral folic acid (5 mg twice daily for 3 months, then maintenance if necessary).
• Pregnancy: Adequate folate is critical for neural tube closure in the fetus.

Myelodysplastic Syndrome (MDS)

• Low-Risk: Best supportive care (transfusions, iron chelation), hematopoietic growth factors (EPO/G-CSF), Lenalidomide (specifically for isolated del(5q)), Azacitidine (hypomethylating agent).
• High-Risk: Intensive chemotherapy or Allogeneic Stem Cell Transplantation (SCT) – the only curative option.

Past-Paper High Yield

• Peripheral Smear vs. Bone Marrow Trap: Be hyper-vigilant when asked about peripheral blood findings in B12 deficiency. The peripheral blood features macro-ovalocytes and hypersegmented neutrophils. Megaloblasts are found exclusively in the bone marrow. If an exam question asks to identify peripheral cells and includes distractors like "macrospheres" (not a real hematologic term) or "blasts" (indicative of leukemia/MDS), recognize that severe dyserythropoiesis in B12 deficiency can occasionally push nucleated RBCs into the periphery, but blasts are incorrect for nutritional megaloblastic anemia.
• Neurological Manifestations: B12 deficiency causes subacute combined degeneration (loss of vibration/proprioception). Folate deficiency does not. This is the classic differentiator in clinical vignettes.
• Hypokalemia Warning: You must monitor potassium levels closely in the first few days of B12 replacement therapy, as rapid reticulocytosis can cause fatal hypokalemia.
• MDS Chromosome: Isolated del(5q) is a specific WHO subtype of MDS that presents with anemia, normal/increased platelets, and has a targeted treatment (Lenalidomide).

Memory Pearls

• B12 deficiency = Bad nerves (subacute combined degeneration).
• B12 peripheral smear = Big oval cells (macro-ovalocytes) and Big PMNs (hypersegmented).
• Subacute Combined Degeneration: Posterior (Proprioception) and Lateral (Leg weakness/motor) columns.
• MDS Hallmark: Elderly patient + refractory pancytopenia + ringed sideroblasts + rule out B12/folate first.

Venous Thromboembolism (VTE)

Core Concepts

• Pathogenesis (Virchow's Triad): Thrombosis is a multifactorial "accident" occurring when genetic and acquired risk factors compound to tip the hemostatic balance. Most hospitalized patients have at least one risk factor.
  • Venous Stasis: Immobility, age > 40, CHF, stroke, paralysis/spinal cord injury, anesthesia, obesity, varicose veins, hyperviscosity (polycythemia), severe COPD.
  • Hypercoagulability: Cancer, high estrogen states, pregnancy, inflammatory bowel disease (IBD), nephrotic syndrome, sepsis, smoking, thrombophilias.
  • Endothelial Damage: Surgery, trauma, central venous lines, prior VTE.
• Inherited Thrombophilias:
  1. Factor V Leiden mutation (most common inherited)
  2. Prothrombin (Factor II) G20210A mutation
  3. Protein C deficiency
  4. Protein S deficiency
  5. Antithrombin III (ATIII) deficiency
• Importance of VTE: It is a common, costly, and largely preventable disease. Left unprophylaxed, it carries a high risk of life-threatening events (PE) and severe long-term morbidity (Post-Thrombotic Syndrome).

Diagnosis / Clinical Features

• Deep Vein Thrombosis (DVT): Presents classically with unilateral, painful swelling, erythema ("hotness"), and edema of the affected extremity (e.g., following long-distance travel).
• Pulmonary Embolism (PE): Presents with shortness of breath, repeated attacks of cough, hemoptysis, and pleuritic chest pain.

Investigations

• Imaging: Duplex Ultrasound is the primary modality for confirming DVT (e.g., in the common femoral vein).
• Coagulation Monitoring:
  • aPTT: Used to monitor Unfractionated Heparin (Target: 1.5–2.5x normal).
  • PT/INR: Used to monitor Warfarin (Target INR: 2.0–3.0). INR = (Patient PT / Control PT)^ISI.

Management

• Acute Anticoagulation (Parenteral):
  • Unfractionated Heparin (UFH): Requires >18 monosaccharide units to inhibit thrombin. Given as 80 units/kg loading dose → 18 units/kg/hr infusion.
  • Low Molecular Weight Heparin (LMWH): <18 monosaccharide units; preferentially inhibits Factor Xa. E.g., Enoxaparin (1 mg/kg BID) or Tinzaparin (175 units/kg once daily).
  • Pentasaccharide: Pure Factor Xa inhibition.
• Long-term Anticoagulation (Oral):
  • Warfarin (Vitamin K Antagonist): Inhibits synthesis of Factors II, VII, IX, X, and Proteins C & S.
    • Kinetics: Highly protein-bound (99% to albumin). Half-life is 25–60 hours. Peak plasma concentration in 2–8 hours, but antithrombotic effect takes days because pre-formed factors must clear.
    • Bridging: Must overlap with Heparin for at least 5 days and until INR is therapeutic (2.0–3.0). Factor VII and Protein C deplete rapidly, creating a transient prothrombotic state before Prothrombin (Factor II) and Factor X deplete.
  • Direct Oral Anticoagulants (NOACs/DOACs):
    • Factor Xa Inhibitors: Apixaban, Rivaroxaban.
    • Direct Thrombin (IIa) Inhibitors: Dabigatran.
    • Indications: Treatment/prevention of VTE, stroke prevention in non-valvular AF, VTE prophylaxis post-hip/knee replacement.
    • Contraindications: Prosthetic heart valves, clinically significant active bleeding, severe renal impairment (dose adjustment required for moderate), liver disease, pregnancy/breastfeeding, age < 18.
• Other Modalities (Severe/Refractory Cases): Thrombolytic therapy, venous thrombectomy, pulmonary embolectomy, IVC filters.
• Myeloproliferative Neoplasms (MPNs): Patients with MPNs (e.g., polycythemia) are at high risk for VTE. Ruxolitinib (selective JAK 1/2 inhibitor) is used 2nd-line after hydroxyurea to improve systemic symptoms, though it currently shows no distinct survival benefit.

Complications / Prognosis

• High Early Mortality: Cumulative mortality for PE is ~17.5% within the first 90 days, with the majority of deaths occurring very early (within 7–14 days). Untreated PE mortality can be up to 30%.
• Post-Thrombotic Syndrome (PTS): Occurs in ~40% of patients following a DVT. Characterized by chronic venous stasis, pain, edema, and skin ulceration.
• Pulmonary Hypertension (CTEPH): Develops in ~5% of patients post-PE.
• Warfarin-Specific Complications:
  • Bleeding: Most common complication.
  • Teratogenicity: Contraindicated in pregnancy (causes birth defects and abortion).
  • Skin Necrosis / Microvascular Thrombosis: Occurs typically in the first few days of therapy, especially in patients with unrecognized heterozygous Protein C or S deficiency, if given a large initial dose without adequate heparin overlap.

Past-Paper High Yield

• The Rationale for Heparin Bridging: You will be tested on the timeline of Vitamin K-dependent factor clearance. Protein C (an anticoagulant) has a short half-life and clears quickly, alongside Factor VII. Prothrombin (Factor II) takes the longest to clear. Starting Warfarin alone causes a rapid drop in Protein C, leading to a temporary hypercoagulable state and risking Warfarin-induced skin necrosis.
• Heparin Chain Lengths: UFH inhibits both Thrombin (IIa) and Xa because its long chain (>18 units) can physically wrap around both Antithrombin and Thrombin. LMWH is too short to wrap around Thrombin, making it selectively target Factor Xa.
• Prosthetic Valves & NOACs: NOACs (Apixaban, Rivaroxaban, Dabigatran) are strictly contraindicated in patients with mechanical/prosthetic heart valves (Warfarin is required).